{
    "meta": {
        "total_records": 999,
        "timestamp": "2026-10-12T06:05:15Z"
    },
    "data": [
        {
            "title": "Download website data in JSON data format",
            "category": "Human;Veterinary;Herbal;Corporate",
            "first_published_date": "19/11/2025",
            "last_updated_date": "08/10/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/download-website-data-json-data-format"
        },
        {
            "title": "Demonstration of therapeutic equivalence for nasal products",
            "category": "Human",
            "first_published_date": "26/07/2024",
            "last_updated_date": "08/10/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-therapeutic-equivalence-nasal-products"
        },
        {
            "title": "Good pharmacogenomic practice",
            "category": "Human",
            "first_published_date": "04/08/2014",
            "last_updated_date": "06/10/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/good-pharmacogenomic-practice"
        },
        {
            "title": "Clinical requirements for medicines intended for the treatment of sickle cell disease",
            "category": "Human",
            "first_published_date": "24/09/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-requirements-medicines-intended-treatment-sickle-cell-disease"
        },
        {
            "title": "Clinical requirements for medicines intended for the treatment of thalassaemia",
            "category": "Human",
            "first_published_date": "24/09/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-requirements-medicines-intended-treatment-thalassaemia"
        },
        {
            "title": "ICH guideline M13B on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver",
            "category": "Human",
            "first_published_date": "09/04/2025",
            "last_updated_date": "21/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-m13b-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver"
        },
        {
            "title": "User safety for pharmaceutical veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "18/03/2010",
            "last_updated_date": "18/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/user-safety-pharmaceutical-veterinary-medicinal-products"
        },
        {
            "title": "User safety of topically administered products",
            "category": "Veterinary",
            "first_published_date": "24/03/2014",
            "last_updated_date": "18/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/user-safety-topically-administered-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of systemic sclerosis",
            "category": "Human",
            "first_published_date": "18/06/2025",
            "last_updated_date": "18/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-systemic-sclerosis"
        },
        {
            "title": "Questions and answers on post approval change management protocols (veterinary)",
            "category": "Veterinary",
            "first_published_date": "18/09/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-post-approval-change-management-protocols-veterinary"
        },
        {
            "title": "Guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances",
            "category": "Veterinary",
            "first_published_date": "30/04/2018",
            "last_updated_date": "18/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-summary-product-characteristics-spc-veterinary-medicinal-products-containing-antimicrobial-substances"
        },
        {
            "title": "ICH E14/S7B (R1) Q&As: The clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs - Questions and Answers",
            "category": "Human",
            "first_published_date": "01/02/2016",
            "last_updated_date": "16/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e14-s7b-r1-qas-clinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-questions-answers"
        },
        {
            "title": "ICH M12 on drug interaction studies",
            "category": "Human",
            "first_published_date": "21/07/2022",
            "last_updated_date": "11/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m12-drug-interaction-studies"
        },
        {
            "title": "Clinical investigation of medicinal products for treatment of migraine",
            "category": "Human",
            "first_published_date": "24/01/2007",
            "last_updated_date": "10/09/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-migraine"
        },
        {
            "title": "Performance enhancers",
            "category": "Veterinary",
            "first_published_date": "01/05/1991",
            "last_updated_date": "12/08/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/performance-enhancers"
        },
        {
            "title": "Non-clinical requirements for severely debilitating or life-threatening diseases",
            "category": "Human",
            "first_published_date": "30/07/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-requirements-severely-debilitating-or-life-threatening-diseases"
        },
        {
            "title": "Fixed combination products",
            "category": "Veterinary",
            "first_published_date": "18/12/2006",
            "last_updated_date": "24/07/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/fixed-combination-products"
        },
        {
            "title": "ICH E6 Good clinical practice",
            "category": "Human",
            "first_published_date": "01/07/2002",
            "last_updated_date": "15/07/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e6-good-clinical-practice"
        },
        {
            "title": "Clinical pharmacology and pharmacokinetics: questions and answers",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "14/07/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-pharmacology-pharmacokinetics-questions-answers"
        },
        {
            "title": "Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths",
            "category": "Human",
            "first_published_date": "14/07/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/semaglutide-flextouch-solution-injection-pre-filled-pen-product-specific-bioequivalence-guidance-various-strengths"
        },
        {
            "title": "Clinical evaluation of antifungal agents for the treatment and prophylaxis invasive fungal disease",
            "category": "Human",
            "first_published_date": "30/04/2010",
            "last_updated_date": "29/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-antifungal-agents-treatment-prophylaxis-invasive-fungal-disease"
        },
        {
            "title": "Data requirements for the replacement of established master seeds (MS) already used in authorised immunological veterinary medicinal products (IVMPS) by new master seed of the same origin",
            "category": "Veterinary",
            "first_published_date": "20/07/2009",
            "last_updated_date": "26/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-replacement-established-master-seeds-ms-already-used-authorised-immunological-veterinary-medicinal-products-ivmps-new-master-seed-same-origin"
        },
        {
            "title": "Guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances",
            "category": "Veterinary",
            "first_published_date": "29/01/2021",
            "last_updated_date": "26/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-exceptional-circumstances"
        },
        {
            "title": "Clinical evaluation of medicinal products used in weight control  - addendum on weight control in children",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "25/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-medicinal-products-used-weight-control-addendum-weight-control-children"
        },
        {
            "title": "ICH E22 General considerations for patient preference studies",
            "category": "Human",
            "first_published_date": "12/12/2025",
            "last_updated_date": "24/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e22-general-considerations-patient-preference-studies"
        },
        {
            "title": "Data recommendations for herbal medicinal products and traditional herbal medicinal products used in paediatric patients",
            "category": "Human;Herbal",
            "first_published_date": "16/06/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-recommendations-herbal-medicinal-products-traditional-herbal-medicinal-products-used-paediatric-patients"
        },
        {
            "title": "Development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making",
            "category": "Human",
            "first_published_date": "16/02/2024",
            "last_updated_date": "03/06/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making"
        },
        {
            "title": "Need for maximum residue limit (MRL) evaluation for biological substances",
            "category": "Veterinary",
            "first_published_date": "23/07/2021",
            "last_updated_date": "29/05/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-maximum-residue-limit-mrl-evaluation-biological-substances"
        },
        {
            "title": "Development of new medicinal products for the treatment of smoking",
            "category": "Human",
            "first_published_date": "18/12/2008",
            "last_updated_date": "29/05/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-new-medicinal-products-treatment-smoking"
        },
        {
            "title": "VICH GL61 Pharmaceutical Development",
            "category": "Veterinary",
            "first_published_date": "17/04/2024",
            "last_updated_date": "29/05/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl61-pharmaceutical-development"
        },
        {
            "title": "Product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "05/11/2014",
            "last_updated_date": "19/05/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/product-specific-bioequivalence-guidance"
        },
        {
            "title": "Development and manufacture of synthetic peptides",
            "category": "Human;Veterinary",
            "first_published_date": "20/09/2022",
            "last_updated_date": "12/05/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-manufacture-synthetic-peptides"
        },
        {
            "title": "Liraglutide 6 mg/mL solution for injection in a prefilled pen product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/04/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/liraglutide-6-mg-ml-solution-injection-prefilled-pen-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/04/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/tafamidis-soft-gelatin-capsules-20-mg-61-mg-product-specific-bioequivalence-guidance"
        },
        {
            "title": "VICH GL18(R2) impurities: residual solvents in new veterinary medicinal products, active substances and excipients",
            "category": "Veterinary",
            "first_published_date": "26/09/2011",
            "last_updated_date": "29/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl18r2-impurities-residual-solvents-new-veterinary-medicinal-products-active-substances-excipients"
        },
        {
            "title": "ICH Q3C (R9) Residual solvents",
            "category": "Human",
            "first_published_date": "11/02/2011",
            "last_updated_date": "29/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3c-r9-residual-solvents"
        },
        {
            "title": "Demonstration of biosimilarity of biological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "24/04/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-biosimilarity-biological-veterinary-medicinal-products"
        },
        {
            "title": "Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union",
            "category": "Veterinary",
            "first_published_date": "29/11/2011",
            "last_updated_date": "24/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-macrolides-lincosamides-streptogramins-mls-animals-european-union"
        },
        {
            "title": "Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use",
            "category": "Human",
            "first_published_date": "26/03/2015",
            "last_updated_date": "09/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-normal-immunoglobulin-subcutaneous-intramuscular-use"
        },
        {
            "title": "Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)",
            "category": "Human",
            "first_published_date": "24/07/2015",
            "last_updated_date": "09/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig"
        },
        {
            "title": "Declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Veterinary;Herbal",
            "first_published_date": "26/07/2007",
            "last_updated_date": "01/04/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/declaration-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Paediatric addendum to the guideline on clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension",
            "category": "Human",
            "first_published_date": "07/02/2012",
            "last_updated_date": "31/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-pulmonary-arterial-hypertension"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis",
            "category": "Human",
            "first_published_date": "21/12/2015",
            "last_updated_date": "31/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis"
        },
        {
            "title": "Reflection paper on a tailored clinical approach in biosimilar development",
            "category": "Human",
            "first_published_date": "01/02/2024",
            "last_updated_date": "27/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-paper-tailored-clinical-approach-biosimilar-development"
        },
        {
            "title": "Melatonin product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/03/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/melatonin-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Eltrombopag product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "25/03/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/eltrombopag-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Plant testing strategy in the risk assessment for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "20/12/2011",
            "last_updated_date": "20/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/plant-testing-strategy-risk-assessment-veterinary-medicinal-products"
        },
        {
            "title": "Guidance and template on the risk management plan (RMP) for novel therapy veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "20/03/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guidance-template-risk-management-plan-rmp-novel-therapy-veterinary-medicinal-products"
        },
        {
            "title": "Chemistry of active substances (chemistry of new active substances)",
            "category": "Human",
            "first_published_date": "01/10/2015",
            "last_updated_date": "20/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chemistry-active-substances-chemistry-new-active-substances"
        },
        {
            "title": "Qualification of non-mutagenic impurities",
            "category": "Human",
            "first_published_date": "23/11/2018",
            "last_updated_date": "13/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/qualification-non-mutagenic-impurities"
        },
        {
            "title": "Development of anticancer medicinal products in paediatric patients",
            "category": "Human",
            "first_published_date": "13/03/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-anticancer-medicinal-products-paediatric-patients"
        },
        {
            "title": "ICH E2D post-approval safety data management",
            "category": "Human",
            "first_published_date": "30/11/2003",
            "last_updated_date": "06/03/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2d-post-approval-safety-data-management"
        },
        {
            "title": "Non-clinical development and evaluation of microbiome-based medicinal products",
            "category": "Human",
            "first_published_date": "02/03/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-development-evaluation-microbiome-based-medicinal-products"
        },
        {
            "title": "ICH Q14 Analytical procedure development",
            "category": "Human",
            "first_published_date": "01/04/2022",
            "last_updated_date": "24/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q14-analytical-procedure-development"
        },
        {
            "title": "ICH M4Q - The Common Technical Document for the registration of pharmaceuticals for human use - Quality",
            "category": "Human",
            "first_published_date": "01/07/2003",
            "last_updated_date": "20/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4q-common-technical-document-registration-pharmaceuticals-human-use-quality"
        },
        {
            "title": "Guideline on quality aspects of mRNA vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "08/01/2025",
            "last_updated_date": "20/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-quality-aspects-mrna-vaccines-veterinary-use"
        },
        {
            "title": "ICH Q2(R2) Validation of analytical procedures",
            "category": "Human",
            "first_published_date": "01/11/1994",
            "last_updated_date": "20/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q2r2-validation-analytical-procedures"
        },
        {
            "title": "Risk management requirements for elemental impurities in veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "16/10/2017",
            "last_updated_date": "20/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-management-requirements-elemental-impurities-veterinary-medicinal-products"
        },
        {
            "title": "ICH E20 adaptive designs for clinical trials",
            "category": "Human",
            "first_published_date": "30/06/2025",
            "last_updated_date": "16/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e20-adaptive-designs-clinical-trials"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of Myasthenia Gravis",
            "category": "Human",
            "first_published_date": "13/02/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-myasthenia-gravis"
        },
        {
            "title": "ICH M15 guideline on general principles for model-informed drug development",
            "category": "Human",
            "first_published_date": "29/11/2004",
            "last_updated_date": "11/02/2026",
            "url": "https://www.ema.europa.eu/en/ich-m15-guideline-general-principles-model-informed-drug-development-step-2b-scientific-guideline"
        },
        {
            "title": "Aliskiren product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/06/2018",
            "last_updated_date": "10/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/aliskiren-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ledipasvir/sofosbuvir product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "31/01/2018",
            "last_updated_date": "10/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ledipasvir-sofosbuvir-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Epidemiological data on blood transmissible infections",
            "category": "Human",
            "first_published_date": "12/10/2010",
            "last_updated_date": "04/02/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/epidemiological-data-blood-transmissible-infections"
        },
        {
            "title": "Use of Bayesian methods in clinical development",
            "category": "Human",
            "first_published_date": "30/01/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-bayesian-methods-clinical-development"
        },
        {
            "title": "Clinical evaluation of diagnostic agents",
            "category": "Human",
            "first_published_date": "23/07/2009",
            "last_updated_date": "30/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-diagnostic-agents"
        },
        {
            "title": "Questions and answers on how to use a CEP in the context of a Marketing Authorisation Application or a Marketing Authorisation Variation",
            "category": "Human;Veterinary",
            "first_published_date": "13/02/2024",
            "last_updated_date": "28/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-how-use-cep-context-marketing-authorisation-application-or-marketing-authorisation-variation"
        },
        {
            "title": "ICH Q3E Extractables and leachables",
            "category": "Human",
            "first_published_date": "18/08/2025",
            "last_updated_date": "28/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3e-extractables-leachables"
        },
        {
            "title": "Questions and answers regarding co-processed excipients used in solid oral dosage forms",
            "category": "Human;Veterinary",
            "first_published_date": "11/09/2024",
            "last_updated_date": "28/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-regarding-co-processed-excipients-used-solid-oral-dosage-forms"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of peripheral-arterial occlusive disease",
            "category": "Human",
            "first_published_date": "25/04/2002",
            "last_updated_date": "27/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease"
        },
        {
            "title": "Pharmaceutical quality of inhalation and nasal products",
            "category": "Human",
            "first_published_date": "01/04/2006",
            "last_updated_date": "27/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmaceutical-quality-inhalation-nasal-products"
        },
        {
            "title": "Questions and answers on the use of Product Lifecycle Management (PLCM) document",
            "category": "Human",
            "first_published_date": "26/01/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-use-product-lifecycle-management-plcm-document"
        },
        {
            "title": "Demonstration of efficacy of ectoparasiticides",
            "category": "Veterinary",
            "first_published_date": "01/09/1994",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-efficacy-ectoparasiticides"
        },
        {
            "title": "Owner assessment as efficacy parameter",
            "category": "Veterinary",
            "first_published_date": "23/01/2026",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/owner-assessment-efficacy-parameter"
        },
        {
            "title": "Veterinary medicinal products controlling Varroa destructor parasitosis in bees",
            "category": "Veterinary",
            "first_published_date": "18/11/2010",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees"
        },
        {
            "title": "Testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats",
            "category": "Veterinary",
            "first_published_date": "12/11/2007",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/testing-evaluation-efficacy-antiparasitic-substances-treatment-prevention-tick-flea-infestations-dogs-cats"
        },
        {
            "title": "Environmental risk assessment for immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/07/1996",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Design of studies to evaluate the safety and efficacy of fish vaccines",
            "category": "Veterinary",
            "first_published_date": "29/11/2011",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/design-studies-evaluate-safety-efficacy-fish-vaccines"
        },
        {
            "title": "User safety for immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "23/04/2007",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/user-safety-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)",
            "category": "Veterinary",
            "first_published_date": "29/07/2013",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-combined-vaccines-associations-immunological-veterinary-medicinal-products-ivmps"
        },
        {
            "title": "Investigation and assessment of cardiovascular safety of anticancer medicinal products",
            "category": "Human",
            "first_published_date": "31/07/2024",
            "last_updated_date": "23/01/2026",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-assessment-cardiovascular-safety-anticancer-medicinal-products"
        },
        {
            "title": "Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations",
            "category": "Human",
            "first_published_date": "23/02/2024",
            "last_updated_date": "18/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/allergen-products-development-immunotherapy-allergy-diagnosis-moderate-low-sized-study-populations"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome",
            "category": "Human",
            "first_published_date": "21/09/2006",
            "last_updated_date": "12/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-patients-acute-respiratory-distress-syndrome"
        },
        {
            "title": "Stability testing for applications for variations to marketing authorisation",
            "category": "Human",
            "first_published_date": "09/04/2014",
            "last_updated_date": "12/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-testing-applications-variations-marketing-authorisation"
        },
        {
            "title": "Questions and answers on post approval change management protocols (human)",
            "category": "Human",
            "first_published_date": "13/04/2012",
            "last_updated_date": "11/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-post-approval-change-management-protocols-human"
        },
        {
            "title": "Radiopharmaceuticals",
            "category": "Human",
            "first_published_date": "26/11/2008",
            "last_updated_date": "10/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/radiopharmaceuticals"
        },
        {
            "title": "Dextrans",
            "category": "Human",
            "first_published_date": "19/11/2018",
            "last_updated_date": "09/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dextrans"
        },
        {
            "title": "Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'",
            "category": "Human",
            "first_published_date": "01/07/2003",
            "last_updated_date": "05/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use"
        },
        {
            "title": "Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU",
            "category": "Human",
            "first_published_date": "15/04/2014",
            "last_updated_date": "04/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of Parkinson's disease",
            "category": "Human",
            "first_published_date": "06/07/2012",
            "last_updated_date": "01/12/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-parkinsons-disease"
        },
        {
            "title": "Procedural advice for veterinary vaccine antigen master file (VAMF) certification - Procedural Guidance",
            "category": "Veterinary",
            "first_published_date": "12/11/2021",
            "last_updated_date": "28/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/procedural-advice-veterinary-vaccine-antigen-master-file-vamf-certification-procedural-guidance"
        },
        {
            "title": "Procedural advice for vaccine platform technology master file (vPTMF) certification - Procedural Guidance",
            "category": "Veterinary",
            "first_published_date": "20/05/2022",
            "last_updated_date": "28/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/procedural-advice-vaccine-platform-technology-master-file-vptmf-certification-procedural-guidance"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of epileptic disorders",
            "category": "Human",
            "first_published_date": "22/07/2010",
            "last_updated_date": "21/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-epileptic-disorders"
        },
        {
            "title": "Assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species",
            "category": "Veterinary",
            "first_published_date": "14/11/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-non-food-producing-animal-species"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF)",
            "category": "Human",
            "first_published_date": "30/09/2025",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-idiopathic-pulmonary-fibrosis-ipf"
        },
        {
            "title": "Development of new medicinal products for the treatment of ulcerative colitis",
            "category": "Human",
            "first_published_date": "14/01/2008",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-new-medicinal-products-treatment-ulcerative-colitis"
        },
        {
            "title": "Clinical investigation of medicinal products for the management of Crohn's disease",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-management-crohns-disease"
        },
        {
            "title": "ICH E21 guideline on inclusion of pregnant and breastfeeding individuals in clinical trials",
            "category": "Human",
            "first_published_date": "28/05/2025",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e21-guideline-inclusion-pregnant-breastfeeding-individuals-clinical-trials"
        },
        {
            "title": "Non-inferiority and equivalence comparisons in clinical trials",
            "category": "Human",
            "first_published_date": "13/11/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-inferiority-equivalence-comparisons-clinical-trials-0"
        },
        {
            "title": "Switching between superiority and non-inferiority",
            "category": "Human",
            "first_published_date": "27/07/2000",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/switching-between-superiority-non-inferiority"
        },
        {
            "title": "Non-inferiority and equivalence comparisons in clinical trials",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "13/11/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-inferiority-equivalence-comparisons-clinical-trials"
        },
        {
            "title": "Quality aspects of phage therapy medicinal products",
            "category": "Human",
            "first_published_date": "22/12/2023",
            "last_updated_date": "24/10/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-aspects-phage-therapy-medicinal-products"
        },
        {
            "title": "Non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation",
            "category": "Human",
            "first_published_date": "23/10/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-human-primates-safety-testing-human-medicinal-products-opportunities-3rs-implementation"
        },
        {
            "title": "ICH M14 guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines",
            "category": "Human",
            "first_published_date": "30/05/2024",
            "last_updated_date": "10/10/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines"
        },
        {
            "title": "VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing",
            "category": "Veterinary",
            "first_published_date": "19/11/2014",
            "last_updated_date": "02/10/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing"
        },
        {
            "title": "VICH GL22 Safety studies for veterinary drug residues in human food: reproduction studies",
            "category": "Veterinary",
            "first_published_date": "16/06/2004",
            "last_updated_date": "02/10/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl22-safety-studies-veterinary-drug-residues-human-food-reproduction-studies"
        },
        {
            "title": "VICH GL62 on target animal safety of veterinary monoclonal antibody products (VMAPs) St4",
            "category": "Veterinary",
            "first_published_date": "02/10/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl62-target-animal-safety-veterinary-monoclonal-antibody-products-vmaps-st4"
        },
        {
            "title": "In-use stability testing of veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/02/2002",
            "last_updated_date": "01/10/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-stability-testing-veterinary-medicinal-products"
        },
        {
            "title": "Clinical evaluation of medicinal products intended for treatment of hepatitis B",
            "category": "Human",
            "first_published_date": "23/02/2006",
            "last_updated_date": "30/09/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-medicinal-products-intended-treatment-hepatitis-b"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of psoriatic arthritis",
            "category": "Human",
            "first_published_date": "14/12/2006",
            "last_updated_date": "30/09/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-psoriatic-arthritis"
        },
        {
            "title": "The procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus",
            "category": "Veterinary",
            "first_published_date": "17/09/2015",
            "last_updated_date": "19/09/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-virus"
        },
        {
            "title": "Duration of immunity achieved by veterinary vaccines",
            "category": "Veterinary",
            "first_published_date": "01/10/2000",
            "last_updated_date": "19/09/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/duration-immunity-achieved-veterinary-vaccines"
        },
        {
            "title": "Everolimus product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "14/08/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/everolimus-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Deferasirox product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "18/12/2020",
            "last_updated_date": "14/08/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/deferasirox-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Good agricultural and collection practice for starting materials of herbal origin",
            "category": "Human;Herbal",
            "first_published_date": "20/02/2006",
            "last_updated_date": "12/08/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/good-agricultural-collection-practice-starting-materials-herbal-origin"
        },
        {
            "title": "Clinical investigation of medicines for the treatment of Alzheimer's disease",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "06/08/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicines-treatment-alzheimers-disease"
        },
        {
            "title": "Cholic acid product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "31/01/2018",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cholic-acid-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Dabrafenib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/07/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dabrafenib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Azacitidine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/07/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/azacitidine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Aprepitant product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/07/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/aprepitant-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Vortioxetine hydrobromide / vortioxetine lactate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vortioxetine-hydrobromide-vortioxetine-lactate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Zonisamide product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "25/05/2015",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/zonisamide-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Paclitaxel product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/07/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paclitaxel-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Colchicine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "08/03/2019",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/colchicine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ticagrelor product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ticagrelor-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Emtricitabine / rilpivirine / tenofovir disoproxil product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/emtricitabine-rilpivirine-tenofovir-disoproxil-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Rilpivirine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "28/07/2017",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/rilpivirine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Rivaroxaban product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/rivaroxaban-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Sitagliptin product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2015",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sitagliptin-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Tacrolimus granules product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "30/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/tacrolimus-granules-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Fingolimod product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "29/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/fingolimod-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Entecavir product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "29/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/entecavir-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Demonstration of efficacy for veterinary medicinal products containing anticoccidial substances",
            "category": "Veterinary",
            "first_published_date": "01/11/1992",
            "last_updated_date": "25/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances"
        },
        {
            "title": "Safety and residue data requirements for the establishment of maximum residue limits in minor species",
            "category": "Veterinary",
            "first_published_date": "25/02/2021",
            "last_updated_date": "24/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/safety-residue-data-requirements-establishment-maximum-residue-limits-minor-species"
        },
        {
            "title": "Requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD)",
            "category": "Human",
            "first_published_date": "22/01/2009",
            "last_updated_date": "21/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd"
        },
        {
            "title": "Dronedarone product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "28/07/2017",
            "last_updated_date": "10/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dronedarone-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Sirolimus product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/07/2015",
            "last_updated_date": "10/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sirolimus-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ibuprofen product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "03/08/2017",
            "last_updated_date": "01/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ibuprofen-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Dolutegravir product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "28/07/2017",
            "last_updated_date": "01/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dolutegravir-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Levothyroxine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "15/06/2020",
            "last_updated_date": "01/07/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/levothyroxine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ursodeoxycholic acid product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/12/2021",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ursodeoxycholic-acid-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Prasugrel product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/prasugrel-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Paracetamol product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "28/07/2017",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paracetamol-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Oseltamivir product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/oseltamivir-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Metformin  product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/06/2023",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/metformin-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Dabigatran etexilate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dabigatran-etexilate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Memantine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/04/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/memantine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Posaconazole product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/posaconazole-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Lessons learned from the COVID-19 pandemic: Scientific considerations on non-clinical aspects",
            "category": "Human",
            "first_published_date": "30/06/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lessons-learned-covid-19-pandemic-scientific-considerations-non-clinical-aspects"
        },
        {
            "title": "Lurasidone product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/06/2023",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lurasidone-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Apixaban product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/06/2018",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/apixaban-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Acenocoumarol product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "09/11/2020",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/acenocoumarol-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Voriconazole product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/07/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/voriconazole-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Tadalafil product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/06/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/tadalafil-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Repaglinide product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "30/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/repaglinide-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Quality aspects of pharmaceutical veterinary medicines for administration via drinking water",
            "category": "Veterinary",
            "first_published_date": "15/04/2005",
            "last_updated_date": "20/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water"
        },
        {
            "title": "Methodology of environmental risk assessment for ectoparasiticidal VMPs for cats and dogs",
            "category": "Veterinary",
            "first_published_date": "20/06/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/methodology-environmental-risk-assessment-ectoparasiticidal-vmps-cats-dogs"
        },
        {
            "title": "Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence",
            "category": "Human",
            "first_published_date": "03/05/2024",
            "last_updated_date": "17/06/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence"
        },
        {
            "title": "ICH M11 guideline, clinical study protocol template and technical specifications",
            "category": "Human",
            "first_published_date": "26/10/2022",
            "last_updated_date": "23/05/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m11-guideline-clinical-study-protocol-template-technical-specifications"
        },
        {
            "title": "Consumer safety of active substances of immunological veterinary medicinal products acting against endogenous targets",
            "category": "Veterinary",
            "first_published_date": "23/05/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/consumer-safety-active-substances-immunological-veterinary-medicinal-products-acting-against-endogenous-targets"
        },
        {
            "title": "ICH Q1 guideline on stability testing of drug substances and drug products",
            "category": "Human",
            "first_published_date": "30/04/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1-guideline-stability-testing-drug-substances-drug-products"
        },
        {
            "title": "Assessment of public health risks related to antimicrobial resistance acquired via the environment, resulting from the use of a veterinary medicinal product",
            "category": "Veterinary",
            "first_published_date": "16/04/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-public-health-risks-related-antimicrobial-resistance-acquired-environment-resulting-use-veterinary-medicinal-product"
        },
        {
            "title": "Evaluation of medicinal products indicated for treatment of bacterial infections",
            "category": "Human",
            "first_published_date": "22/04/2004",
            "last_updated_date": "14/04/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-medicinal-products-indicated-treatment-bacterial-infections"
        },
        {
            "title": "Template for the qualified person's (QP) declaration concerning good manufacturing practice compliance of active substance manufacture \"The QP declaration template\"",
            "category": "Human;Veterinary",
            "first_published_date": "17/06/2014",
            "last_updated_date": "11/04/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/template-qualified-persons-qp-declaration-concerning-good-manufacturing-practice-compliance-active-substance-manufacture-qp-declaration-template"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of depression",
            "category": "Human",
            "first_published_date": "30/05/2013",
            "last_updated_date": "11/04/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-depression"
        },
        {
            "title": "Tolvaptan product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "02/04/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/tolvaptan-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Scientific data requirements for plasma master file",
            "category": "Human",
            "first_published_date": "15/11/2006",
            "last_updated_date": "31/03/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/scientific-data-requirements-plasma-master-file"
        },
        {
            "title": "Development of a guideline on the quality aspects of mRNA vaccines",
            "category": "Human",
            "first_published_date": "23/06/2023",
            "last_updated_date": "31/03/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-guideline-quality-aspects-mrna-vaccines"
        },
        {
            "title": "Methylphenidate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/03/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/methylphenidate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Investigation of bioequivalence",
            "category": "Human",
            "first_published_date": "29/01/2010",
            "last_updated_date": "26/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-bioequivalence"
        },
        {
            "title": "ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms",
            "category": "Human",
            "first_published_date": "07/02/2023",
            "last_updated_date": "26/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms"
        },
        {
            "title": "Clinical evaluation of new vaccines",
            "category": "Human",
            "first_published_date": "18/10/2006",
            "last_updated_date": "26/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-new-vaccines"
        },
        {
            "title": "Demonstration of efficacy for veterinary medicinal products containing antimicrobial substances",
            "category": "Veterinary",
            "first_published_date": "03/02/2016",
            "last_updated_date": "21/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances"
        },
        {
            "title": "Conduct of efficacy studies for intramammary products for use in cattle",
            "category": "Veterinary",
            "first_published_date": "08/03/2000",
            "last_updated_date": "21/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/conduct-efficacy-studies-intramammary-products-use-cattle"
        },
        {
            "title": "Guideline on assessment and reporting of mechanistic models used in the context of model informed drug development",
            "category": "Human",
            "first_published_date": "14/02/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-assessment-reporting-mechanistic-models-used-context-model-informed-drug-development"
        },
        {
            "title": "Overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs",
            "category": "Veterinary",
            "first_published_date": "06/04/2018",
            "last_updated_date": "13/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/overview-current-regulatory-testing-requirements-veterinary-medicinal-products-opportunities-implementation-3rs"
        },
        {
            "title": "Overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs",
            "category": "Human",
            "first_published_date": "06/04/2018",
            "last_updated_date": "13/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/overview-current-regulatory-testing-requirements-medicinal-products-human-use-opportunities-implementation-3rs"
        },
        {
            "title": "Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "12/02/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/budesonide-gastro-resistant-hard-capsules-prolonged-release-properties-3-mg-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Budesonide, gastro-resistant hard capsules, 3 mg, gastro- resistant granules, 9 mg product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "12/02/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/budesonide-gastro-resistant-hard-capsules-3-mg-gastro-resistant-granules-9-mg-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "12/02/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Nilotinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "12/02/2025",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/nilotinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials",
            "category": "Human",
            "first_published_date": "21/02/2019",
            "last_updated_date": "06/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials"
        },
        {
            "title": "ICH Q8, Q9 and Q10 - questions and answers",
            "category": "Human",
            "first_published_date": "01/06/2009",
            "last_updated_date": "05/02/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q8-q9-q10-questions-answers"
        },
        {
            "title": "Assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animal species",
            "category": "Veterinary",
            "first_published_date": "04/03/2015",
            "last_updated_date": "24/01/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animal-species"
        },
        {
            "title": "Veterinary medicinal products for zootechnical purposes",
            "category": "Veterinary",
            "first_published_date": "01/03/1992",
            "last_updated_date": "24/01/2025",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/veterinary-medicinal-products-zootechnical-purposes"
        },
        {
            "title": "Trametinib product-specific bioequivalence guideline",
            "category": "Human",
            "first_published_date": "19/12/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/trametinib-product-specific-bioequivalence-guideline"
        },
        {
            "title": "ICH Q4B Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions",
            "category": "Human",
            "first_published_date": "01/11/2007",
            "last_updated_date": "18/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-evaluation-recommendation-pharmacopoeial-texts-use-ich-regions"
        },
        {
            "title": "ICH S7B Non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals",
            "category": "Human",
            "first_published_date": "31/05/2005",
            "last_updated_date": "17/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s7b-non-clinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation-human-pharmaceuticals"
        },
        {
            "title": "VICH GL8 Stability testing for medicated premixes",
            "category": "Veterinary",
            "first_published_date": "10/12/1999",
            "last_updated_date": "16/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl8-stability-testing-medicated-premixes"
        },
        {
            "title": "Live recombinant vector vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "01/12/2004",
            "last_updated_date": "13/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/live-recombinant-vector-vaccines-veterinary-use"
        },
        {
            "title": "Assessing the toxicological risk to human health and groundwater communities from veterinary pharmaceuticals in groundwater",
            "category": "Veterinary",
            "first_published_date": "24/02/2017",
            "last_updated_date": "13/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessing-toxicological-risk-human-health-groundwater-communities-veterinary-pharmaceuticals-groundwater"
        },
        {
            "title": "Clinical requirements for non replacement therapy in haemophilia A and B",
            "category": "Human",
            "first_published_date": "31/10/2023",
            "last_updated_date": "04/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-requirements-non-replacement-therapy-haemophilia-b"
        },
        {
            "title": "Clinical evaluation of medicinal products used in weight control",
            "category": "Human",
            "first_published_date": "15/11/2007",
            "last_updated_date": "03/12/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-medicinal-products-used-weight-control"
        },
        {
            "title": "Stability testing for applications for variations to a marketing authorisation for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "13/10/2023",
            "last_updated_date": "25/11/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-testing-applications-variations-marketing-authorisation-veterinary-medicinal-products"
        },
        {
            "title": "Quality data requirements for applications for biological veterinary medicinal products intended for limited markets",
            "category": "Veterinary",
            "first_published_date": "15/09/2023",
            "last_updated_date": "18/10/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-data-requirements-applications-biological-veterinary-medicinal-products-intended-limited-markets"
        },
        {
            "title": "Efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "20/07/2006",
            "last_updated_date": "18/10/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/efficacy-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23-regulation-eu-2019-6"
        },
        {
            "title": "Safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "15/09/2023",
            "last_updated_date": "18/10/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/safety-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23-regulation-eu-2019-6"
        },
        {
            "title": "Safety and efficacy data requirements for applications for immunological VMPs intended for limited markets but not eligible for authorisation under Art 23 of Reg (EU) 2019-6",
            "category": "Human",
            "first_published_date": "15/09/2023",
            "last_updated_date": "18/10/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/safety-efficacy-data-requirements-applications-immunological-vmps-intended-limited-markets-not-eligible-authorisation-under-art-23-reg-eu-2019-6"
        },
        {
            "title": "Clinical evaluation of therapeutic radiopharmaceuticals in oncology",
            "category": "Human",
            "first_published_date": "11/10/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-therapeutic-radiopharmaceuticals-oncology"
        },
        {
            "title": "Quality and equivalence of locally applied, locally acting cutaneous products",
            "category": "Human",
            "first_published_date": "22/04/2015",
            "last_updated_date": "01/10/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-equivalence-locally-applied-locally-acting-cutaneous-products"
        },
        {
            "title": "Use of Artificial Intelligence (AI) in the medicinal product lifecycle",
            "category": "Human",
            "first_published_date": "19/07/2023",
            "last_updated_date": "30/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-artificial-intelligence-ai-medicinal-product-lifecycle"
        },
        {
            "title": "Patient experience data (PED) reflection paper",
            "category": "Human",
            "first_published_date": "19/07/2023",
            "last_updated_date": "30/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/patient-experience-data-ped-reflection-paper"
        },
        {
            "title": "Efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/02/2021",
            "last_updated_date": "20/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/efficacy-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6"
        },
        {
            "title": "Data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/02/2021",
            "last_updated_date": "20/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6"
        },
        {
            "title": "Safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/02/2021",
            "last_updated_date": "20/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/safety-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6"
        },
        {
            "title": "Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation",
            "category": "Human",
            "first_published_date": "21/04/2023",
            "last_updated_date": "16/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation"
        },
        {
            "title": "Environmental risk assessment of medicinal products for human use",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "12/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-medicinal-products-human-use"
        },
        {
            "title": "Questions and answers on the guideline on the environmental risk assessment of medicinal products for human use",
            "category": "Human",
            "first_published_date": "11/04/2011",
            "last_updated_date": "11/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-guideline-environmental-risk-assessment-medicinal-products-human-use"
        },
        {
            "title": "Clinical development of medicinal products for the treatment and prevention of bipolar disorder",
            "category": "Human",
            "first_published_date": "26/04/2001",
            "last_updated_date": "09/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-treatment-prevention-bipolar-disorder"
        },
        {
            "title": "ICH guideline E11A on pediatric extrapolation",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "03/09/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-e11a-pediatric-extrapolation"
        },
        {
            "title": "Dossier requirements for anticancer medicinal products for dogs and cats",
            "category": "Veterinary",
            "first_published_date": "20/04/2009",
            "last_updated_date": "26/07/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dossier-requirements-anticancer-medicinal-products-dogs-cats"
        },
        {
            "title": "Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "26/07/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paliperidone-palmitate-depot-suspension-injection-every-3-months-175-263-350-525-mg-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Conduct of bioequivalence studies for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "20/04/2011",
            "last_updated_date": "26/07/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/conduct-bioequivalence-studies-veterinary-medicinal-products"
        },
        {
            "title": "Poorly extractable and/or non- radiolabelled substances",
            "category": "Veterinary",
            "first_published_date": "29/03/2016",
            "last_updated_date": "26/07/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/poorly-extractable-or-non-radiolabelled-substances"
        },
        {
            "title": "Determining the fate of veterinary medicinal products in manure",
            "category": "Veterinary",
            "first_published_date": "30/03/2011",
            "last_updated_date": "26/07/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/determining-fate-veterinary-medicinal-products-manure"
        },
        {
            "title": "Development and manufacture of oligonucleotides",
            "category": "Human",
            "first_published_date": "22/07/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-manufacture-oligonucleotides"
        },
        {
            "title": "Concept paper on the revision of the COVID-19 vaccines guidance documents",
            "category": "Human",
            "first_published_date": "01/07/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/concept-paper-revision-covid-19-vaccines-guidance-documents"
        },
        {
            "title": "Core summary of product characteristics for human plasma-derived and recombinant coagulation factor IX products",
            "category": "Human",
            "first_published_date": "22/12/2014",
            "last_updated_date": "28/06/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-recombinant-coagulation-factor-ix-products"
        },
        {
            "title": "Clinical investigation of recombinant and human plasma-derived factor IX products",
            "category": "Human",
            "first_published_date": "01/06/2015",
            "last_updated_date": "28/06/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-recombinant-human-plasma-derived-factor-ix-products"
        },
        {
            "title": "Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products",
            "category": "Human",
            "first_published_date": "28/06/2011",
            "last_updated_date": "31/05/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/creutzfeldt-jakob-disease-plasma-derived-urine-derived-medicinal-products"
        },
        {
            "title": "ICH M10 on bioanalytical method validation",
            "category": "Human",
            "first_published_date": "14/03/2019",
            "last_updated_date": "03/05/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m10-bioanalytical-method-validation"
        },
        {
            "title": "Risk assessment of medicinal products on human reproduction and lactation: from data to labelling",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "02/05/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling"
        },
        {
            "title": "Use of near infrared spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations",
            "category": "Human;Veterinary",
            "first_published_date": "05/06/2014",
            "last_updated_date": "02/05/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-near-infrared-spectroscopy-nirs-pharmaceutical-industry-data-requirements-new-submissions-variations"
        },
        {
            "title": "Development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations",
            "category": "Veterinary",
            "first_published_date": "26/04/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-guideline-safety-nanoparticles-context-establishment-maximum-residue-limits-veterinary-marketing-authorisations"
        },
        {
            "title": "Requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD)",
            "category": "Human",
            "first_published_date": "12/04/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd-0"
        },
        {
            "title": "Reflection papers on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)",
            "category": "Human",
            "first_published_date": "01/06/2017",
            "last_updated_date": "04/04/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-papers-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash"
        },
        {
            "title": "Proline",
            "category": "Human",
            "first_published_date": "19/11/2018",
            "last_updated_date": "13/03/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/proline"
        },
        {
            "title": "Liposomal amphotericin B product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/12/2021",
            "last_updated_date": "08/03/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/liposomal-amphotericin-b-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Non-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19",
            "category": "Human",
            "first_published_date": "22/02/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-evaluation-antiviral-medicinal-products-monoclonal-antibodies-prevention-treatment-covid-19"
        },
        {
            "title": "Plasmid DNA vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "01/03/2000",
            "last_updated_date": "26/01/2024",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/plasmid-dna-vaccines-veterinary-use"
        },
        {
            "title": "ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals - Step 5",
            "category": "Human",
            "first_published_date": "22/01/2024",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-pharmaceuticals-step-5"
        },
        {
            "title": "Assessment of SmPC section 5.1: A Guide for Assessors of Centralised Applications",
            "category": "Human",
            "first_published_date": "18/12/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-smpc-section-51-guide-assessors-centralised-applications"
        },
        {
            "title": "Acceptability of names for human medicinal products processed through the centralised procedure",
            "category": "Human",
            "first_published_date": "01/06/2016",
            "last_updated_date": "15/12/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/acceptability-names-human-medicinal-products-processed-through-centralised-procedure"
        },
        {
            "title": "Calculation of dose factor to be submitted to the Union Product Database (UPD)",
            "category": "Veterinary",
            "first_published_date": "13/10/2023",
            "last_updated_date": "15/12/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/calculation-dose-factor-be-submitted-union-product-database-upd"
        },
        {
            "title": "Conduct of pharmacokinetic studies in target animal species",
            "category": "Veterinary",
            "first_published_date": "08/03/2000",
            "last_updated_date": "15/12/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/conduct-pharmacokinetic-studies-target-animal-species"
        },
        {
            "title": "Bosutinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/06/2023",
            "last_updated_date": "28/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/bosutinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Pirfenidone product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/06/2023",
            "last_updated_date": "28/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pirfenidone-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Questions and answers on data requirements when transitioning to low global warming potential (LGWP) propellants in oral pressurised metered dose inhalers",
            "category": "Human",
            "first_published_date": "05/04/2023",
            "last_updated_date": "23/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-data-requirements-when-transitioning-low-global-warming-potential-lgwp-propellants-oral-pressurised-metered-dose-inhalers"
        },
        {
            "title": "Regulatory acceptance of 3R (replacement, reduction, refinement) testing approaches",
            "category": "Human;Veterinary",
            "first_published_date": "19/02/1997",
            "last_updated_date": "23/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/regulatory-acceptance-3r-replacement-reduction-refinement-testing-approaches"
        },
        {
            "title": "Fampridine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/06/2023",
            "last_updated_date": "22/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/fampridine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs",
            "category": "Veterinary",
            "first_published_date": "16/12/2022",
            "last_updated_date": "21/11/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-ectoparasiticidal-veterinary-medicinal-products-used-cats-dogs"
        },
        {
            "title": "VICH GL60 Good manufacturing practice for active ingredients used in veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "07/11/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl60-good-manufacturing-practice-active-ingredients-used-veterinary-medicinal-products"
        },
        {
            "title": "Influenza vaccines - non-clinical and clinical module",
            "category": "Human",
            "first_published_date": "31/07/2014",
            "last_updated_date": "31/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/influenza-vaccines-non-clinical-clinical-module"
        },
        {
            "title": "DNA and host cell protein impurities, routine testing versus validation studies",
            "category": "Human",
            "first_published_date": "10/06/1997",
            "last_updated_date": "19/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dna-host-cell-protein-impurities-routine-testing-versus-validation-studies"
        },
        {
            "title": "Quality, safety and efficacy of bacteriophages as veterinary medicines",
            "category": "Veterinary",
            "first_published_date": "28/01/2022",
            "last_updated_date": "13/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-safety-efficacy-bacteriophages-veterinary-medicines"
        },
        {
            "title": "Quality and safety aspects of RNA interference and RNA antisense oligonucleotide therapies as veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "28/01/2022",
            "last_updated_date": "13/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-safety-aspects-rna-interference-rna-antisense-oligonucleotide-therapies-veterinary-medicinal-products"
        },
        {
            "title": "Modelling and simulation: questions and answers",
            "category": "Human",
            "first_published_date": "21/11/2018",
            "last_updated_date": "06/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/modelling-simulation-questions-answers"
        },
        {
            "title": "ICH guideline E19 on a selective approach to safety data collection in specific late-stage pre-approval or post-approval clinical trials",
            "category": "Human",
            "first_published_date": "29/03/2019",
            "last_updated_date": "06/10/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval-clinical-trials"
        },
        {
            "title": "Development of a reflection paper on modern manufacturing techniques used for herbal preparations",
            "category": "Human;Herbal",
            "first_published_date": "17/08/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-reflection-paper-modern-manufacturing-techniques-used-herbal-preparations"
        },
        {
            "title": "Requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats",
            "category": "Veterinary",
            "first_published_date": "18/09/2015",
            "last_updated_date": "21/07/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-quality-production-control-safety-efficacy-allergen-products-use-horses-dogs-cats"
        },
        {
            "title": "Quality data requirements for applications for veterinary medicinal products other than biologicals intended for limited markets",
            "category": "Veterinary",
            "first_published_date": "21/07/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-data-requirements-applications-veterinary-medicinal-products-other-biologicals-intended-limited-markets"
        },
        {
            "title": "Development, production, characterisation and specifications for monoclonal antibodies and related products",
            "category": "Human",
            "first_published_date": "18/12/2008",
            "last_updated_date": "21/07/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-production-characterisation-specifications-monoclonal-antibodies-related-products"
        },
        {
            "title": "Availability and characteristics of diagnostic tests to improve the responsible use of antibiotics in animals",
            "category": "Veterinary",
            "first_published_date": "21/07/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/availability-characteristics-diagnostic-tests-improve-responsible-use-antibiotics-animals"
        },
        {
            "title": "Stability testing of existing active substances and related finished products",
            "category": "Veterinary",
            "first_published_date": "05/08/2008",
            "last_updated_date": "21/07/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-testing-existing-active-substances-related-finished-products"
        },
        {
            "title": "Excipients in the dossier for application for marketing authorisation for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/02/1999",
            "last_updated_date": "21/07/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/excipients-dossier-application-marketing-authorisation-veterinary-medicinal-products"
        },
        {
            "title": "ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk",
            "category": "Human",
            "first_published_date": "24/09/2014",
            "last_updated_date": "19/07/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk"
        },
        {
            "title": "Use of herbal medicinal products containing estragole",
            "category": "Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "09/06/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-estragole"
        },
        {
            "title": "ICH S5 (R3) Guideline on detection of reproductive and developmental toxicity for human pharmaceuticals",
            "category": "Human",
            "first_published_date": "30/09/1993",
            "last_updated_date": "22/05/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s5-r3-guideline-detection-reproductive-developmental-toxicity-human-pharmaceuticals"
        },
        {
            "title": "ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b",
            "category": "Human",
            "first_published_date": "24/06/2021",
            "last_updated_date": "20/04/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-step-2b"
        },
        {
            "title": "ICH Q5A(R2) Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin",
            "category": "Human;Veterinary",
            "first_published_date": "01/10/1997",
            "last_updated_date": "27/03/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q5ar2-guideline-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin"
        },
        {
            "title": "Quality of modified release dosage forms for veterinary use",
            "category": "Veterinary",
            "first_published_date": "01/07/2003",
            "last_updated_date": "20/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-modified-release-dosage-forms-veterinary-use"
        },
        {
            "title": "Declaration of storage conditions: 1. in the product information of pharmaceutical veterinary medicinal products, 2. for active substances (Annex)",
            "category": "Veterinary",
            "first_published_date": "20/12/2007",
            "last_updated_date": "20/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/declaration-storage-conditions-1-product-information-pharmaceutical-veterinary-medicinal-products-2-active-substances-annex"
        },
        {
            "title": "Quality aspects of single-dose veterinary spot-on products",
            "category": "Veterinary",
            "first_published_date": "11/02/2009",
            "last_updated_date": "20/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-aspects-single-dose-veterinary-spot-products"
        },
        {
            "title": "Additional quality requirements for products intended for incorporation into animal  feeding-stuffs (medicated premixes)",
            "category": "Veterinary",
            "first_published_date": "01/12/1996",
            "last_updated_date": "20/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/additional-quality-requirements-products-intended-incorporation-animal-feeding-stuffs-medicated-premixes"
        },
        {
            "title": "Parametric release",
            "category": "Veterinary",
            "first_published_date": "01/07/2016",
            "last_updated_date": "17/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/parametric-release"
        },
        {
            "title": "Control of impurities of pharmacopoeial substances: compliance with the European Pharmacopoeia general monograph “Substances for Pharmaceutical Use” and general chapter “Control of Impurities in Substances for Pharmaceutical Use”",
            "category": "Veterinary",
            "first_published_date": "01/03/2004",
            "last_updated_date": "17/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/control-impurities-pharmacopoeial-substances-compliance-european-pharmacopoeia-general-monograph-substances-pharmaceutical-use-general-chapter-control-impurities-substances-pharmaceutical-use"
        },
        {
            "title": "Chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances - Veterinary",
            "category": "Veterinary",
            "first_published_date": "17/11/2016",
            "last_updated_date": "17/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chemical-structure-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances-veterinary"
        },
        {
            "title": "Development pharmaceutics for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/08/1999",
            "last_updated_date": "17/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-pharmaceutics-veterinary-medicinal-products"
        },
        {
            "title": "Chemistry of active substances for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/10/2015",
            "last_updated_date": "17/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chemistry-active-substances-veterinary-medicinal-products"
        },
        {
            "title": "Adjuvants in vaccines for human use",
            "category": "Human",
            "first_published_date": "20/01/2005",
            "last_updated_date": "16/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adjuvants-vaccines-human-use"
        },
        {
            "title": "Need for a paediatric addendum of the guideline on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease",
            "category": "Human",
            "first_published_date": "31/10/2017",
            "last_updated_date": "14/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-prophylaxis-venous-thromboembolic-disease"
        },
        {
            "title": "ICH Q9 Quality risk management",
            "category": "Human",
            "first_published_date": "19/01/2006",
            "last_updated_date": "06/02/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q9-quality-risk-management"
        },
        {
            "title": "Open consultations",
            "category": "Human;Veterinary;Herbal",
            "first_published_date": "27/01/2023",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/news-events/open-consultations"
        },
        {
            "title": "Guidance for the application of Article 34 of Regulation (EU) 2019/6 - prescription status",
            "category": "Veterinary",
            "first_published_date": "25/03/2022",
            "last_updated_date": "27/01/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guidance-application-article-34-regulation-eu-2019-6-prescription-status"
        },
        {
            "title": "ICH guideline Q13 on continuous manufacturing of drug substances and drug products",
            "category": "Human",
            "first_published_date": "29/07/2021",
            "last_updated_date": "06/01/2023",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-q13-continuous-manufacturing-drug-substances-drug-products"
        },
        {
            "title": "Summary of product characteristics for antiparasitic veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "15/12/2017",
            "last_updated_date": "16/12/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/summary-product-characteristics-antiparasitic-veterinary-medicinal-products"
        },
        {
            "title": "Lanreotide acetate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/05/2022",
            "last_updated_date": "16/12/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lanreotide-acetate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "ICH E8 General considerations for clinical studies",
            "category": "Human",
            "first_published_date": "01/03/1998",
            "last_updated_date": "02/12/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e8-general-considerations-clinical-studies"
        },
        {
            "title": "Development and data requirements of potency tests for cell-based therapy products and the relation to clinical efficacy",
            "category": "Veterinary",
            "first_published_date": "28/01/2022",
            "last_updated_date": "18/11/2022",
            "url": "https://www.ema.europa.eu/en/development-data-requirements-potency-tests-cell-based-therapy-products-relation-clinical-efficacy"
        },
        {
            "title": "Criteria to be considered for the evaluation of new active substance (NAS) status of biological substances",
            "category": "Human",
            "first_published_date": "18/11/2022",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/criteria-be-considered-evaluation-new-active-substance-nas-status-biological-substances"
        },
        {
            "title": "Platform trials",
            "category": "Human",
            "first_published_date": "11/11/2022",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/platform-trials"
        },
        {
            "title": "Assessment of genotoxicity of herbal substances/preparations",
            "category": "Human;Herbal",
            "first_published_date": "11/05/2008",
            "last_updated_date": "31/10/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-genotoxicity-herbal-substances-preparations"
        },
        {
            "title": "Core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells",
            "category": "Human",
            "first_published_date": "30/07/2021",
            "last_updated_date": "26/10/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-smpc-labelling-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells"
        },
        {
            "title": "Bioanalytical method validation",
            "category": "Human",
            "first_published_date": "01/08/2011",
            "last_updated_date": "25/10/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/bioanalytical-method-validation"
        },
        {
            "title": "ICH guideline S1B(R1) on testing for carcinogenicity of pharmaceuticals",
            "category": "Human",
            "first_published_date": "30/09/1997",
            "last_updated_date": "10/10/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-s1br1-testing-carcinogenicity-pharmaceuticals"
        },
        {
            "title": "Antimicrobial-resistance surveillance as post-marketing authorisation commitment",
            "category": "Veterinary",
            "first_published_date": "21/10/2008",
            "last_updated_date": "16/09/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/antimicrobial-resistance-surveillance-post-marketing-authorisation-commitment"
        },
        {
            "title": "Boric acid and borates",
            "category": "Human",
            "first_published_date": "04/08/2015",
            "last_updated_date": "28/07/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/boric-acid-borates"
        },
        {
            "title": "Reflection paper on the use of measurable residual disease as a clinical endpoint in multiple myeloma studies",
            "category": "Human",
            "first_published_date": "06/08/2018",
            "last_updated_date": "12/07/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-paper-use-measurable-residual-disease-clinical-endpoint-multiple-myeloma-studies"
        },
        {
            "title": "Development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides in food of animal origin",
            "category": "Veterinary",
            "first_published_date": "30/06/2022",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-harmonised-approach-exposure-assessment-methodologies-residues-veterinary-medicinal-products-feed-additives-pesticides-food-animal-origin"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus",
            "category": "Human",
            "first_published_date": "29/06/2012",
            "last_updated_date": "28/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus"
        },
        {
            "title": "Olaparib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "16/12/2021",
            "last_updated_date": "27/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/olaparib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ibrutinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "16/12/2021",
            "last_updated_date": "27/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ibrutinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Enzalutamide product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "15/12/2021",
            "last_updated_date": "27/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/enzalutamide-product-specific-bioequivalence-guidance"
        },
        {
            "title": "VICH GL20 Efficacy of anthelmintics: specific recommendations for felines",
            "category": "Veterinary",
            "first_published_date": "30/07/2001",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl20-efficacy-anthelmintics-specific-recommendations-felines"
        },
        {
            "title": "VICH GL12 Efficacy of anthelmintics: specific recommendations for bovines",
            "category": "Veterinary",
            "first_published_date": "10/12/1999",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl12-efficacy-anthelmintics-specific-recommendations-bovines"
        },
        {
            "title": "VICH GL21 Efficacy of anthelmintics: specific recommendations for chickens",
            "category": "Veterinary",
            "first_published_date": "30/07/2001",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl21-efficacy-anthelmintics-specific-recommendations-chickens"
        },
        {
            "title": "VICH GL15 Efficacy of anthelmintics: specific recommendations for equines",
            "category": "Veterinary",
            "first_published_date": "30/07/2001",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl15-efficacy-anthelmintics-specific-recommendations-equines"
        },
        {
            "title": "VICH GL14 Efficacy of anthelmintics: specific requirements for caprines",
            "category": "Veterinary",
            "first_published_date": "10/12/1999",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl14-efficacy-anthelmintics-specific-requirements-caprines"
        },
        {
            "title": "VICH GL19 Efficacy of anthelmintics: specific recommendations for canines",
            "category": "Veterinary",
            "first_published_date": "30/07/2001",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl19-efficacy-anthelmintics-specific-recommendations-canines"
        },
        {
            "title": "VICH GL13 Efficacy of anthelmintics: specific requirements for ovines",
            "category": "Veterinary",
            "first_published_date": "10/12/1999",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl13-efficacy-anthelmintics-specific-requirements-ovines"
        },
        {
            "title": "VICH GL16 Efficacy of anthelmintics: specific requirements for porcines",
            "category": "Veterinary",
            "first_published_date": "30/07/2001",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl16-efficacy-anthelmintics-specific-requirements-porcines"
        },
        {
            "title": "VICH GL7 Efficacy of anthelmintics: general requirements",
            "category": "Veterinary",
            "first_published_date": "07/12/2000",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl7-efficacy-anthelmintics-general-requirements"
        },
        {
            "title": "Data requirements for veterinary medicinal products intended to reduce the risk of transmission of vector-borne pathogens in dogs and cats",
            "category": "Veterinary",
            "first_published_date": "18/11/2014",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-veterinary-medicinal-products-intended-reduce-risk-transmission-vector-borne-pathogens-dogs-cats"
        },
        {
            "title": "Requirements for the production and control of immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "21/06/2012",
            "last_updated_date": "24/06/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-production-control-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Evaluation of anticancer medicinal products",
            "category": "Human",
            "first_published_date": "11/01/2013",
            "last_updated_date": "24/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-anticancer-medicinal-products"
        },
        {
            "title": "Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements",
            "category": "Human",
            "first_published_date": "20/04/2016",
            "last_updated_date": "24/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-paediatric-specific-clinical-data-requirements"
        },
        {
            "title": "Data requirements for multi-strain dossiers for inactivated veterinary vaccines",
            "category": "Veterinary",
            "first_published_date": "18/03/2010",
            "last_updated_date": "20/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-multi-strain-dossiers-inactivated-veterinary-vaccines"
        },
        {
            "title": "Environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL38",
            "category": "Veterinary",
            "first_published_date": "17/11/2008",
            "last_updated_date": "20/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-gl38"
        },
        {
            "title": "Specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Veterinary;Herbal",
            "first_published_date": "28/09/2011",
            "last_updated_date": "12/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/specifications-test-procedures-acceptance-criteria-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Quality of herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Veterinary;Herbal",
            "first_published_date": "27/01/2012",
            "last_updated_date": "12/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "ICH Q3D Elemental impurities",
            "category": "Human",
            "first_published_date": "12/01/2015",
            "last_updated_date": "03/05/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3d-elemental-impurities"
        },
        {
            "title": "Impact of the war in Ukraine on methodological aspects of ongoing clinical trials",
            "category": "Human",
            "first_published_date": "13/04/2022",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/impact-war-ukraine-methodological-aspects-ongoing-clinical-trials"
        },
        {
            "title": "Interpretation of Article 72 of Regulation (EU) 2019/6 - Environmental safety documentation and environmental risk assessment of certain veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "15/10/2021",
            "last_updated_date": "25/03/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/interpretation-article-72-regulation-eu-2019-6-environmental-safety-documentation-environmental-risk-assessment-certain-veterinary-medicinal-products"
        },
        {
            "title": "Injection-site residues",
            "category": "Veterinary",
            "first_published_date": "01/10/2004",
            "last_updated_date": "25/03/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/injection-site-residues"
        },
        {
            "title": "Safety and residue data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market",
            "category": "Veterinary",
            "first_published_date": "20/07/2006",
            "last_updated_date": "25/03/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/safety-residue-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market"
        },
        {
            "title": "Determination of withdrawal periods for milk",
            "category": "Veterinary",
            "first_published_date": "01/03/2000",
            "last_updated_date": "25/03/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/determination-withdrawal-periods-milk"
        },
        {
            "title": "Determination of withdrawal periods for edible tissue",
            "category": "Veterinary",
            "first_published_date": "01/04/1996",
            "last_updated_date": "25/03/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/determination-withdrawal-periods-edible-tissue"
        },
        {
            "title": "Interpretation of Article 18(7) of Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/02/2021",
            "last_updated_date": "25/02/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/interpretation-article-187-regulation-eu-2019-6"
        },
        {
            "title": "Criteria for determining that an active substance is essential when considered in the context of Article 37(2)(j) of Regulation 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/02/2022",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/criteria-determining-active-substance-essential-when-considered-context-article-372j-regulation-2019-6"
        },
        {
            "title": "Clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)",
            "category": "Human",
            "first_published_date": "02/08/2010",
            "last_updated_date": "04/02/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig"
        },
        {
            "title": "Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg)",
            "category": "Human",
            "first_published_date": "18/12/2012",
            "last_updated_date": "04/02/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig"
        },
        {
            "title": "Ethanol",
            "category": "Human",
            "first_published_date": "24/02/2014",
            "last_updated_date": "31/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ethanol"
        },
        {
            "title": "Guideline on clinical trials with immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/06/2001",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-clinical-trials-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials",
            "category": "Human",
            "first_published_date": "31/03/2006",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-chemical-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials"
        },
        {
            "title": "Questions and answers on requirements for pre-clinical studies submitted in support of a marketing authorisation application for a veterinary medicinal product",
            "category": "Veterinary",
            "first_published_date": "16/12/2021",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-requirements-pre-clinical-studies-submitted-support-marketing-authorisation-application-veterinary-medicinal-product"
        },
        {
            "title": "Data requirements for vaccine antigen master files (VAMF)",
            "category": "Veterinary",
            "first_published_date": "29/01/2021",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-vaccine-antigen-master-files-vamf"
        },
        {
            "title": "Data requirements for vaccine platform technology master files (PTMF)",
            "category": "Veterinary",
            "first_published_date": "28/01/2021",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-vaccine-platform-technology-master-files-ptmf"
        },
        {
            "title": "Requirements for quality documentation concerning biological investigational medicinal products in clinical trials",
            "category": "Human",
            "first_published_date": "14/05/2012",
            "last_updated_date": "28/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials"
        },
        {
            "title": "EudraVigilance access policy for medicines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "14/12/2018",
            "last_updated_date": "04/01/2022",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/eudravigilance-access-policy-medicines-veterinary-use"
        },
        {
            "title": "Quality documentation for medicinal products when used with a medical device",
            "category": "Human",
            "first_published_date": "03/06/2019",
            "last_updated_date": "08/12/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-documentation-medicinal-products-when-used-medical-device"
        },
        {
            "title": "Guideline on registry-based studies",
            "category": "Human",
            "first_published_date": "26/10/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-registry-based-studies-0"
        },
        {
            "title": "Limited market products deemed not eligible for authorisation under Article 23 of Regulation 2019/6",
            "category": "Veterinary",
            "first_published_date": "15/10/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/limited-market-products-deemed-not-eligible-authorisation-under-article-23-regulation-2019-6"
        },
        {
            "title": "Dasatinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/07/2015",
            "last_updated_date": "07/10/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dasatinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs)",
            "category": "Herbal",
            "first_published_date": "22/12/2014",
            "last_updated_date": "01/10/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas"
        },
        {
            "title": "Lapatinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/06/2018",
            "last_updated_date": "22/09/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lapatinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Palbociclib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "08/02/2019",
            "last_updated_date": "22/09/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/palbociclib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Methods found suitable within the European Union for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "17/07/2015",
            "last_updated_date": "17/09/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/methods-found-suitable-within-european-union-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Higher tier testing to investigate the effects of parasiticidal veterinary medicinal products on dung fauna",
            "category": "Veterinary",
            "first_published_date": "17/09/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/higher-tier-testing-investigate-effects-parasiticidal-veterinary-medicinal-products-dung-fauna"
        },
        {
            "title": "Statistical methodology for the comparative assessment of quality attributes in drug development",
            "category": "Human",
            "first_published_date": "28/06/2013",
            "last_updated_date": "27/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/statistical-methodology-comparative-assessment-quality-attributes-drug-development"
        },
        {
            "title": "Specific efficacy requirements for ectoparasiticides in cattle",
            "category": "Veterinary",
            "first_published_date": "23/07/2004",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/specific-efficacy-requirements-ectoparasiticides-cattle"
        },
        {
            "title": "Specific efficacy requirements for ectoparasiticides in sheep",
            "category": "Veterinary",
            "first_published_date": "10/07/2002",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/specific-efficacy-requirements-ectoparasiticides-sheep"
        },
        {
            "title": "Demonstration of palatability of veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "23/07/2014",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-palatability-veterinary-medicinal-products"
        },
        {
            "title": "Demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish",
            "category": "Veterinary",
            "first_published_date": "17/05/2011",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-target-animal-safety-efficacy-veterinary-medicinal-products-intended-use-farmed-finfish"
        },
        {
            "title": "Promoting the authorisation of alternatives to antimicrobial veterinary medicinal products in the EU",
            "category": "Veterinary",
            "first_published_date": "18/10/2019",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/promoting-authorisation-alternatives-antimicrobial-veterinary-medicinal-products-eu"
        },
        {
            "title": "Statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals)",
            "category": "Veterinary",
            "first_published_date": "23/01/2012",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/statistical-principles-clinical-trials-veterinary-medicinal-products-pharmaceuticals"
        },
        {
            "title": "Conduct of efficacy studies for non-steroidal anti-inflammatory drugs (NSAIDs)",
            "category": "Veterinary",
            "first_published_date": "24/01/2014",
            "last_updated_date": "26/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs-nsaids"
        },
        {
            "title": "Manufacture of the finished dosage form (veterinary)",
            "category": "Veterinary",
            "first_published_date": "01/12/1995",
            "last_updated_date": "23/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/manufacture-finished-dosage-form-veterinary"
        },
        {
            "title": "Environmental risk assessment of veterinary medicinal products intended to be used in aquaculture",
            "category": "Veterinary",
            "first_published_date": "23/07/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-veterinary-medicinal-products-intended-be-used-aquaculture"
        },
        {
            "title": "Data requirements for adjuvants in vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "01/11/1996",
            "last_updated_date": "23/07/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-adjuvants-vaccines-veterinary-use"
        },
        {
            "title": "Concept paper for the revision of residues guidelines to align with the definitions for withdrawal periods provided in Regulation (EU) 2019/6",
            "category": "Veterinary",
            "first_published_date": "25/06/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/concept-paper-revision-residues-guidelines-align-definitions-withdrawal-periods-provided-regulation-eu-2019-6"
        },
        {
            "title": "ICH S1 Regulatory notice on changes to core guideline on rodent carcinogenicity testing of pharmaceuticals",
            "category": "Human",
            "first_published_date": "17/12/2012",
            "last_updated_date": "20/05/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s1-regulatory-notice-changes-core-guideline-rodent-carcinogenicity-testing-pharmaceuticals"
        },
        {
            "title": "Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME and certain marketing authorisation applications targeting an unmet medical need",
            "category": "Human",
            "first_published_date": "09/07/2008",
            "last_updated_date": "22/04/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/toolbox-guidance-scientific-elements-regulatory-tools-support-quality-data-packages-prime-certain-marketing-authorisation-applications-targeting-unmet-medical-need"
        },
        {
            "title": "ICH M4 Common technical document (CTD) for the registration of pharmaceuticals for human use - organisation of CTD",
            "category": "Human",
            "first_published_date": "01/02/2004",
            "last_updated_date": "19/03/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd"
        },
        {
            "title": "Antimicrobial resistance in the environment: considerations for current and future risk assessment of veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "21/11/2018",
            "last_updated_date": "01/03/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/antimicrobial-resistance-environment-considerations-current-future-risk-assessment-veterinary-medicinal-products"
        },
        {
            "title": "Use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health",
            "category": "Veterinary",
            "first_published_date": "21/09/2018",
            "last_updated_date": "01/03/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-aminopenicillins-their-beta-lactamase-inhibitor-combinations-animals-european-union-development-resistance-impact-human-animal-health"
        },
        {
            "title": "Quality and safety assessment for the plasma master file (PMF) certification with regard to donor deferral criteria for sexual risk behaviour",
            "category": "Human",
            "first_published_date": "26/02/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-safety-assessment-plasma-master-file-pmf-certification-regard-donor-deferral-criteria-sexual-risk-behaviour"
        },
        {
            "title": "Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2",
            "category": "Human",
            "first_published_date": "25/02/2021",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2"
        },
        {
            "title": "Sorafenib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/07/2015",
            "last_updated_date": "05/02/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sorafenib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "CVMP activities related to antimicrobials",
            "category": "Veterinary",
            "first_published_date": "20/12/2016",
            "last_updated_date": "02/02/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cvmp-activities-related-antimicrobials"
        },
        {
            "title": "Quality of water for pharmaceutical use",
            "category": "Human;Veterinary",
            "first_published_date": "01/05/2002",
            "last_updated_date": "01/02/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-water-pharmaceutical-use"
        },
        {
            "title": "Data Monitoring Committees issues",
            "category": "Human",
            "first_published_date": "01/08/2018",
            "last_updated_date": "29/01/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-monitoring-committees-issues"
        },
        {
            "title": "Dose review and adjustment of established veterinary antibiotics in the context summary of product characteristic (SPC) harmonisation",
            "category": "Veterinary",
            "first_published_date": "27/07/2018",
            "last_updated_date": "13/01/2021",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dose-review-adjustment-established-veterinary-antibiotics-context-summary-product-characteristic-spc-harmonisation"
        },
        {
            "title": "Quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells",
            "category": "Human",
            "first_published_date": "03/05/2012",
            "last_updated_date": "17/12/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically-modified-cells"
        },
        {
            "title": "ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs",
            "category": "Human",
            "first_published_date": "01/11/2005",
            "last_updated_date": "08/12/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e14-clinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs"
        },
        {
            "title": "Abiraterone acetate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/08/2016",
            "last_updated_date": "23/11/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/abiraterone-acetate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "EMA considerations on COVID-19 vaccine approval",
            "category": "Human",
            "first_published_date": "19/11/2020",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ema-considerations-covid-19-vaccine-approval"
        },
        {
            "title": "Pharmaceutical development of medicines for use in the older population",
            "category": "Human",
            "first_published_date": "05/04/2013",
            "last_updated_date": "22/10/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmaceutical-development-medicines-use-older-population"
        },
        {
            "title": "Guideline on registry-based studies",
            "category": "Human",
            "first_published_date": "24/09/2020",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-registry-based-studies"
        },
        {
            "title": "Stem cell-based products for veterinary use: Specific question on target animal safety addressed by CVMP/ADVENT",
            "category": "Veterinary",
            "first_published_date": "24/07/2020",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stem-cell-based-products-veterinary-use-specific-question-target-animal-safety-addressed-cvmp-advent"
        },
        {
            "title": "Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation",
            "category": "Human",
            "first_published_date": "29/07/2016",
            "last_updated_date": "01/07/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation"
        },
        {
            "title": "Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials",
            "category": "Human",
            "first_published_date": "25/03/2020",
            "last_updated_date": "29/06/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical-trials"
        },
        {
            "title": "Questions and answers on management of extraneous agents in immunological veterinary medicinal products (IVMPs)",
            "category": "Veterinary",
            "first_published_date": "26/06/2020",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-management-extraneous-agents-immunological-veterinary-medicinal-products-ivmps"
        },
        {
            "title": "Environmental risk assessment for parasiticide veterinary medicinal products used in companion animals",
            "category": "Veterinary",
            "first_published_date": "07/05/2020",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-parasiticide-veterinary-medicinal-products-used-companion-animals"
        },
        {
            "title": "Etonogestrel and ethinylestradiol vaginal delivery system product-specific bioequivalence",
            "category": "Human",
            "first_published_date": "27/05/2019",
            "last_updated_date": "01/04/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/etonogestrel-ethinylestradiol-vaginal-delivery-system-product-specific-bioequivalence"
        },
        {
            "title": "ICH Q12 Technical and regulatory considerations for pharmaceutical product lifecycle management",
            "category": "Human",
            "first_published_date": "18/12/2017",
            "last_updated_date": "04/03/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q12-technical-regulatory-considerations-pharmaceutical-product-lifecycle-management"
        },
        {
            "title": "ICH E9 statistical principles for clinical trials",
            "category": "Human",
            "first_published_date": "01/09/1998",
            "last_updated_date": "18/02/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e9-statistical-principles-clinical-trials"
        },
        {
            "title": "ICH M9 on biopharmaceutics classification system based biowaivers",
            "category": "Human",
            "first_published_date": "06/08/2018",
            "last_updated_date": "11/02/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m9-biopharmaceutics-classification-system-based-biowaivers"
        },
        {
            "title": "Assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "17/09/2015",
            "last_updated_date": "31/01/2020",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-persistent-bioaccumulative-toxic-pbt-or-very-persistent-very-bioaccumulative-vpvb-substances-veterinary-medicinal-products"
        },
        {
            "title": "Alectinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "08/02/2019",
            "last_updated_date": "19/12/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/alectinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "VICH GL58 stability testing of new veterinary drug substances and medicinal products in climatic zones III and IV",
            "category": "Veterinary",
            "first_published_date": "27/07/2018",
            "last_updated_date": "17/12/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl58-stability-testing-new-veterinary-drug-substances-medicinal-products-climatic-zones-iii-iv"
        },
        {
            "title": "Questions and answers on comparability considerations for advanced therapy medicinal products (ATMP)",
            "category": "Human",
            "first_published_date": "13/12/2019",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-comparability-considerations-advanced-therapy-medicinal-products-atmp"
        },
        {
            "title": "Limited market for veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "21/11/2019",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/limited-market-veterinary-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of gout",
            "category": "Human",
            "first_published_date": "14/06/2012",
            "last_updated_date": "14/11/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-gout"
        },
        {
            "title": "Pharmacokinetic and clinical evaluation of modified-release dosage forms",
            "category": "Human",
            "first_published_date": "27/11/2014",
            "last_updated_date": "29/10/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms"
        },
        {
            "title": "Gefitinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/06/2018",
            "last_updated_date": "15/10/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/gefitinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Ezetimibe product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/12/2018",
            "last_updated_date": "15/10/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ezetimibe-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Cabozantinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "17/12/2018",
            "last_updated_date": "15/10/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cabozantinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Investigation of medicinal products in the term and preterm neonate",
            "category": "Human",
            "first_published_date": "26/06/2009",
            "last_updated_date": "01/07/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-medicinal-products-term-preterm-neonate"
        },
        {
            "title": "Stem cell-based products for veterinary use: Specific questions on extraneous agents to be addressed by Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)",
            "category": "Veterinary",
            "first_published_date": "27/06/2016",
            "last_updated_date": "28/06/2019",
            "url": "https://www.ema.europa.eu/en/stem-cell-based-products-veterinary-use-specific-questions-extraneous-agents-be-addressed-ad-hoc"
        },
        {
            "title": "Stem cell-based products for veterinary use: specific questions on sterility to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)",
            "category": "Veterinary",
            "first_published_date": "26/02/2016",
            "last_updated_date": "28/06/2019",
            "url": "https://www.ema.europa.eu/en/stem-cell-based-products-veterinary-use-specific-questions-sterility-be-addressed-ad-hoc-expert"
        },
        {
            "title": "VICH GL36 Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish a microbiological ADI",
            "category": "Veterinary",
            "first_published_date": "25/07/2012",
            "last_updated_date": "03/04/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl36-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-microbiological-adi"
        },
        {
            "title": "VICH GL57 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species",
            "category": "Veterinary",
            "first_published_date": "26/01/2018",
            "last_updated_date": "03/04/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl57-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-species-marker-residue-depletion-studies-establish-product-withdrawal-periods-aquatic-species"
        },
        {
            "title": "Investigation of subgroups in confirmatory clinical trials",
            "category": "Human",
            "first_published_date": "03/02/2014",
            "last_updated_date": "14/03/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-subgroups-confirmatory-clinical-trials"
        },
        {
            "title": "Sterilisation of the medicinal product, active substance, excipient and primary container",
            "category": "Human;Veterinary",
            "first_published_date": "13/04/2016",
            "last_updated_date": "08/03/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sterilisation-medicinal-product-active-substance-excipient-primary-container"
        },
        {
            "title": "Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry",
            "category": "Human",
            "first_published_date": "28/02/2019",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt-registry"
        },
        {
            "title": "Adjustment for cross-over in estimating effects in oncology trials",
            "category": "Human",
            "first_published_date": "28/02/2019",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adjustment-cross-over-estimating-effects-oncology-trials"
        },
        {
            "title": "Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of  herbal medicinal products with PAs",
            "category": "Human;Herbal",
            "first_published_date": "09/06/2016",
            "last_updated_date": "28/02/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pas"
        },
        {
            "title": "Template for information exchange for the preparation of the assessment report supporting the establishment of European Union monographs and European Union list entries",
            "category": "Herbal",
            "first_published_date": "16/03/2016",
            "last_updated_date": "25/02/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/template-information-exchange-preparation-assessment-report-supporting-establishment-european-union-monographs-european-union-list-entries"
        },
        {
            "title": "Non-clinical documentation in applications for marketing authorisation / registration of well-established and traditional herbal medicinal products",
            "category": "Herbal",
            "first_published_date": "07/09/2006",
            "last_updated_date": "25/02/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-documentation-applications-marketing-authorisation-registration-well-established-traditional-herbal-medicinal-products"
        },
        {
            "title": "Octreotide acetate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/06/2018",
            "last_updated_date": "08/02/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/octreotide-acetate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "24/02/2017",
            "last_updated_date": "09/01/2019",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-control-dna-reactive-mutagenic-impurities-veterinary-medicinal-products"
        },
        {
            "title": "Allergen products development in moderate to low-sized study populations",
            "category": "Human",
            "first_published_date": "20/12/2018",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/allergen-products-development-moderate-low-sized-study-populations"
        },
        {
            "title": "Clinical development of fixed combination medicinal products",
            "category": "Human",
            "first_published_date": "19/02/2009",
            "last_updated_date": "17/12/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-fixed-combination-medicinal-products"
        },
        {
            "title": "Non-clinical requirements for radiopharmaceuticals",
            "category": "Human",
            "first_published_date": "01/08/2017",
            "last_updated_date": "22/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-requirements-radiopharmaceuticals"
        },
        {
            "title": "Off-label use of antimicrobials in veterinary medicine in the European Union",
            "category": "Veterinary",
            "first_published_date": "25/07/2017",
            "last_updated_date": "21/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/label-use-antimicrobials-veterinary-medicine-european-union"
        },
        {
            "title": "Sodium laurilsulfate",
            "category": "Human",
            "first_published_date": "04/08/2015",
            "last_updated_date": "19/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sodium-laurilsulfate"
        },
        {
            "title": "Aspartame and phenylalanine",
            "category": "Human",
            "first_published_date": "04/05/2016",
            "last_updated_date": "19/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/aspartame-phenylalanine"
        },
        {
            "title": "Polysorbates",
            "category": "Human",
            "first_published_date": "19/11/2018",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/polysorbates"
        },
        {
            "title": "Lactose",
            "category": "Human",
            "first_published_date": "19/11/2018",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lactose"
        },
        {
            "title": "Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines",
            "category": "Human",
            "first_published_date": "24/04/2001",
            "last_updated_date": "08/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-bovine-spongiform-encephalopathies-bse-vaccines"
        },
        {
            "title": "Questions and answers on the Haemagglutination Inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations",
            "category": "Human",
            "first_published_date": "01/02/2018",
            "last_updated_date": "08/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-haemagglutination-inhibition-hi-test-qualification-influenza-vaccine-inactivated-seed-preparations"
        },
        {
            "title": "Quality aspects included in the product information for vaccines for human use",
            "category": "Human",
            "first_published_date": "26/11/2003",
            "last_updated_date": "07/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-aspects-included-product-information-vaccines-human-use"
        },
        {
            "title": "Equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract",
            "category": "Human",
            "first_published_date": "01/11/1995",
            "last_updated_date": "07/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting-products-gastrointestinal-tract"
        },
        {
            "title": "Treatment and prophylaxis of respiratory syncytial virus (RSV) disease",
            "category": "Human",
            "first_published_date": "26/10/2016",
            "last_updated_date": "07/11/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/treatment-prophylaxis-respiratory-syncytial-virus-rsv-disease"
        },
        {
            "title": "Extrapolation of efficacy and safety in paediatric medicine development",
            "category": "Human",
            "first_published_date": "04/04/2016",
            "last_updated_date": "30/10/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/extrapolation-efficacy-safety-paediatric-medicine-development"
        },
        {
            "title": "Reflection paper on resistance in ectoparasites",
            "category": "Veterinary",
            "first_published_date": "21/09/2018",
            "last_updated_date": "21/09/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-paper-resistance-ectoparasites"
        },
        {
            "title": "The adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles",
            "category": "Human",
            "first_published_date": "19/09/2018",
            "last_updated_date": "19/09/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adequacy-mahalanobis-distance-assess-comparability-drug-dissolution-profiles"
        },
        {
            "title": "Biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor (Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues)",
            "category": "Human",
            "first_published_date": "22/02/2006",
            "last_updated_date": "15/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/biosimilar-medicinal-products-containing-recombinant-granulocyte-colony-stimulating-factor-annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active"
        },
        {
            "title": "Procedure for the review and revision of European Union herbal monographs and European Union list entries",
            "category": "Human;Herbal",
            "first_published_date": "14/08/2018",
            "last_updated_date": "14/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/procedure-review-revision-european-union-herbal-monographs-european-union-list-entries"
        },
        {
            "title": "Core summary for product characteristics for human albumin solution",
            "category": "Human",
            "first_published_date": "17/11/2005",
            "last_updated_date": "13/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-albumin-solution"
        },
        {
            "title": "Clinical investigation of recombinant and human plasma-derived factor VIII products",
            "category": "Human",
            "first_published_date": "11/02/2016",
            "last_updated_date": "13/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-recombinant-human-plasma-derived-factor-viii-products"
        },
        {
            "title": "Core summary of product characteristics for human plasma-derived and recombinant coagulation factor VIII products",
            "category": "Human",
            "first_published_date": "11/02/2016",
            "last_updated_date": "13/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-recombinant-coagulation-factor-viii-products"
        },
        {
            "title": "Vismodegib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "31/01/2018",
            "last_updated_date": "03/08/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vismodegib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Similar biological medicinal products containing recombinant erythropoietins",
            "category": "Human",
            "first_published_date": "14/04/2010",
            "last_updated_date": "23/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-recombinant-erythropoietins"
        },
        {
            "title": "Similar medicinal products containing somatropin (Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues)",
            "category": "Human",
            "first_published_date": "22/02/2006",
            "last_updated_date": "20/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-medicinal-products-containing-somatropin-annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-clinical-issues"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of axial spondyloarthritis",
            "category": "Human",
            "first_published_date": "23/04/2009",
            "last_updated_date": "13/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-axial-spondyloarthritis"
        },
        {
            "title": "Quality, preclinical and clinical aspects of gene therapy medicinal products",
            "category": "Human",
            "first_published_date": "24/04/2001",
            "last_updated_date": "13/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-preclinical-clinical-aspects-gene-therapy-medicinal-products"
        },
        {
            "title": "Regulatory requirements for the development of medicinal products for Acute Kidney Injury (AKI)",
            "category": "Human",
            "first_published_date": "09/07/2018",
            "last_updated_date": "09/07/2018",
            "url": "https://www.ema.europa.eu/en/regulatory-requirements-development-medicinal-products-acute-kidney-injury-aki-scientific-guideline"
        },
        {
            "title": "Use of aminoglycosides in animals in the European Union: development of resistance and impact on human and animal health",
            "category": "Veterinary",
            "first_published_date": "23/07/2014",
            "last_updated_date": "05/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-aminoglycosides-animals-european-union-development-resistance-impact-human-animal-health"
        },
        {
            "title": "Pegylated liposomal doxorubicin hydrochloride product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "05/07/2018",
            "last_updated_date": "05/07/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pegylated-liposomal-doxorubicin-hydrochloride-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Paliperidone product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "26/06/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paliperidone-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Dimethyl fumarate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "03/08/2017",
            "last_updated_date": "26/06/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dimethyl-fumarate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Availability of veterinary medicinal products - extrapolation of maximum residue limits",
            "category": "Veterinary",
            "first_published_date": "18/06/2018",
            "last_updated_date": "18/06/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/availability-veterinary-medicinal-products-extrapolation-maximum-residue-limits"
        },
        {
            "title": "ICH guideline E17 on general principles for planning and design of multi-regional clinical trials",
            "category": "Human",
            "first_published_date": "28/07/2016",
            "last_updated_date": "14/06/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-guideline-e17-general-principles-planning-design-multi-regional-clinical-trials"
        },
        {
            "title": "ICH S9 Non-clinical evaluation for anticancer pharmaceuticals",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "16/05/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s9-non-clinical-evaluation-anticancer-pharmaceuticals"
        },
        {
            "title": "Indications for veterinary vaccines",
            "category": "Veterinary",
            "first_published_date": "16/04/2018",
            "last_updated_date": "16/04/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/indications-veterinary-vaccines"
        },
        {
            "title": "Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs",
            "category": "Human",
            "first_published_date": "06/04/2018",
            "last_updated_date": "06/04/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guidance-individual-laboratories-transfer-quality-control-methods-validated-collaborative-trials-view-implementing-3rs"
        },
        {
            "title": "Public consultation concerning the European Union template for good manufacturing practice (GMP) non-compliance statement",
            "category": "Human",
            "first_published_date": "03/04/2018",
            "last_updated_date": "03/04/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/public-consultation-concerning-european-union-template-good-manufacturing-practice-gmp-non-compliance-statement"
        },
        {
            "title": "Core SmPC and package leaflet for sodium iodide (131 I) for therapeutic use",
            "category": "Human",
            "first_published_date": "22/03/2018",
            "last_updated_date": "22/03/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-smpc-package-leaflet-sodium-iodide-131-i-therapeutic-use"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of chronic heart failure",
            "category": "Human",
            "first_published_date": "16/12/1999",
            "last_updated_date": "01/03/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-chronic-heart-failure"
        },
        {
            "title": "Clinical investigation of new medicinal products for the treatment of acute coronary syndrome",
            "category": "Human",
            "first_published_date": "17/02/2000",
            "last_updated_date": "01/03/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome"
        },
        {
            "title": "Physical frailty: instruments for baseline characterisation of older populations in clinical trials",
            "category": "Human",
            "first_published_date": "21/12/2015",
            "last_updated_date": "22/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/physical-frailty-instruments-baseline-characterisation-older-populations-clinical-trials"
        },
        {
            "title": "Guideline on safety and efficacy follow-up and risk  management of advanced therapy medicinal products",
            "category": "Human",
            "first_published_date": "01/02/2018",
            "last_updated_date": "01/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products"
        },
        {
            "title": "Reflection paper on investigation of pharmacokinetics in the obese population",
            "category": "Human",
            "first_published_date": "01/02/2018",
            "last_updated_date": "01/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reflection-paper-investigation-pharmacokinetics-obese-population"
        },
        {
            "title": "Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to specifically address the clinical development of new agents to treat disease due to Mycobacterium Tuberculosis",
            "category": "Human",
            "first_published_date": "29/01/2010",
            "last_updated_date": "01/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-specifically-address-clinical-development-new-agents-treat-disease-due-mycobacterium-tuberculosis"
        },
        {
            "title": "Influenza vaccines - quality module",
            "category": "Human",
            "first_published_date": "02/06/2014",
            "last_updated_date": "01/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/influenza-vaccines-quality-module"
        },
        {
            "title": "Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products",
            "category": "Human",
            "first_published_date": "19/07/2007",
            "last_updated_date": "01/02/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational-medicinal-products"
        },
        {
            "title": "Agomelatine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "31/01/2018",
            "last_updated_date": "31/01/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/agomelatine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Posaconazole product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "31/01/2018",
            "last_updated_date": "31/01/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/posaconazole-product-specific-bioequivalence-guidance-0"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for technetium (99mTc) macrosalb",
            "category": "Human",
            "first_published_date": "24/01/2018",
            "last_updated_date": "24/01/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-technetium-99mtc-macrosalb"
        },
        {
            "title": "Use of methyl- and propylparaben as excipients in human medicinal products for oral use",
            "category": "Human",
            "first_published_date": "23/01/2018",
            "last_updated_date": "23/01/2018",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-methyl-propylparaben-excipients-human-medicinal-products-oral-use"
        },
        {
            "title": "Monoclonal antibodies for veterinary use: specific questions to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)",
            "category": "Veterinary",
            "first_published_date": "26/02/2016",
            "last_updated_date": "11/12/2017",
            "url": "https://www.ema.europa.eu/en/monoclonal-antibodies-veterinary-use-specific-questions-be-addressed-ad-hoc-expert-group-veterinary"
        },
        {
            "title": "Juvenile animal studies (JAS) and impact on anti-cancer medicine development and use in children",
            "category": "Human",
            "first_published_date": "30/11/2017",
            "last_updated_date": "30/11/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/juvenile-animal-studies-jas-impact-anti-cancer-medicine-development-use-children"
        },
        {
            "title": "Assessment of clinical safety and efficacy in the preparation of EU herbal monographs for well-established and traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "07/09/2006",
            "last_updated_date": "28/11/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-clinical-safety-efficacy-preparation-eu-herbal-monographs-well-established-traditional-herbal-medicinal-products"
        },
        {
            "title": "Allogenic mesenchymal stem cell-based products for veterinary use: specific questions on tumorigenicity",
            "category": "Veterinary",
            "first_published_date": "21/11/2017",
            "last_updated_date": "21/11/2017",
            "url": "https://www.ema.europa.eu/en/allogenic-mesenchymal-stem-cell-based-products-veterinary-use-specific-questions-tumorigenicity"
        },
        {
            "title": "Clinical development of medicinal products for the treatment of autism spectrum disorder (ASD)",
            "category": "Human",
            "first_published_date": "04/03/2016",
            "last_updated_date": "21/11/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-treatment-autism-spectrum-disorder-asd"
        },
        {
            "title": "Manufacture of the finished dosage form (human)",
            "category": "Human",
            "first_published_date": "01/04/1996",
            "last_updated_date": "17/11/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/manufacture-finished-dosage-form-human"
        },
        {
            "title": "Development of a reflection paper on new analytical methods/technologies in the quality control of herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "31/10/2017",
            "last_updated_date": "31/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-reflection-paper-new-analytical-methods-technologies-quality-control-herbal-medicinal-products"
        },
        {
            "title": "Sodium used as an excipient in medicinal products for human use",
            "category": "Human",
            "first_published_date": "24/06/2015",
            "last_updated_date": "10/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sodium-used-excipient-medicinal-products-human-use"
        },
        {
            "title": "Cyclodextrins",
            "category": "Human",
            "first_published_date": "01/12/2014",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cyclodextrins"
        },
        {
            "title": "Benzoic acid and benzoates",
            "category": "Human",
            "first_published_date": "24/02/2014",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/benzoic-acid-benzoates"
        },
        {
            "title": "Fragrances containing allergens",
            "category": "Human",
            "first_published_date": "04/05/2016",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/fragrances-containing-allergens"
        },
        {
            "title": "Fructose and sorbitol",
            "category": "Human",
            "first_published_date": "04/05/2016",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/fructose-sorbitol"
        },
        {
            "title": "Benzyl alcohol",
            "category": "Human",
            "first_published_date": "24/02/2014",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/benzyl-alcohol"
        },
        {
            "title": "Propylene glycol and esters",
            "category": "Human",
            "first_published_date": "01/12/2014",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/propylene-glycol-esters"
        },
        {
            "title": "Wheat starch containing gluten",
            "category": "Human",
            "first_published_date": "01/08/2014",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/wheat-starch-containing-gluten"
        },
        {
            "title": "Phosphates",
            "category": "Human",
            "first_published_date": "07/10/2017",
            "last_updated_date": "09/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/phosphates"
        },
        {
            "title": "ICH E18 Guideline on genomic sampling and management of genomic data",
            "category": "Human",
            "first_published_date": "01/02/2016",
            "last_updated_date": "06/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e18-guideline-genomic-sampling-management-genomic-data"
        },
        {
            "title": "ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population",
            "category": "Human",
            "first_published_date": "01/01/2001",
            "last_updated_date": "06/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population"
        },
        {
            "title": "ICH Q11 Development and manufacture of drug substances (chemical entities and biotechnological/biological entities)",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "06/10/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q11-development-manufacture-drug-substances-chemical-entities-biotechnological-biological-entities"
        },
        {
            "title": "Core summary of product characteristics and package leaflet for (68Ge/68Ga) generator",
            "category": "Human",
            "first_published_date": "01/06/2016",
            "last_updated_date": "08/09/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-package-leaflet-68ge-68ga-generator"
        },
        {
            "title": "Dissolution specification for generic oral immediate release products",
            "category": "Human;Veterinary",
            "first_published_date": "13/05/2016",
            "last_updated_date": "15/08/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dissolution-specification-generic-oral-immediate-release-products"
        },
        {
            "title": "Predictive biomarker-based assay development in the context of drug development and lifecycle",
            "category": "Human",
            "first_published_date": "28/07/2017",
            "last_updated_date": "28/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/predictive-biomarker-based-assay-development-context-drug-development-lifecycle"
        },
        {
            "title": "Co-development of pharmacogenomic biomarkers and assays in the context of drug development",
            "category": "Human",
            "first_published_date": "12/07/2011",
            "last_updated_date": "28/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/co-development-pharmacogenomic-biomarkers-assays-context-drug-development"
        },
        {
            "title": "ICH E2B (R3) Electronic transmission of individual case safety reports (ICSRs) - data elements and message specification - implementation guide",
            "category": "Human",
            "first_published_date": "01/09/2005",
            "last_updated_date": "27/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements-message-specification-implementation-guide"
        },
        {
            "title": "Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "10/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Elvitegravir product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "10/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/elvitegravir-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Crizotinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "22/12/2016",
            "last_updated_date": "10/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/crizotinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Addendum on terms and concepts of pharmacogenomic features related to metabolism to the Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products",
            "category": "Human",
            "first_published_date": "07/07/2017",
            "last_updated_date": "07/07/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/addendum-terms-concepts-pharmacogenomic-features-related-metabolism-guideline-use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products"
        },
        {
            "title": "Authorisation of veterinary  medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances",
            "category": "Veterinary",
            "first_published_date": "26/02/2016",
            "last_updated_date": "23/05/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/authorisation-veterinary-medicinal-products-containing-potential-persistent-bioaccumulative-toxic-pbt-or-very-persistent-very-bioaccumulative-vpvb-substances"
        },
        {
            "title": "Role of pharmacokinetics in the development of medicinal products in the paediatric population",
            "category": "Human",
            "first_published_date": "28/06/2006",
            "last_updated_date": "04/05/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/role-pharmacokinetics-development-medicinal-products-paediatric-population"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for iopamidol 300",
            "category": "Human",
            "first_published_date": "26/04/2017",
            "last_updated_date": "26/04/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-iopamidol-300"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for iopamidol 370",
            "category": "Human",
            "first_published_date": "26/04/2017",
            "last_updated_date": "26/04/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-iopamidol-370"
        },
        {
            "title": "Anthelmintic resistance",
            "category": "Veterinary",
            "first_published_date": "23/04/2014",
            "last_updated_date": "24/04/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/anthelmintic-resistance"
        },
        {
            "title": "Data requirements for immunological veterinary medicinal products intended for minor use or minor species",
            "category": "Veterinary",
            "first_published_date": "23/04/2010",
            "last_updated_date": "21/04/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-species"
        },
        {
            "title": "Investigation of drug interactions",
            "category": "Human",
            "first_published_date": "01/07/2012",
            "last_updated_date": "07/04/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-drug-interactions"
        },
        {
            "title": "Multiplicity issues in clinical trials",
            "category": "Human",
            "first_published_date": "19/09/2002",
            "last_updated_date": "31/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/multiplicity-issues-clinical-trials"
        },
        {
            "title": "Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - condition specific guidance",
            "category": "Human",
            "first_published_date": "15/02/2016",
            "last_updated_date": "31/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/appendix-4-guideline-evaluation-anticancer-medicinal-products-man-condition-specific-guidance"
        },
        {
            "title": "Influenza vaccines – submission and procedural requirements",
            "category": "Human",
            "first_published_date": "02/07/2015",
            "last_updated_date": "14/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/influenza-vaccines-submission-procedural-requirements"
        },
        {
            "title": "Exenatide product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/08/2016",
            "last_updated_date": "03/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/exenatide-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Vandetanib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/08/2016",
            "last_updated_date": "03/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vandetanib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Vemurafenib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/08/2016",
            "last_updated_date": "03/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vemurafenib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Paliperidone palmitate product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "01/08/2016",
            "last_updated_date": "03/03/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paliperidone-palmitate-product-specific-bioequivalence-guidance"
        },
        {
            "title": "VICH GL56 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods",
            "category": "Veterinary",
            "first_published_date": "24/02/2017",
            "last_updated_date": "24/02/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl56-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-species-study-design-recommendations-residue-studies-honey-establishing-mrls-withdrawal-periods"
        },
        {
            "title": "Development of a guideline on quality requirements of medicinal products containing a device component for delivery or use of the medicinal product",
            "category": "Human",
            "first_published_date": "16/02/2017",
            "last_updated_date": "16/02/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-guideline-quality-requirements-medicinal-products-containing-device-component-delivery-or-use-medicinal-product"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for nanocolloidal technetium (99mTc) albumin",
            "category": "Human",
            "first_published_date": "01/02/2016",
            "last_updated_date": "03/02/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-nanocolloidal-technetium-99mtc-albumin"
        },
        {
            "title": "Setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities",
            "category": "Human;Veterinary",
            "first_published_date": "24/11/2014",
            "last_updated_date": "09/01/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities"
        },
        {
            "title": "Levodopa/carbidopa/entacapone product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "03/01/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/levodopa-carbidopa-entacapone-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Pazopanib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "30/11/2016",
            "last_updated_date": "03/01/2017",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pazopanib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Clinical development of medicinal products intended for the treatment of pain",
            "category": "Human",
            "first_published_date": "21/12/2015",
            "last_updated_date": "22/12/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-intended-treatment-pain"
        },
        {
            "title": "Scientific guidance on post-authorisation efficacy studies",
            "category": "Human",
            "first_published_date": "06/11/2015",
            "last_updated_date": "22/12/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/scientific-guidance-post-authorisation-efficacy-studies"
        },
        {
            "title": "VICH GL54 Studies to evaluate the safety of residues of  veterinary drugs in human food: general approach to establish an acute reference dose (ARfD)",
            "category": "Veterinary",
            "first_published_date": "20/03/2015",
            "last_updated_date": "19/12/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-acute-reference-dose-arfd"
        },
        {
            "title": "Veterinary medicinal products for fluid therapy in case of diarrhoea",
            "category": "Veterinary",
            "first_published_date": "01/03/1992",
            "last_updated_date": "16/12/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/veterinary-medicinal-products-fluid-therapy-case-diarrhoea"
        },
        {
            "title": "Clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "29/11/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-non-surgical-patients"
        },
        {
            "title": "Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure",
            "category": "Human",
            "first_published_date": "10/06/2015",
            "last_updated_date": "18/11/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paediatric-addendum-chmp-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure"
        },
        {
            "title": "Lenalidomide product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "01/11/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/lenalidomide-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Asenapine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "27/05/2016",
            "last_updated_date": "01/11/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/asenapine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Points to consider for assessors - New factor VIII and factor IX products: potency determination for labelling and assays for testing post-infusion samples",
            "category": "Human",
            "first_published_date": "07/10/2016",
            "last_updated_date": "07/10/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/points-consider-assessors-new-factor-viii-factor-ix-products-potency-determination-labelling-assays-testing-post-infusion-samples"
        },
        {
            "title": "Core summary of products characteristics for human anti-D immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "20/09/2007",
            "last_updated_date": "29/09/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-products-characteristics-human-anti-d-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Core summary of product characteristics for human anti-D immunoglobulin for intravenous use",
            "category": "Human",
            "first_published_date": "20/09/2007",
            "last_updated_date": "29/09/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-anti-d-immunoglobulin-intravenous-use"
        },
        {
            "title": "Production and quality control of animal immunoglobins and immunosera for human use",
            "category": "Human",
            "first_published_date": "24/07/2002",
            "last_updated_date": "05/08/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/production-quality-control-animal-immunoglobins-immunosera-human-use"
        },
        {
            "title": "Potency testing of cell-based immunotherapy medicinal products for the treatment of cancer",
            "category": "Human",
            "first_published_date": "10/10/2007",
            "last_updated_date": "05/08/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer"
        },
        {
            "title": "Clinical development of medicinal products for the treatment of cystic fibrosis",
            "category": "Human",
            "first_published_date": "29/11/2009",
            "last_updated_date": "01/08/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-treatment-cystic-fibrosis"
        },
        {
            "title": "VICH GL52 Bioequivalence: blood level bioequivalence study",
            "category": "Veterinary",
            "first_published_date": "17/09/2015",
            "last_updated_date": "01/08/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl52-bioequivalence-blood-level-bioequivalence-study"
        },
        {
            "title": "Use of herbal medicinal products containing pulegone and menthofuran",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "27/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-pulegone-menthofuran"
        },
        {
            "title": "Use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products",
            "category": "Human",
            "first_published_date": "27/07/2000",
            "last_updated_date": "26/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-pharmacokinetics-pharmacodynamics-development-antibacterial-medicinal-products"
        },
        {
            "title": "EMEA implementation of electronic submissions: statements of intent",
            "category": "Human",
            "first_published_date": "26/07/2016",
            "last_updated_date": "26/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/emea-implementation-electronic-submissions-statements-intent"
        },
        {
            "title": "Stem cell-based products for veterinary use: specific questions on target animal safety to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)",
            "category": "Veterinary",
            "first_published_date": "25/07/2016",
            "last_updated_date": "25/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stem-cell-based-products-veterinary-use-specific-questions-target-animal-safety-be-addressed-ad-hoc-expert-group-veterinary-novel-therapies-advent"
        },
        {
            "title": "ICH: M 4: Common technical document for the registration of pharmaceuticals for human use: Organisation of CTD",
            "category": "Human",
            "first_published_date": "22/07/2016",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m-4-common-technical-document-registration-pharmaceuticals-human-use-organisation-ctd"
        },
        {
            "title": "Preclinical pharmacological and toxicological testing of vaccines",
            "category": "Human",
            "first_published_date": "17/12/1997",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/preclinical-pharmacological-toxicological-testing-vaccines"
        },
        {
            "title": "ICH: M 4 S: Common technical document for the registration of pharmaceuticals for human use - Safety",
            "category": "Human",
            "first_published_date": "22/07/2016",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m-4-s-common-technical-document-registration-pharmaceuticals-human-use-safety"
        },
        {
            "title": "Practical guidelines relating to non-eCTD electronic submissions",
            "category": "Human",
            "first_published_date": "22/07/2016",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/practical-guidelines-relating-non-ectd-electronic-submissions"
        },
        {
            "title": "ICH: M 4 E: Common technical document for the registration of pharmaceuticals for human use - Efficacy",
            "category": "Human",
            "first_published_date": "22/07/2016",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m-4-e-common-technical-document-registration-pharmaceuticals-human-use-efficacy"
        },
        {
            "title": "ICH: M 4 Q: Common technical document for the registration of pharmaceuticals for human use - Quality",
            "category": "Human",
            "first_published_date": "22/07/2016",
            "last_updated_date": "22/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m-4-q-common-technical-document-registration-pharmaceuticals-human-use-quality"
        },
        {
            "title": "Active substance master file procedure",
            "category": "Human;Veterinary",
            "first_published_date": "13/07/2016",
            "last_updated_date": "13/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/active-substance-master-file-procedure"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of lipid disorders",
            "category": "Human",
            "first_published_date": "16/01/2014",
            "last_updated_date": "08/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-lipid-disorders"
        },
        {
            "title": "Clinical investigation on medicinal products in the treatment of hypertension",
            "category": "Human",
            "first_published_date": "21/12/2010",
            "last_updated_date": "08/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-hypertension"
        },
        {
            "title": "Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function",
            "category": "Human",
            "first_published_date": "02/02/2016",
            "last_updated_date": "01/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy",
            "category": "Human",
            "first_published_date": "21/12/2015",
            "last_updated_date": "01/07/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-duchenne-becker-muscular-dystrophy"
        },
        {
            "title": "Polycyclic aromatic hydrocarbons in herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "29/06/2016",
            "last_updated_date": "29/06/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/polycyclic-aromatic-hydrocarbons-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for gadoteric acid",
            "category": "Human",
            "first_published_date": "01/06/2016",
            "last_updated_date": "01/06/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-gadoteric-acid"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for fluorodopa (18F)",
            "category": "Human",
            "first_published_date": "01/06/2016",
            "last_updated_date": "01/06/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-fluorodopa-18f"
        },
        {
            "title": "ICH S3A Toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers",
            "category": "Human",
            "first_published_date": "31/05/2016",
            "last_updated_date": "31/05/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s3a-toxicokinetics-assessment-systemic-exposure-toxicity-studies-questions-answers"
        },
        {
            "title": "Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man - the use of patient-reported outcome (PRO) measures in oncology studies",
            "category": "Human",
            "first_published_date": "22/04/2016",
            "last_updated_date": "22/04/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/appendix-2-guideline-evaluation-anticancer-medicinal-products-man-use-patient-reported-outcome-pro-measures-oncology-studies"
        },
        {
            "title": "Quality Working Party questions and answers on API mix",
            "category": "Human;Veterinary",
            "first_published_date": "21/04/2016",
            "last_updated_date": "21/04/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-working-party-questions-answers-api-mix"
        },
        {
            "title": "Core summary of product characteristics and package leaflet for gadopentetate dimeglumine",
            "category": "Human",
            "first_published_date": "14/03/2016",
            "last_updated_date": "14/03/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-package-leaflet-gadopentetate-dimeglumine"
        },
        {
            "title": "Limitations to the use of ethylene oxide in the manufacture of medicinal products (human)",
            "category": "Veterinary",
            "first_published_date": "10/03/2016",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/limitations-use-ethylene-oxide-manufacture-medicinal-products-human"
        },
        {
            "title": "VICH GL55 Harmonisation of criteria to waive target animal batch safety testing for live vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "26/02/2016",
            "last_updated_date": "26/02/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl55-harmonisation-criteria-waive-target-animal-batch-safety-testing-live-vaccines-veterinary-use"
        },
        {
            "title": "Assessment of the effect of antimicrobial substances on dairy starter cultures",
            "category": "Human",
            "first_published_date": "01/02/2016",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-effect-antimicrobial-substances-dairy-starter-cultures"
        },
        {
            "title": "VICH GL49 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: validation of analytical methods used in residue depletion studies",
            "category": "Veterinary",
            "first_published_date": "27/02/2015",
            "last_updated_date": "01/01/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl49-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-animals-validation-analytical-methods-used-residue-depletion-studies"
        },
        {
            "title": "Core summary of product characteristics for plasma-derived fibrin sealant/haemostatic products",
            "category": "Human",
            "first_published_date": "25/06/2015",
            "last_updated_date": "01/01/2016",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-plasma-derived-fibrin-sealant-haemostatic-products"
        },
        {
            "title": "Chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances",
            "category": "Human",
            "first_published_date": "19/12/2015",
            "last_updated_date": "19/12/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chemical-structure-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances"
        },
        {
            "title": "Guidance on statistical principles for clinical trials for immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "18/12/2015",
            "last_updated_date": "18/12/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/guidance-statistical-principles-clinical-trials-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of asthma",
            "category": "Human",
            "first_published_date": "15/12/2015",
            "last_updated_date": "15/12/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-asthma"
        },
        {
            "title": "Non-clinical local tolerance testing of medicinal products",
            "category": "Human",
            "first_published_date": "27/11/2015",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-local-tolerance-testing-medicinal-products"
        },
        {
            "title": "Key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products",
            "category": "Human",
            "first_published_date": "20/11/2015",
            "last_updated_date": "20/11/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/key-aspects-use-pharmacogenomic-methodologies-pharmacovigilance-evaluation-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis",
            "category": "Human",
            "first_published_date": "20/11/2015",
            "last_updated_date": "20/11/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis"
        },
        {
            "title": "Use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "17/09/2015",
            "last_updated_date": "17/09/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-heat-treatment-inactivate-endogenous-retroviruses-live-immunological-veterinary-medicinal-products"
        },
        {
            "title": "Replacement of cell lines used for the production of immunological veterinary medicinal products (IVMPs)",
            "category": "Veterinary",
            "first_published_date": "17/09/2015",
            "last_updated_date": "17/09/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/replacement-cell-lines-used-production-immunological-veterinary-medicinal-products-ivmps"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of chronic constipation",
            "category": "Human",
            "first_published_date": "14/09/2015",
            "last_updated_date": "14/09/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-chronic-constipation"
        },
        {
            "title": "Core summary of product characteristics for human fibrinogen products",
            "category": "Human",
            "first_published_date": "24/07/2015",
            "last_updated_date": "24/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-fibrinogen-products"
        },
        {
            "title": "Clinical investigation of hepatitis B immunoglobulins",
            "category": "Human",
            "first_published_date": "24/07/2015",
            "last_updated_date": "24/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-hepatitis-b-immunoglobulins"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for sodium fluoride (18F)",
            "category": "Human",
            "first_published_date": "20/07/2015",
            "last_updated_date": "20/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-sodium-fluoride-18f"
        },
        {
            "title": "Sunitinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/07/2015",
            "last_updated_date": "07/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/sunitinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Capecitabine product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/07/2015",
            "last_updated_date": "07/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/capecitabine-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Viral safety of plasma-derived medicinal products with respect to hepatitis E virus",
            "category": "Human",
            "first_published_date": "01/07/2015",
            "last_updated_date": "01/07/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus"
        },
        {
            "title": "Use of cocrystals of active substances in medicinal products",
            "category": "Human;Veterinary",
            "first_published_date": "16/06/2015",
            "last_updated_date": "16/06/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-cocrystals-active-substances-medicinal-products"
        },
        {
            "title": "Assessment of cardiovascular safety profile of medicinal products",
            "category": "Human",
            "first_published_date": "12/06/2015",
            "last_updated_date": "12/06/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-cardiovascular-safety-profile-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of acute heart failure",
            "category": "Human",
            "first_published_date": "10/06/2015",
            "last_updated_date": "10/06/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-acute-heart-failure"
        },
        {
            "title": "Telithromycin product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "07/06/2015",
            "last_updated_date": "07/06/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/telithromycin-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Microbiological aspects of herbal medicinal products and traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "05/06/2015",
            "last_updated_date": "05/06/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/microbiological-aspects-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Adventitious agent safety of urine-derived medicinal products",
            "category": "Human",
            "first_published_date": "29/05/2015",
            "last_updated_date": "29/05/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adventitious-agent-safety-urine-derived-medicinal-products"
        },
        {
            "title": "Removal of the target animal batch safetytest (TABST) from European Pharmacopoeia monographs",
            "category": "Veterinary",
            "first_published_date": "18/05/2015",
            "last_updated_date": "18/05/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/removal-target-animal-batch-safetytest-tabst-european-pharmacopoeia-monographs"
        },
        {
            "title": "Imatinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "10/04/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/imatinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Carglumic acid product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "10/04/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/carglumic-acid-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Erlotinib product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "10/04/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/erlotinib-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Miglustat product-specific bioequivalence guidance",
            "category": "Human",
            "first_published_date": "10/04/2015",
            "last_updated_date": "10/04/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/miglustat-product-specific-bioequivalence-guidance"
        },
        {
            "title": "Questions and answers on quality of herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "10/11/2010",
            "last_updated_date": "07/04/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-quality-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of multiple sclerosis",
            "category": "Human",
            "first_published_date": "31/03/2015",
            "last_updated_date": "31/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-multiple-sclerosis"
        },
        {
            "title": "Adjustment for baseline covariates in clinical trials",
            "category": "Human",
            "first_published_date": "27/03/2015",
            "last_updated_date": "27/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adjustment-baseline-covariates-clinical-trials"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis",
            "category": "Human",
            "first_published_date": "27/03/2015",
            "last_updated_date": "27/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-lupus-nephritis"
        },
        {
            "title": "Data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product",
            "category": "Human;Herbal",
            "first_published_date": "27/03/2015",
            "last_updated_date": "27/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-innovator-medicinal-product"
        },
        {
            "title": "Paediatric addendum to the guideline on clinical investigation on medicinal products in the treatment of hypertension",
            "category": "Human",
            "first_published_date": "26/03/2015",
            "last_updated_date": "26/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-hypertension"
        },
        {
            "title": "Non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues",
            "category": "Human",
            "first_published_date": "11/03/2015",
            "last_updated_date": "11/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin-insulin-analogues"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for (99Mo/99mTc) generator",
            "category": "Human",
            "first_published_date": "06/03/2015",
            "last_updated_date": "06/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-99mo-99mtc-generator"
        },
        {
            "title": "ICH M8 Electronic common technical document (eCTD) v4.0 draft ICH implementation guide v2.0",
            "category": "Human",
            "first_published_date": "03/03/2015",
            "last_updated_date": "03/03/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m8-electronic-common-technical-document-ectd-v40-draft-ich-implementation-guide-v20"
        },
        {
            "title": "VICH GL48 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: Marker-residue-depletion studies to establish product withdrawal periods",
            "category": "Veterinary",
            "first_published_date": "27/02/2015",
            "last_updated_date": "27/02/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl48-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-animals-marker-residue-depletion-studies-establish-product-withdrawal-periods"
        },
        {
            "title": "Pharmacokinetic studies in man",
            "category": "Human",
            "first_published_date": "01/02/2015",
            "last_updated_date": "01/02/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacokinetic-studies-man"
        },
        {
            "title": "Clinical investigation of corticosteroids intended for use on the skin",
            "category": "Human",
            "first_published_date": "01/02/2015",
            "last_updated_date": "01/02/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-corticosteroids-intended-use-skin"
        },
        {
            "title": "Medicinal products (non-steroidal anti-inflammatory compounds) for the treatment of chronic disorders",
            "category": "Human",
            "first_published_date": "01/02/2015",
            "last_updated_date": "01/02/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/medicinal-products-non-steroidal-anti-inflammatory-compounds-treatment-chronic-disorders"
        },
        {
            "title": "Risk of antimicrobial resistance transfer from companion animals",
            "category": "Veterinary",
            "first_published_date": "30/01/2015",
            "last_updated_date": "30/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-antimicrobial-resistance-transfer-companion-animals"
        },
        {
            "title": "Risk characterisation and assessment of maximum residue limits (MRL) for biocides",
            "category": "Veterinary",
            "first_published_date": "30/01/2015",
            "last_updated_date": "30/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-characterisation-assessment-maximum-residue-limits-mrl-biocides"
        },
        {
            "title": "ICH M2 Electronic common technical document (eCTD) - file format criteria",
            "category": "Human",
            "first_published_date": "12/01/2015",
            "last_updated_date": "12/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m2-electronic-common-technical-document-ectd-file-format-criteria"
        },
        {
            "title": "Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues",
            "category": "Human",
            "first_published_date": "09/01/2015",
            "last_updated_date": "09/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-clinical-issues"
        },
        {
            "title": "Assessment of the risk of transmission of animal spongiform encephalopathy agents by master seed materials used in the production of veterinary vaccines",
            "category": "Veterinary",
            "first_published_date": "16/02/2001",
            "last_updated_date": "01/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-risk-transmission-animal-spongiform-encephalopathy-agents-master-seed-materials-used-production-veterinary-vaccines"
        },
        {
            "title": "Evaluation of bovine spongiform encephalopathies (BSE)-risk via the use of materials of bovine origin in or during the manufacture of vaccines",
            "category": "Human",
            "first_published_date": "28/02/2001",
            "last_updated_date": "01/01/2015",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-bovine-spongiform-encephalopathies-bse-risk-use-materials-bovine-origin-or-during-manufacture-vaccines"
        },
        {
            "title": "Quality of transdermal patches",
            "category": "Human",
            "first_published_date": "16/12/2014",
            "last_updated_date": "16/12/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-transdermal-patches"
        },
        {
            "title": "Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies",
            "category": "Human",
            "first_published_date": "15/12/2014",
            "last_updated_date": "15/12/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies"
        },
        {
            "title": "Clinical aspects related to tissue engineered products",
            "category": "Human",
            "first_published_date": "11/12/2014",
            "last_updated_date": "11/12/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-aspects-related-tissue-engineered-products"
        },
        {
            "title": "Use of phthalates as excipients in human medicinal products",
            "category": "Human",
            "first_published_date": "24/11/2014",
            "last_updated_date": "24/11/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-phthalates-excipients-human-medicinal-products"
        },
        {
            "title": "Compliance of authorised equine influenza vaccines with OIE requirements",
            "category": "Veterinary",
            "first_published_date": "19/11/2014",
            "last_updated_date": "19/11/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/compliance-authorised-equine-influenza-vaccines-oie-requirements"
        },
        {
            "title": "Data requirements for changes to the strain composition of authorised equine influenza vaccines in line with OIE recommendations",
            "category": "Veterinary",
            "first_published_date": "19/11/2014",
            "last_updated_date": "19/11/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-changes-strain-composition-authorised-equine-influenza-vaccines-line-oie-recommendations"
        },
        {
            "title": "Evaluation of medicinal products for the treatment of irritable bowel syndrome",
            "category": "Human",
            "first_published_date": "25/09/2014",
            "last_updated_date": "25/09/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-medicinal-products-treatment-irritable-bowel-syndrome"
        },
        {
            "title": "Quality of oral modified release products",
            "category": "Human",
            "first_published_date": "31/07/2014",
            "last_updated_date": "31/07/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-oral-modified-release-products"
        },
        {
            "title": "Transferring quality control methods validated in collaborative trials to a product/laboratory specific context",
            "category": "Veterinary",
            "first_published_date": "18/07/2014",
            "last_updated_date": "18/07/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/transferring-quality-control-methods-validated-collaborative-trials-product-laboratory-specific-context"
        },
        {
            "title": "Clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation",
            "category": "Human",
            "first_published_date": "16/07/2014",
            "last_updated_date": "16/07/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-prevention-stroke-systemic-embolic-events-patients-non-valvular-atrial-fibrillation"
        },
        {
            "title": "ICH M5 Data elements and standards for drug dictionaries",
            "category": "Human",
            "first_published_date": "14/07/2014",
            "last_updated_date": "14/07/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m5-data-elements-standards-drug-dictionaries"
        },
        {
            "title": "Clinical investigation of medicinal products to prevent development/slow progression of chronic renal insufficiency",
            "category": "Human",
            "first_published_date": "01/07/2014",
            "last_updated_date": "01/07/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-prevent-development-slow-progression-chronic-renal-insufficiency"
        },
        {
            "title": "Benzalkonium chloride",
            "category": "Human",
            "first_published_date": "30/06/2014",
            "last_updated_date": "30/06/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/benzalkonium-chloride"
        },
        {
            "title": "Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues",
            "category": "Human",
            "first_published_date": "03/06/2014",
            "last_updated_date": "03/06/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues"
        },
        {
            "title": "Gaucher disease: a strategic collaborative approach from the European Medicines Agency and Food and Drug Administration",
            "category": "Human",
            "first_published_date": "14/05/2014",
            "last_updated_date": "14/05/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/gaucher-disease-strategic-collaborative-approach-european-medicines-agency-food-drug-administration"
        },
        {
            "title": "Quality of essential oils as active substances in herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "02/05/2014",
            "last_updated_date": "02/05/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-essential-oils-active-substances-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission",
            "category": "Human",
            "first_published_date": "30/04/2014",
            "last_updated_date": "30/04/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/process-validation-manufacture-biotechnology-derived-active-substances-data-be-provided-regulatory-submission"
        },
        {
            "title": "Clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia",
            "category": "Human",
            "first_published_date": "28/03/2014",
            "last_updated_date": "28/03/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-intended-treatment-chronic-primary-immune-thrombocytopenia"
        },
        {
            "title": "Declaration of the quantitative composition/potency labelling of biological medicinalproducts that contain modified proteins as active substance",
            "category": "Human",
            "first_published_date": "21/03/2014",
            "last_updated_date": "21/03/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/declaration-quantitative-composition-potency-labelling-biological-medicinalproducts-contain-modified-proteins-active-substance"
        },
        {
            "title": "Use of porcine trypsin used in the manufacture of human biological medicinal products",
            "category": "Human",
            "first_published_date": "28/02/2014",
            "last_updated_date": "28/02/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-porcine-trypsin-used-manufacture-human-biological-medicinal-products"
        },
        {
            "title": "Process validation for finished products – information and data to be provided in regulatory submissions",
            "category": "Human;Veterinary",
            "first_published_date": "28/02/2014",
            "last_updated_date": "28/02/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/process-validation-finished-products-information-data-be-provided-regulatory-submissions"
        },
        {
            "title": "Use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health",
            "category": "Veterinary",
            "first_published_date": "20/02/2014",
            "last_updated_date": "20/02/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-pleuromutilins-food-producing-animals-european-union-development-resistance-impact-human-animal-health"
        },
        {
            "title": "ICH Q4B Annex 6 Uniformity of dosage unites general chapter",
            "category": "Human",
            "first_published_date": "31/01/2014",
            "last_updated_date": "31/01/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-6-uniformity-dosage-unites-general-chapter"
        },
        {
            "title": "ICH S10 Photosafety evaluation of pharmaceuticals",
            "category": "Human",
            "first_published_date": "31/01/2014",
            "last_updated_date": "31/01/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s10-photosafety-evaluation-pharmaceuticals"
        },
        {
            "title": "Development of block-copolymer-micelle medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "10/01/2014",
            "last_updated_date": "10/01/2014",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-block-copolymer-micelle-medicinal-products"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for technetium (99mTc) sestamibi",
            "category": "Human",
            "first_published_date": "17/12/2013",
            "last_updated_date": "17/12/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-technetium-99mtc-sestamibi"
        },
        {
            "title": "Use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "03/12/2013",
            "last_updated_date": "03/12/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-recovered-recycled-solvents-manufacture-herbal-preparations-use-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Routes of administration of vaccines to poultry",
            "category": "Veterinary",
            "first_published_date": "18/11/2013",
            "last_updated_date": "18/11/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/routes-administration-vaccines-poultry"
        },
        {
            "title": "Injection-site residues: considerations for risk assessment and residue surveillance",
            "category": "Veterinary",
            "first_published_date": "18/10/2013",
            "last_updated_date": "18/10/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/injection-site-residues-considerations-risk-assessment-residue-surveillance"
        },
        {
            "title": "ICH Q4B Annex 12 Analytical sieving",
            "category": "Human",
            "first_published_date": "01/09/2013",
            "last_updated_date": "01/09/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-12-analytical-sieving"
        },
        {
            "title": "Surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products",
            "category": "Human;Herbal",
            "first_published_date": "15/08/2013",
            "last_updated_date": "15/08/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/surface-coatings-general-issues-consideration-regarding-parenteral-administration-coated-nanomedicine-products"
        },
        {
            "title": "Management of clinical risks deriving from insertional mutagenesis",
            "category": "Human",
            "first_published_date": "01/08/2013",
            "last_updated_date": "01/08/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/management-clinical-risks-deriving-insertional-mutagenesis"
        },
        {
            "title": "Pharmaceutical development of medicines for paediatric use",
            "category": "Human",
            "first_published_date": "31/07/2013",
            "last_updated_date": "31/07/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmaceutical-development-medicines-paediatric-use"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of urinary incontinence",
            "category": "Human",
            "first_published_date": "19/07/2013",
            "last_updated_date": "19/07/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-urinary-incontinence"
        },
        {
            "title": "Use of starting materials and intermediates collected from different sources in the manufacturing of non-recombinant biological medicinal products",
            "category": "Human",
            "first_published_date": "12/07/2013",
            "last_updated_date": "12/07/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-starting-materials-intermediates-collected-different-sources-manufacturing-non-recombinant-biological-medicinal-products"
        },
        {
            "title": "Quality of biological active substances produced by transgene expression in animals",
            "category": "Human",
            "first_published_date": "10/06/2013",
            "last_updated_date": "10/06/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-biological-active-substances-produced-transgene-expression-animals"
        },
        {
            "title": "Potential medication errors in the context of benefit risk balance and risk minimisation measures",
            "category": "Human",
            "first_published_date": "07/06/2013",
            "last_updated_date": "07/06/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/potential-medication-errors-context-benefit-risk-balance-risk-minimisation-measures"
        },
        {
            "title": "Use of bovine serum in the manufacture of human biological medicinal products",
            "category": "Human",
            "first_published_date": "04/06/2013",
            "last_updated_date": "04/06/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-bovine-serum-manufacture-human-biological-medicinal-products"
        },
        {
            "title": "ICH Q4B Annex 14 Bacterial endotoxins tests",
            "category": "Human",
            "first_published_date": "17/12/2012",
            "last_updated_date": "16/05/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-14-bacterial-endotoxins-tests"
        },
        {
            "title": "Extrapolation of efficacy and safety in medicine development",
            "category": "Human",
            "first_published_date": "23/04/2013",
            "last_updated_date": "23/04/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/extrapolation-efficacy-safety-medicine-development"
        },
        {
            "title": "Assessing the toxicological risk to humans and the environment of veterinary pharmaceuticals in groundwater",
            "category": "Veterinary",
            "first_published_date": "19/04/2013",
            "last_updated_date": "19/04/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessing-toxicological-risk-humans-environment-veterinary-pharmaceuticals-groundwater"
        },
        {
            "title": "Immune tolerance induction in haemophilia A patients with inhibitors",
            "category": "Human",
            "first_published_date": "26/03/2013",
            "last_updated_date": "26/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/immune-tolerance-induction-haemophilia-patients-inhibitors"
        },
        {
            "title": "Data requirements for intravenous liposomal products developed with reference to an innovator liposomal product",
            "category": "Human;Herbal",
            "first_published_date": "13/03/2013",
            "last_updated_date": "13/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product"
        },
        {
            "title": "VICH GL50 Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use",
            "category": "Veterinary",
            "first_published_date": "13/03/2013",
            "last_updated_date": "13/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl50-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use"
        },
        {
            "title": "VICH GL34 Biologicals: testing for the detection of Mycoplasma contamination",
            "category": "Veterinary",
            "first_published_date": "13/03/2013",
            "last_updated_date": "13/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl34-biologicals-testing-detection-mycoplasma-contamination"
        },
        {
            "title": "VICH GL51 Quality: statistical evaluation of stability data",
            "category": "Veterinary",
            "first_published_date": "13/03/2013",
            "last_updated_date": "13/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl51-quality-statistical-evaluation-stability-data"
        },
        {
            "title": "Risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products",
            "category": "Human",
            "first_published_date": "08/03/2013",
            "last_updated_date": "08/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-based-approach-according-annex-i-part-iv-directive-2001-83-ec-applied-advanced-therapy-medicinal-products"
        },
        {
            "title": "Similar biological medicinal products containing recombinant follicle-stimulating hormone",
            "category": "Human",
            "first_published_date": "06/03/2013",
            "last_updated_date": "06/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-recombinant-follicle-stimulating-hormone"
        },
        {
            "title": "Similar biological medicinal products containing interferon beta",
            "category": "Human",
            "first_published_date": "06/03/2013",
            "last_updated_date": "06/03/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-interferon-beta"
        },
        {
            "title": "ICH E16 Genomic biomarkers related to drug response: context, structure and format of qualification submissions",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "11/02/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions"
        },
        {
            "title": "ICH Q4B Annex 13 Bulk density and tapped density of powders",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "11/02/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-13-bulk-density-tapped-density-powders"
        },
        {
            "title": "ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals",
            "category": "Human",
            "first_published_date": "11/02/2013",
            "last_updated_date": "11/02/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals"
        },
        {
            "title": "ICH Q4B Annex 7 Dissolution test",
            "category": "Human",
            "first_published_date": "01/02/2013",
            "last_updated_date": "01/02/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-7-dissolution-test"
        },
        {
            "title": "Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials",
            "category": "Human",
            "first_published_date": "11/01/2013",
            "last_updated_date": "11/01/2013",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using-progression-free-survival-pfs-or-disease-free-survival-dfs-confirmatory-trials"
        },
        {
            "title": "ICH E2C (R2) Periodic benefit-risk evaluation report",
            "category": "Human",
            "first_published_date": "31/12/2012",
            "last_updated_date": "31/12/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2c-r2-periodic-benefit-risk-evaluation-report"
        },
        {
            "title": "CHMP Safety Working Party's response to the Paediatric Committee regarding the use of PEGylated drug products in the paediatric population",
            "category": "Human",
            "first_published_date": "23/11/2012",
            "last_updated_date": "23/11/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-drug-products-paediatric-population"
        },
        {
            "title": "Considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative, or a different salt or ester as new active substance in relation to the relevant reference active substance",
            "category": "Human",
            "first_published_date": "21/11/2012",
            "last_updated_date": "21/11/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/considerations-given-designation-single-stereo-isomeric-form-enantiomer-complex-derivative-or-different-salt-or-ester-new-active-substance-relation-relevant-reference-active-substance"
        },
        {
            "title": "Approach to establish a pharmacological acceptable daily intake (ADI)",
            "category": "Veterinary",
            "first_published_date": "19/11/2012",
            "last_updated_date": "19/11/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/approach-establish-pharmacological-acceptable-daily-intake-adi"
        },
        {
            "title": "Clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia",
            "category": "Human",
            "first_published_date": "09/10/2012",
            "last_updated_date": "09/10/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia"
        },
        {
            "title": "Paediatric addendum to the guideline on clinical investigation of medicinal products in the treatment of lipid disorders",
            "category": "Human",
            "first_published_date": "02/10/2012",
            "last_updated_date": "02/10/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders"
        },
        {
            "title": "Involvement of children and young people at the Paediatric Committee",
            "category": "Human",
            "first_published_date": "17/09/2012",
            "last_updated_date": "17/09/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/involvement-children-young-people-paediatric-committee"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for fludeoxyglucose (18F)",
            "category": "Human",
            "first_published_date": "14/08/2012",
            "last_updated_date": "14/08/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-fludeoxyglucose-18f"
        },
        {
            "title": "Clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)",
            "category": "Human",
            "first_published_date": "08/08/2012",
            "last_updated_date": "08/08/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease-copd"
        },
        {
            "title": "Setting specifications for related impurities in antibiotics",
            "category": "Human;Veterinary",
            "first_published_date": "13/07/2012",
            "last_updated_date": "13/07/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/setting-specifications-related-impurities-antibiotics"
        },
        {
            "title": "Use of herbal medicinal products containing thujone",
            "category": "Human;Herbal",
            "first_published_date": "20/02/2012",
            "last_updated_date": "29/06/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-thujone"
        },
        {
            "title": "Non-pharmacopoeial reference standards for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "27/06/2012",
            "last_updated_date": "27/06/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-pharmacopoeial-reference-standards-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues",
            "category": "Human",
            "first_published_date": "15/06/2012",
            "last_updated_date": "15/06/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-clinical-issues"
        },
        {
            "title": "Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use",
            "category": "Human",
            "first_published_date": "15/06/2012",
            "last_updated_date": "15/06/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use"
        },
        {
            "title": "Clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery",
            "category": "Human",
            "first_published_date": "30/05/2012",
            "last_updated_date": "30/05/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-patients-undergoing-high-vte-risk-surgery"
        },
        {
            "title": "Real time release testing",
            "category": "Human;Veterinary",
            "first_published_date": "14/04/2012",
            "last_updated_date": "14/04/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/real-time-release-testing"
        },
        {
            "title": "DNA vaccines",
            "category": "Human",
            "first_published_date": "30/03/2012",
            "last_updated_date": "30/03/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dna-vaccines"
        },
        {
            "title": "Pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems (non-polymeric surfactants)",
            "category": "Human",
            "first_published_date": "20/03/2012",
            "last_updated_date": "20/03/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmaceutical-development-intravenous-medicinal-products-containing-active-substances-solubilised-micellar-systems-non-polymeric-surfactants"
        },
        {
            "title": "Non-clinical and clinical development for oral and topical HIV pre-exposure prophylaxis (PrEP)",
            "category": "Human",
            "first_published_date": "15/03/2012",
            "last_updated_date": "15/03/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-development-oral-topical-hiv-pre-exposure-prophylaxis-prep"
        },
        {
            "title": "Risk-mitigation measures related to the environmental risk assessment of veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "15/03/2012",
            "last_updated_date": "15/03/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-mitigation-measures-related-environmental-risk-assessment-veterinary-medicinal-products"
        },
        {
            "title": "ICH Quality Implementation Working Group: points to consider for ICH Q8/Q9/Q10 guidelines",
            "category": "Human",
            "first_published_date": "01/03/2012",
            "last_updated_date": "01/03/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-quality-implementation-working-group-points-consider-ich-q8-q9-q10-guidelines"
        },
        {
            "title": "Necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population",
            "category": "Human",
            "first_published_date": "28/02/2012",
            "last_updated_date": "28/02/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/necessity-initiatives-stimulate-conduct-clinical-studies-herbal-medicinal-products-paediatric-population"
        },
        {
            "title": "Introducing a review and update of existing EU guidelines on residues studies to bring these into line with the VICH metabolism and residues guidelines GL46 to 49",
            "category": "Veterinary",
            "first_published_date": "15/02/2012",
            "last_updated_date": "15/02/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/introducing-review-update-existing-eu-guidelines-residues-studies-bring-these-line-vich-metabolism-residues-guidelines-gl46-49"
        },
        {
            "title": "Design modifications of gene therapy medicinal products during development",
            "category": "Human",
            "first_published_date": "09/02/2012",
            "last_updated_date": "09/02/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/design-modifications-gene-therapy-medicinal-products-during-development"
        },
        {
            "title": "Use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products",
            "category": "Human",
            "first_published_date": "02/02/2012",
            "last_updated_date": "02/02/2012",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products"
        },
        {
            "title": "Warning on transmissible agents in summary of product characteristics and package leaflets for plasma-derived medicinal products",
            "category": "Human",
            "first_published_date": "14/12/2011",
            "last_updated_date": "14/12/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/warning-transmissible-agents-summary-product-characteristics-package-leaflets-plasma-derived-medicinal-products"
        },
        {
            "title": "ICH S2 (R1) Genotoxicity testing and data interpretation for pharmaceuticals intended for human use",
            "category": "Human",
            "first_published_date": "01/12/2011",
            "last_updated_date": "01/12/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s2-r1-genotoxicity-testing-data-interpretation-pharmaceuticals-intended-human-use"
        },
        {
            "title": "Appendix IV of the guideline on the investigation on bioequivalence: presentation of biopharmaceutical and bioanalytical data in module 2.7.1",
            "category": "Human",
            "first_published_date": "18/11/2011",
            "last_updated_date": "18/11/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/appendix-iv-guideline-investigation-bioequivalence-presentation-biopharmaceutical-bioanalytical-data-module-271"
        },
        {
            "title": "Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to address indication-specific clinical data requirements",
            "category": "Human",
            "first_published_date": "06/10/2011",
            "last_updated_date": "06/10/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-indication-specific-clinical-data-requirements"
        },
        {
            "title": "Core summary of product characteristics (SmPC) and package leaflet for radiopharmaceuticals",
            "category": "Human",
            "first_published_date": "23/09/2011",
            "last_updated_date": "23/09/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-smpc-package-leaflet-radiopharmaceuticals"
        },
        {
            "title": "ICH E2F Development safety update report",
            "category": "Human",
            "first_published_date": "01/09/2011",
            "last_updated_date": "01/09/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2f-development-safety-update-report"
        },
        {
            "title": "Quality aspects on the isolation of candidate influenza vaccine viruses in cell culture",
            "category": "Human",
            "first_published_date": "17/08/2011",
            "last_updated_date": "17/08/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-aspects-isolation-candidate-influenza-vaccine-viruses-cell-culture"
        },
        {
            "title": "Treatment of premenstrual dysphoric disorder",
            "category": "Human",
            "first_published_date": "05/08/2011",
            "last_updated_date": "05/08/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/treatment-premenstrual-dysphoric-disorder"
        },
        {
            "title": "Plasma-derived medicinal products",
            "category": "Human",
            "first_published_date": "29/07/2011",
            "last_updated_date": "29/07/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/plasma-derived-medicinal-products"
        },
        {
            "title": "Methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection",
            "category": "Human",
            "first_published_date": "12/07/2011",
            "last_updated_date": "12/07/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/methodological-issues-pharmacogenomic-biomarkers-relation-clinical-development-patient-selection"
        },
        {
            "title": "Creutzfeldt-Jakob disease and advanced therapy medicinal products",
            "category": "Human",
            "first_published_date": "28/06/2011",
            "last_updated_date": "28/06/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/creutzfeldt-jakob-disease-advanced-therapy-medicinal-products"
        },
        {
            "title": "VICH GL46 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: metabolism study to determine the quantity and identify the nature of residues",
            "category": "Veterinary",
            "first_published_date": "07/04/2011",
            "last_updated_date": "07/04/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl46-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-animals-metabolism-study-determine-quantity-identify-nature-residues"
        },
        {
            "title": "VICH GL47 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: laboratory animal comparative metabolism studies",
            "category": "Veterinary",
            "first_published_date": "07/04/2011",
            "last_updated_date": "07/04/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl47-studies-evaluate-metabolism-residue-kinetics-veterinary-drugs-food-producing-animals-laboratory-animal-comparative-metabolism-studies"
        },
        {
            "title": "Potency declaration/labelling for biological medicinal products which contain modified proteins as active substance",
            "category": "Human",
            "first_published_date": "14/03/2011",
            "last_updated_date": "14/03/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/potency-declaration-labelling-biological-medicinal-products-which-contain-modified-proteins-active-substance"
        },
        {
            "title": "Evaluation of drugs for the treatment of gastroesophageal reflux disease (GORD)",
            "category": "Human",
            "first_published_date": "14/03/2011",
            "last_updated_date": "14/03/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-drugs-treatment-gastroesophageal-reflux-disease-gord"
        },
        {
            "title": "Medicinal products for the treatment of insomnia",
            "category": "Human",
            "first_published_date": "25/02/2011",
            "last_updated_date": "25/02/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/medicinal-products-treatment-insomnia"
        },
        {
            "title": "Meticillin-resistant Staphylococcus pseudintermedius",
            "category": "Veterinary",
            "first_published_date": "10/02/2011",
            "last_updated_date": "10/02/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/meticillin-resistant-staphylococcus-pseudintermedius"
        },
        {
            "title": "Stem cell-based medicinal products",
            "category": "Human",
            "first_published_date": "03/02/2011",
            "last_updated_date": "03/02/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stem-cell-based-medicinal-products"
        },
        {
            "title": "Need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available",
            "category": "Human",
            "first_published_date": "11/01/2011",
            "last_updated_date": "11/01/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-active-control-therapeutic-areas-where-use-placebo-deemed-ethical-one-or-more-established-medicines-are-available"
        },
        {
            "title": "Level of purification of extracts to be considered as herbal preparations",
            "category": "Human;Herbal",
            "first_published_date": "03/01/2011",
            "last_updated_date": "03/01/2011",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/level-purification-extracts-be-considered-herbal-preparations"
        },
        {
            "title": "Data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of regulation (EC) No 470/2009",
            "category": "Veterinary",
            "first_published_date": "18/11/2010",
            "last_updated_date": "18/11/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-be-provided-support-request-include-substance-list-substances-considered-not-falling-within-scope-regulation-ec-no-470-2009"
        },
        {
            "title": "Stability testing of herbal medicinal products and traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "12/11/2010",
            "last_updated_date": "12/11/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-testing-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "ICH M2 Business requirements",
            "category": "Human",
            "first_published_date": "18/12/2009",
            "last_updated_date": "24/09/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m2-business-requirements"
        },
        {
            "title": "ICH M2 Electronic common technical document (eCTD)",
            "category": "Human",
            "first_published_date": "01/05/2004",
            "last_updated_date": "24/09/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m2-electronic-common-technical-document-ectd"
        },
        {
            "title": "Missing data in confirmatory clinical trials",
            "category": "Human",
            "first_published_date": "20/09/2010",
            "last_updated_date": "20/09/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/missing-data-confirmatory-clinical-trials"
        },
        {
            "title": "Addendum to the note for guidance on antiarrhythmics on atrial fibrillation and atrial flutter",
            "category": "Human",
            "first_published_date": "20/09/2010",
            "last_updated_date": "20/09/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/addendum-note-guidance-antiarrhythmics-atrial-fibrillation-atrial-flutter"
        },
        {
            "title": "ICH Q4B Annex 11 Capillary electrophoresis",
            "category": "Human",
            "first_published_date": "01/09/2010",
            "last_updated_date": "01/09/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-11-capillary-electrophoresis"
        },
        {
            "title": "Quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines",
            "category": "Human",
            "first_published_date": "10/08/2010",
            "last_updated_date": "10/08/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-non-clinical-clinical-aspects-live-recombinant-viral-vectored-vaccines"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)",
            "category": "Human",
            "first_published_date": "05/08/2010",
            "last_updated_date": "05/08/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-attention-deficit-hyperactivity-disorder-adhd"
        },
        {
            "title": "ICH E7 Studies in support of special populations: geriatrics - questions and answers",
            "category": "Human",
            "first_published_date": "27/07/2010",
            "last_updated_date": "27/07/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e7-studies-support-special-populations-geriatrics-questions-answers"
        },
        {
            "title": "Non-clinical evaluation of drug-induced liver injury (DILI)",
            "category": "Human",
            "first_published_date": "19/07/2010",
            "last_updated_date": "19/07/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-evaluation-drug-induced-liver-injury-dili"
        },
        {
            "title": "Questions and answers on the withdrawal of the note for guidance on single dose toxicity",
            "category": "Human",
            "first_published_date": "19/07/2010",
            "last_updated_date": "19/07/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-withdrawal-note-guidance-single-dose-toxicity"
        },
        {
            "title": "Need for a guideline on the clinical development of thrombopoetin receptor agonists for the treatment of chronic immune (idiopathic) thrombocytopenic purpura",
            "category": "Human",
            "first_published_date": "13/06/2010",
            "last_updated_date": "13/06/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-guideline-clinical-development-thrombopoetin-receptor-agonists-treatment-chronic-immune-idiopathic-thrombocytopenic-purpura"
        },
        {
            "title": "VICH GL45 Bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products",
            "category": "Veterinary",
            "first_published_date": "28/05/2010",
            "last_updated_date": "28/05/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl45-bracketing-matrixing-designs-stability-testing-new-veterinary-drug-substances-medicinal-products"
        },
        {
            "title": "In-vitro cultured chondrocyte containing products for cartilage repair of the knee",
            "category": "Human",
            "first_published_date": "18/05/2010",
            "last_updated_date": "18/05/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vitro-cultured-chondrocyte-containing-products-cartilage-repair-knee"
        },
        {
            "title": "Environmental risk assessment of herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "28/04/2010",
            "last_updated_date": "28/04/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessment-herbal-medicinal-products"
        },
        {
            "title": "Repeated dose toxicity",
            "category": "Human",
            "first_published_date": "29/03/2010",
            "last_updated_date": "29/03/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/repeated-dose-toxicity"
        },
        {
            "title": "Demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals",
            "category": "Veterinary",
            "first_published_date": "18/03/2010",
            "last_updated_date": "18/03/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/demonstration-possible-impact-maternally-derived-antibodies-vaccine-efficacy-young-animals"
        },
        {
            "title": "Data requirements to support in-use stability claims for veterinary vaccines",
            "category": "Veterinary",
            "first_published_date": "18/03/2010",
            "last_updated_date": "18/03/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-support-use-stability-claims-veterinary-vaccines"
        },
        {
            "title": "Control of the active substance in the finished product for immunological veterinary medicinal products (IVMPs)",
            "category": "Veterinary",
            "first_published_date": "18/03/2010",
            "last_updated_date": "18/03/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/control-active-substance-finished-product-immunological-veterinary-medicinal-products-ivmps"
        },
        {
            "title": "Development of medicinal products for the treatment of alcohol dependence",
            "category": "Human",
            "first_published_date": "01/03/2010",
            "last_updated_date": "01/03/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-medicinal-products-treatment-alcohol-dependence"
        },
        {
            "title": "Data requirements for swine influenza vaccines against pandemic (H1N1) 2009 influenza",
            "category": "Veterinary",
            "first_published_date": "16/02/2010",
            "last_updated_date": "16/02/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-requirements-swine-influenza-vaccines-against-pandemic-h1n1-2009-influenza"
        },
        {
            "title": "Ethanol content in herbal medicinal products and traditional herbal medicinal products used in children",
            "category": "Herbal",
            "first_published_date": "01/02/2010",
            "last_updated_date": "01/02/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ethanol-content-herbal-medicinal-products-traditional-herbal-medicinal-products-used-children"
        },
        {
            "title": "Need for an addendum on the clinical investigation of medicinal products intended for treatment of glucocorticoid-induced osteoporosis",
            "category": "Human",
            "first_published_date": "29/01/2010",
            "last_updated_date": "29/01/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-addendum-clinical-investigation-medicinal-products-intended-treatment-glucocorticoid-induced-osteoporosis"
        },
        {
            "title": "Selection of test materials for genotoxicity testing for traditional herbal medicinal products/herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "18/01/2010",
            "last_updated_date": "18/01/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-products-herbal-medicinal-products"
        },
        {
            "title": "Questions and answers on gene therapy",
            "category": "Human",
            "first_published_date": "12/01/2010",
            "last_updated_date": "12/01/2010",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-gene-therapy"
        },
        {
            "title": "ICH Q4B Annex 10 Polyacrylamide gel electrophoresis",
            "category": "Human",
            "first_published_date": "01/12/2009",
            "last_updated_date": "01/12/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-10-polyacrylamide-gel-electrophoresis"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension",
            "category": "Human",
            "first_published_date": "01/12/2009",
            "last_updated_date": "01/12/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-pulmonary-arterial-hypertension"
        },
        {
            "title": "ICH 4 QB Annex 9 Tablet friability",
            "category": "Human",
            "first_published_date": "01/12/2009",
            "last_updated_date": "01/12/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-4-qb-annex-9-tablet-friability"
        },
        {
            "title": "Xenogeneic cell-based medicinal products",
            "category": "Human",
            "first_published_date": "30/11/2009",
            "last_updated_date": "30/11/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/xenogeneic-cell-based-medicinal-products"
        },
        {
            "title": "Follow-up of patients administered with gene therapy medicinal products",
            "category": "Human",
            "first_published_date": "12/11/2009",
            "last_updated_date": "12/11/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/follow-patients-administered-gene-therapy-medicinal-products"
        },
        {
            "title": "Extrapolation of results from clinical studies conducted outside Europe to the EU-population",
            "category": "Human",
            "first_published_date": "12/11/2009",
            "last_updated_date": "12/11/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/extrapolation-results-clinical-studies-conducted-outside-europe-eu-population"
        },
        {
            "title": "ICH Considerations: oncolytic viruses",
            "category": "Human",
            "first_published_date": "21/10/2009",
            "last_updated_date": "21/10/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-considerations-oncolytic-viruses"
        },
        {
            "title": "Higher-tier testing of veterinary medicinal products to dung fauna",
            "category": "Veterinary",
            "first_published_date": "23/09/2009",
            "last_updated_date": "23/09/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/higher-tier-testing-veterinary-medicinal-products-dung-fauna"
        },
        {
            "title": "Appendix 1 to the guideline on clinical evaluation of diagnostic agents on imaging agents",
            "category": "Human",
            "first_published_date": "23/07/2009",
            "last_updated_date": "23/07/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/appendix-1-guideline-clinical-evaluation-diagnostic-agents-imaging-agents"
        },
        {
            "title": "ICH Considerations: general principles to address virus and vector shedding",
            "category": "Human",
            "first_published_date": "01/07/2009",
            "last_updated_date": "01/07/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-considerations-general-principles-address-virus-vector-shedding"
        },
        {
            "title": "Questions and answers on the possibility to extrapolate pre-inactivation titres as part of validation of an inactivation process",
            "category": "Veterinary",
            "first_published_date": "22/06/2009",
            "last_updated_date": "22/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-possibility-extrapolate-pre-inactivation-titres-part-validation-inactivation-process"
        },
        {
            "title": "Joint scientific report of ECDC, EFSA and EMA on meticillin-resistant Staphylococcus aureus (MRSA) in livestock, companion animals and food",
            "category": "Veterinary",
            "first_published_date": "16/06/2009",
            "last_updated_date": "16/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/joint-scientific-report-ecdc-efsa-ema-meticillin-resistant-staphylococcus-aureus-mrsa-livestock-companion-animals-food"
        },
        {
            "title": "ICH Q8 (R2) Pharmaceutical development",
            "category": "Human",
            "first_published_date": "01/06/2009",
            "last_updated_date": "01/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q8-r2-pharmaceutical-development"
        },
        {
            "title": "ICH Q4B Annex 4A Microbiological examination of non-sterile products: microbial enumeration tests",
            "category": "Human",
            "first_published_date": "01/06/2009",
            "last_updated_date": "01/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-4a-microbiological-examination-non-sterile-products-microbial-enumeration-tests"
        },
        {
            "title": "ICH Q4B Annex 5 Disintegration test",
            "category": "Human",
            "first_published_date": "01/06/2009",
            "last_updated_date": "01/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-5-disintegration-test"
        },
        {
            "title": "ICH Q4B Annex 8 Sterility test",
            "category": "Human",
            "first_published_date": "01/06/2009",
            "last_updated_date": "01/06/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-8-sterility-test"
        },
        {
            "title": "Non-clinical and clinical development of similar biological medicinal products containing recombinant interferon alpha  or pegylated recombinant interferon alpha",
            "category": "Human",
            "first_published_date": "23/04/2009",
            "last_updated_date": "23/04/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-development-similar-biological-medicinal-products-containing-recombinant-interferon-alpha-or-pegylated-recombinant-interferon-alpha"
        },
        {
            "title": "Clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C",
            "category": "Human",
            "first_published_date": "23/04/2009",
            "last_updated_date": "23/04/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-evaluation-direct-acting-antiviral-agents-intended-treatment-chronic-hepatitis-c"
        },
        {
            "title": "Replacement of rabbit pyrogen testing by an alternative test for plasma derived medicinal products",
            "category": "Human",
            "first_published_date": "23/04/2009",
            "last_updated_date": "23/04/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/replacement-rabbit-pyrogen-testing-alternative-test-plasma-derived-medicinal-products"
        },
        {
            "title": "VICH GL33 Safety studies for veterinary drug residues in human food: general approach to testing",
            "category": "Veterinary",
            "first_published_date": "20/04/2009",
            "last_updated_date": "20/04/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl33-safety-studies-veterinary-drug-residues-human-food-general-approach-testing"
        },
        {
            "title": "Meticillin-resistant Staphylococcus aureus in food-producing and companion animals in the European Union: epidemiology and control options for human and animal health",
            "category": "Veterinary",
            "first_published_date": "26/03/2009",
            "last_updated_date": "26/03/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/meticillin-resistant-staphylococcus-aureus-food-producing-companion-animals-european-union-epidemiology-control-options-human-animal-health"
        },
        {
            "title": "Non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins",
            "category": "Human",
            "first_published_date": "19/03/2009",
            "last_updated_date": "19/03/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins"
        },
        {
            "title": "Use of third- and fourth-generation cephalosporins in food-producing animals in the European Union: development of resistance and impact on human and animal health",
            "category": "Veterinary",
            "first_published_date": "16/03/2009",
            "last_updated_date": "16/03/2009",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-third-fourth-generation-cephalosporins-food-producing-animals-european-union-development-resistance-impact-human-animal-health"
        },
        {
            "title": "Dossier structure and content for pandemic-influenza-vaccine marketing-authorisation application",
            "category": "Human",
            "first_published_date": "18/12/2008",
            "last_updated_date": "18/12/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/dossier-structure-content-pandemic-influenza-vaccine-marketing-authorisation-application"
        },
        {
            "title": "ICH Q4B Annex 4C Test for microbiological examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use",
            "category": "Human",
            "first_published_date": "01/12/2008",
            "last_updated_date": "01/12/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-4c-test-microbiological-examination-non-sterile-products-acceptance-criteria-pharmaceutical-preparations-substances-pharmaceutical-use"
        },
        {
            "title": "ICH Q4B Annex 4B Test for microbiological examination of non-sterile products: tests for specified microorganisms",
            "category": "Human",
            "first_published_date": "01/12/2008",
            "last_updated_date": "01/12/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-4b-test-microbiological-examination-non-sterile-products-tests-specified-microorganisms"
        },
        {
            "title": "Clinical development of medicinal products for treatment of HIV infection",
            "category": "Human",
            "first_published_date": "20/11/2008",
            "last_updated_date": "20/11/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-treatment-hiv-infection"
        },
        {
            "title": "Clinical development of products for specific immunotherapy for the treatment of allergic diseases",
            "category": "Human",
            "first_published_date": "20/11/2008",
            "last_updated_date": "20/11/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-products-specific-immunotherapy-treatment-allergic-diseases"
        },
        {
            "title": "Allergen products: production and quality issues",
            "category": "Human",
            "first_published_date": "20/11/2008",
            "last_updated_date": "20/11/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/allergen-products-production-quality-issues"
        },
        {
            "title": "Requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue",
            "category": "Veterinary",
            "first_published_date": "17/11/2008",
            "last_updated_date": "17/11/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue"
        },
        {
            "title": "Evaluation of medicinal products for cardiovascular disease prevention",
            "category": "Human",
            "first_published_date": "25/09/2008",
            "last_updated_date": "25/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-medicinal-products-cardiovascular-disease-prevention"
        },
        {
            "title": "Assessment of bioavailability of bound residues in food commodities of animal origin in the context of Council Regulation (EEC) No 2377/90",
            "category": "Veterinary",
            "first_published_date": "22/09/2008",
            "last_updated_date": "22/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-bioavailability-bound-residues-food-commodities-animal-origin-context-council-regulation-eec-no-2377-90"
        },
        {
            "title": "New approach developed by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives for exposure and maximum residue limit assessment of residues of veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "22/09/2008",
            "last_updated_date": "22/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/new-approach-developed-joint-food-agriculture-organization-world-health-organization-expert-committee-food-additives-exposure-maximum-residue-limit-assessment-residues-veterinary-medicinal-products"
        },
        {
            "title": "VICH GL44 Target animal safety for veterinary live and inactivated vaccines",
            "category": "Veterinary",
            "first_published_date": "22/09/2008",
            "last_updated_date": "22/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl44-target-animal-safety-veterinary-live-inactivated-vaccines"
        },
        {
            "title": "VICH GL43 Target animal safety: pharmaceuticals",
            "category": "Veterinary",
            "first_published_date": "22/09/2008",
            "last_updated_date": "22/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl43-target-animal-safety-pharmaceuticals"
        },
        {
            "title": "Development of a guideline on preparation of herbal teas",
            "category": "Human;Herbal",
            "first_published_date": "04/09/2008",
            "last_updated_date": "04/09/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-guideline-preparation-herbal-teas"
        },
        {
            "title": "Virus safety evaluation of biotechnological investigational medicinal products",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "24/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/virus-safety-evaluation-biotechnological-investigational-medicinal-products"
        },
        {
            "title": "Clinical investigation of immunosuppressants for solid organ transplantation",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "24/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-immunosuppressants-solid-organ-transplantation"
        },
        {
            "title": "Development of medicinal products for the treatment of post-traumatic stress disorder",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "24/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-medicinal-products-treatment-post-traumatic-stress-disorder"
        },
        {
            "title": "Quality of biological active substances produced by stable transgene expression in higher plants",
            "category": "Human",
            "first_published_date": "24/07/2008",
            "last_updated_date": "24/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-biological-active-substances-produced-stable-transgene-expression-higher-plants"
        },
        {
            "title": "Markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "15/07/2008",
            "last_updated_date": "15/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/markers-used-quantitative-qualitative-analysis-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "Medicinal gases: pharmaceutical documentation (including recommendation on non-clinical safety requirements for well established medicinal gases)",
            "category": "Human",
            "first_published_date": "09/07/2008",
            "last_updated_date": "09/07/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/medicinal-gases-pharmaceutical-documentation-including-recommendation-non-clinical-safety-requirements-well-established-medicinal-gases"
        },
        {
            "title": "Quality of combination herbal medicinal products/traditional herbal medicinal products",
            "category": "Human;Veterinary;Herbal",
            "first_published_date": "23/06/2008",
            "last_updated_date": "23/06/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-combination-herbal-medicinal-products-traditional-herbal-medicinal-products"
        },
        {
            "title": "ICH Q4B Annex 2 Test for extractable volume in parenteral preparations",
            "category": "Human",
            "first_published_date": "01/06/2008",
            "last_updated_date": "01/06/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-2-test-extractable-volume-parenteral-preparations"
        },
        {
            "title": "ICH Q4B Annex 3 Test for particulate contamination: sub-visible particles",
            "category": "Human",
            "first_published_date": "01/06/2008",
            "last_updated_date": "01/06/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-3-test-particulate-contamination-sub-visible-particles"
        },
        {
            "title": "ICH Q10 Pharmaceutical quality system",
            "category": "Human",
            "first_published_date": "01/06/2008",
            "last_updated_date": "01/06/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q10-pharmaceutical-quality-system"
        },
        {
            "title": "Clinical and non-clinical evaluation during the consultation procedure on medicinal substances contained in drug-eluting (medicinal-substance-eluting) coronary stents",
            "category": "Human",
            "first_published_date": "30/05/2008",
            "last_updated_date": "30/05/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-non-clinical-evaluation-during-consultation-procedure-medicinal-substances-contained-drug-eluting-medicinal-substance-eluting-coronary-stents"
        },
        {
            "title": "Human cell-based medicinal products",
            "category": "Human",
            "first_published_date": "21/05/2008",
            "last_updated_date": "21/05/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/human-cell-based-medicinal-products"
        },
        {
            "title": "Adaptogenic concept",
            "category": "Human;Herbal",
            "first_published_date": "08/05/2008",
            "last_updated_date": "08/05/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/adaptogenic-concept"
        },
        {
            "title": "ICH S1C (R2) Dose selection for carcinogenicity studies of pharmaceuticals",
            "category": "Human",
            "first_published_date": "30/04/2008",
            "last_updated_date": "30/04/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s1c-r2-dose-selection-carcinogenicity-studies-pharmaceuticals"
        },
        {
            "title": "Harmonisation and update of the clinical aspects in the authorised conditions of use for radiopharmaceuticals and other diagnostic medicinal products",
            "category": "Human",
            "first_published_date": "24/04/2008",
            "last_updated_date": "24/04/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/harmonisation-update-clinical-aspects-authorised-conditions-use-radiopharmaceuticals-other-diagnostic-medicinal-products"
        },
        {
            "title": "Pharmacogenomics in oncology",
            "category": "Human",
            "first_published_date": "01/04/2008",
            "last_updated_date": "01/04/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacogenomics-oncology"
        },
        {
            "title": "Water for injection prepared by reverse osmosis",
            "category": "Human;Veterinary",
            "first_published_date": "05/03/2008",
            "last_updated_date": "05/03/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/water-injection-prepared-reverse-osmosis"
        },
        {
            "title": "Need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications",
            "category": "Human",
            "first_published_date": "24/01/2008",
            "last_updated_date": "24/01/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-non-clinical-testing-juvenile-animals-human-pharmaceuticals-paediatric-indications"
        },
        {
            "title": "Non-clinical development of fixed combinations of medicinal products",
            "category": "Human",
            "first_published_date": "24/01/2008",
            "last_updated_date": "24/01/2008",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-development-fixed-combinations-medicinal-products"
        },
        {
            "title": "Consideration of adjuvants and preservatives under Council Regulation (EEC) No 2377/90 laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin",
            "category": "Veterinary",
            "first_published_date": "17/12/2007",
            "last_updated_date": "17/12/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/consideration-adjuvants-preservatives-under-council-regulation-eec-no-2377-90-laying-down-community-procedure-establishment-maximum-residue-limits-veterinary-medicinal-products-foodstuffs-animal"
        },
        {
            "title": "Immunogenicity assessment of biotechnology-derived therapeutic proteins",
            "category": "Human",
            "first_published_date": "13/12/2007",
            "last_updated_date": "13/12/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins"
        },
        {
            "title": "Non-clinical investigation of the dependence potential of medicinal products",
            "category": "Human",
            "first_published_date": "13/12/2007",
            "last_updated_date": "13/12/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-investigation-dependence-potential-medicinal-products"
        },
        {
            "title": "In vitro investigation of mitochondrial toxicity of anti-HIV nucleoside reverse transcriptase inhibitors",
            "category": "Human",
            "first_published_date": "13/12/2007",
            "last_updated_date": "13/12/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vitro-investigation-mitochondrial-toxicity-anti-hiv-nucleoside-reverse-transcriptase-inhibitors"
        },
        {
            "title": "Carcinogenicity evaluation of medicinal products for the treatment of HIV infection",
            "category": "Human",
            "first_published_date": "13/12/2007",
            "last_updated_date": "13/12/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/carcinogenicity-evaluation-medicinal-products-treatment-hiv-infection"
        },
        {
            "title": "Declaration of storage conditions for medicinal products particulars and active substances (Annex)",
            "category": "Human",
            "first_published_date": "19/11/2007",
            "last_updated_date": "19/11/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/declaration-storage-conditions-medicinal-products-particulars-active-substances-annex"
        },
        {
            "title": "Use of genomics in cardiovascular clinical trials",
            "category": "Human",
            "first_published_date": "15/11/2007",
            "last_updated_date": "15/11/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-genomics-cardiovascular-clinical-trials"
        },
        {
            "title": "Pharmacogenomic samples, testing and data handling",
            "category": "Human",
            "first_published_date": "15/11/2007",
            "last_updated_date": "15/11/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacogenomic-samples-testing-data-handling"
        },
        {
            "title": "ICH Q4B Annex 1 Residue on ignition/sulphated ash",
            "category": "Human",
            "first_published_date": "01/11/2007",
            "last_updated_date": "01/11/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q4b-annex-1-residue-ignition-sulphated-ash"
        },
        {
            "title": "ICH E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories",
            "category": "Human",
            "first_published_date": "01/11/2007",
            "last_updated_date": "01/11/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e15-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-sample-coding-categories"
        },
        {
            "title": "Risks associated with furocoumarins contained in preparations of Angelica archangelica L.",
            "category": "Human;Herbal",
            "first_published_date": "31/10/2007",
            "last_updated_date": "31/10/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risks-associated-furocoumarins-contained-preparations-angelica-archangelica-l"
        },
        {
            "title": "Methodological issues in confirmatory clinical trials planned with an adaptive design",
            "category": "Veterinary",
            "first_published_date": "18/10/2007",
            "last_updated_date": "18/10/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/methodological-issues-confirmatory-clinical-trials-planned-adaptive-design"
        },
        {
            "title": "Clinical  investigation of human anti-D immunoglobulin for intravenous and/or intramuscular use",
            "category": "Human",
            "first_published_date": "20/09/2007",
            "last_updated_date": "20/09/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-human-anti-d-immunoglobulin-intravenous-or-intramuscular-use"
        },
        {
            "title": "VICH GL41 Target animal safety: examination of live veterinary vaccines in target animals for absence of reversion to virulence",
            "category": "Veterinary",
            "first_published_date": "18/09/2007",
            "last_updated_date": "18/09/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion-virulence"
        },
        {
            "title": "Comparability of biotechnology-derived medicinal products after a change in the manufacturing process - non-clinical and clinical issues",
            "category": "Human",
            "first_published_date": "19/07/2007",
            "last_updated_date": "19/07/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process-non-clinical-clinical-issues"
        },
        {
            "title": "Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors",
            "category": "Human",
            "first_published_date": "08/07/2007",
            "last_updated_date": "08/07/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-non-clinical-clinical-issues-relating-specifically-recombinant-adeno-associated-viral-vectors"
        },
        {
            "title": "Reporting the results of population pharmacokinetic analyses",
            "category": "Human",
            "first_published_date": "21/06/2007",
            "last_updated_date": "21/06/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reporting-results-population-pharmacokinetic-analyses"
        },
        {
            "title": "Excipients in the dossier for application for marketing authorisation of a medicinal product",
            "category": "Human",
            "first_published_date": "19/06/2007",
            "last_updated_date": "19/06/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/excipients-dossier-application-marketing-authorisation-medicinal-product"
        },
        {
            "title": "Requirements for an authorisation under exceptional circumstances for vaccines for use in birds against avian influenza",
            "category": "Veterinary",
            "first_published_date": "23/04/2007",
            "last_updated_date": "23/04/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-authorisation-under-exceptional-circumstances-vaccines-use-birds-against-avian-influenza"
        },
        {
            "title": "Processing joint FDA and EMA voluntary genomic data submissions within the framework of the confidentiality arrangement",
            "category": "Human",
            "first_published_date": "01/04/2007",
            "last_updated_date": "01/04/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/processing-joint-fda-ema-voluntary-genomic-data-submissions-within-framework-confidentiality-arrangement"
        },
        {
            "title": "Non-clinical studies required before first clinical use of gene therapy medicinal products",
            "category": "Human",
            "first_published_date": "22/03/2007",
            "last_updated_date": "22/03/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products"
        },
        {
            "title": "Clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy",
            "category": "Human",
            "first_published_date": "21/03/2007",
            "last_updated_date": "21/03/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-trials-haematopoietic-growth-factors-prophylaxis-infection-following-myelosuppressive-or-myeloablative-therapy"
        },
        {
            "title": "VICH GL11 Impurities in new veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "19/02/2007",
            "last_updated_date": "19/02/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl11-impurities-new-veterinary-medicinal-products"
        },
        {
            "title": "VICH GL3 Stability testing of new veterinary drug substances and medicinal products",
            "category": "Veterinary",
            "first_published_date": "19/02/2007",
            "last_updated_date": "19/02/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl3-stability-testing-new-veterinary-drug-substances-medicinal-products"
        },
        {
            "title": "VICH GL10 Impurities in new veterinary drug substances",
            "category": "Veterinary",
            "first_published_date": "19/02/2007",
            "last_updated_date": "19/02/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl10-impurities-new-veterinary-drug-substances"
        },
        {
            "title": "Use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health",
            "category": "Veterinary",
            "first_published_date": "15/02/2007",
            "last_updated_date": "15/02/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-fluoroquinolones-food-producing-animals-european-union-development-resistance-impact-human-animal-health"
        },
        {
            "title": "Scientific requirements for the environmental risk assessment of gene-therapy medicinal products",
            "category": "Human",
            "first_published_date": "08/02/2007",
            "last_updated_date": "08/02/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products"
        },
        {
            "title": "Superseded - Conduct of pharmacovigilance for medicines used by the paediatric population",
            "category": "Human",
            "first_published_date": "25/01/2007",
            "last_updated_date": "25/01/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/superseded-conduct-pharmacovigilance-medicines-used-paediatric-population"
        },
        {
            "title": "Clinical investigation of the pharmacokinetics of therapeutic proteins",
            "category": "Human",
            "first_published_date": "24/01/2007",
            "last_updated_date": "24/01/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-pharmacokinetics-therapeutic-proteins"
        },
        {
            "title": "Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context",
            "category": "Human",
            "first_published_date": "24/01/2007",
            "last_updated_date": "24/01/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/influenza-vaccines-prepared-viruses-potential-cause-pandemic-intended-use-outside-core-dossier-context"
        },
        {
            "title": "Thiomersal: implementation of the warning statement relating to sensitisation",
            "category": "Human",
            "first_published_date": "11/01/2007",
            "last_updated_date": "11/01/2007",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/thiomersal-implementation-warning-statement-relating-sensitisation"
        },
        {
            "title": "Gender differences in cardiovascular diseases",
            "category": "Human",
            "first_published_date": "14/12/2006",
            "last_updated_date": "14/12/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/gender-differences-cardiovascular-diseases"
        },
        {
            "title": "Non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy",
            "category": "Human",
            "first_published_date": "13/12/2006",
            "last_updated_date": "13/12/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-clinical-development-medicinal-products-treatment-nausea-vomiting-associated-cancer-chemotherapy"
        },
        {
            "title": "Environmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms (GMOs)",
            "category": "Human",
            "first_published_date": "11/12/2006",
            "last_updated_date": "11/12/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/environmental-risk-assessments-medicinal-products-containing-or-consisting-genetically-modified-organisms-gmos"
        },
        {
            "title": "Evaluation of new medicinal products in the treatment of primary osteoporosis",
            "category": "Human",
            "first_published_date": "16/11/2006",
            "last_updated_date": "16/11/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-new-medicinal-products-treatment-primary-osteoporosis"
        },
        {
            "title": "Questions and answers on the guideline on the clinical investigation of corticosteroids intended for use on the skin",
            "category": "Human",
            "first_published_date": "16/11/2006",
            "last_updated_date": "16/11/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/questions-answers-guideline-clinical-investigation-corticosteroids-intended-use-skin"
        },
        {
            "title": "ICH Considerations: general principles to address the risk of inadvertent germline integration of gene therapy vectors",
            "category": "Human",
            "first_published_date": "01/11/2006",
            "last_updated_date": "01/11/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-considerations-general-principles-address-risk-inadvertent-germline-integration-gene-therapy-vectors"
        },
        {
            "title": "Use of fumigants",
            "category": "Human;Herbal",
            "first_published_date": "26/10/2006",
            "last_updated_date": "26/10/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-fumigants"
        },
        {
            "title": "ICH Q3A (R2) Impurities in new drug substances",
            "category": "Human",
            "first_published_date": "01/10/2006",
            "last_updated_date": "01/10/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3a-r2-impurities-new-drug-substances"
        },
        {
            "title": "Validation of immunoassay for the detection of hepatitis B virus surface antigen in plasma pools",
            "category": "Human",
            "first_published_date": "21/09/2006",
            "last_updated_date": "21/09/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/validation-immunoassay-detection-hepatitis-b-virus-surface-antigen-plasma-pools"
        },
        {
            "title": "Validation of immunoassay for the detection of antibody to human immunodeficiency virus in plasma pools",
            "category": "Human",
            "first_published_date": "21/09/2006",
            "last_updated_date": "21/09/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/validation-immunoassay-detection-antibody-human-immunodeficiency-virus-plasma-pools"
        },
        {
            "title": "Formulations of choice for the paediatric population",
            "category": "Human",
            "first_published_date": "28/07/2006",
            "last_updated_date": "28/07/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/formulations-choice-paediatric-population"
        },
        {
            "title": "Clinical trials in small populations",
            "category": "Human",
            "first_published_date": "27/07/2006",
            "last_updated_date": "27/07/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-trials-small-populations"
        },
        {
            "title": "Herbal medicinal products containing cimicifugae racemosae rhizoma - serious hepatic reactions",
            "category": "Human;Herbal",
            "first_published_date": "18/07/2006",
            "last_updated_date": "18/07/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-serious-hepatic-reactions"
        },
        {
            "title": "Impact of brain immaturity when investigating medicinal products intended for neonatal use",
            "category": "Human",
            "first_published_date": "02/06/2006",
            "last_updated_date": "02/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/impact-brain-immaturity-when-investigating-medicinal-products-intended-neonatal-use"
        },
        {
            "title": "Clinical investigation of anti-anginal medicinal products in stable angina pectoris",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "01/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-anti-anginal-medicinal-products-stable-angina-pectoris"
        },
        {
            "title": "ICH Q1F Stability data package for registration in climatic zones III and IV",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "01/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1f-stability-data-package-registration-climatic-zones-iii-iv"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of sepsis",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "01/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-sepsis"
        },
        {
            "title": "ICH Q3B (R2) Impurities in new drug products",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "01/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3b-r2-impurities-new-drug-products"
        },
        {
            "title": "ICH E5(R1) Ethnic factors in the acceptability of foreign clinical data - questions and answers",
            "category": "Human",
            "first_published_date": "01/06/2006",
            "last_updated_date": "01/06/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e5r1-ethnic-factors-acceptability-foreign-clinical-data-questions-answers"
        },
        {
            "title": "Potency labelling for insulin analogue containing products with particular reference to the use of \"international units\" or \"units\"",
            "category": "Human",
            "first_published_date": "24/05/2006",
            "last_updated_date": "24/05/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/potency-labelling-insulin-analogue-containing-products-particular-reference-use-international-units-or-units"
        },
        {
            "title": "Extension of the shelf life for the antigen stocks during the type II variation assessment",
            "category": "Veterinary",
            "first_published_date": "19/05/2006",
            "last_updated_date": "19/05/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/extension-shelf-life-antigen-stocks-during-type-ii-variation-assessment"
        },
        {
            "title": "Pharmacogenetics briefing meeting",
            "category": "Human",
            "first_published_date": "27/04/2006",
            "last_updated_date": "27/04/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacogenetics-briefing-meeting"
        },
        {
            "title": "Core summary of product characteristics for human plasma-derived hepatitis B immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "27/04/2006",
            "last_updated_date": "27/04/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-hepatitis-b-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Core summary of product characteristics for human plasma-derived hepatitis B immunoglobulin for intravenous use",
            "category": "Human",
            "first_published_date": "27/04/2006",
            "last_updated_date": "27/04/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-hepatitis-b-immunoglobulin-intravenous-use"
        },
        {
            "title": "Chamomilla containing herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "08/03/2006",
            "last_updated_date": "08/03/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chamomilla-containing-herbal-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products indicated for the treatment of social anxiety",
            "category": "Human",
            "first_published_date": "26/01/2006",
            "last_updated_date": "26/01/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-indicated-treatment-social-anxiety"
        },
        {
            "title": "Allergenic potency of herbal medicinal products containing soya or peanut protein",
            "category": "Human;Herbal",
            "first_published_date": "12/01/2006",
            "last_updated_date": "12/01/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/allergenic-potency-herbal-medicinal-products-containing-soya-or-peanut-protein"
        },
        {
            "title": "Clinical assessment of fixed combinations of herbal substances/herbal preparations",
            "category": "Human;Herbal",
            "first_published_date": "11/01/2006",
            "last_updated_date": "11/01/2006",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-assessment-fixed-combinations-herbal-substances-herbal-preparations"
        },
        {
            "title": "Capsicum/capsaicin containing herbal medicinal products",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "23/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/capsicum-capsaicin-containing-herbal-medicinal-products"
        },
        {
            "title": "CPMP list of herbal drugs with serious risks, dated 1992",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "23/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cpmp-list-herbal-drugs-serious-risks-dated-1992"
        },
        {
            "title": "Use of herbal medicinal products containing methyleugenol",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "23/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-methyleugenol"
        },
        {
            "title": "Risks associated with the use of herbal products containing Aristolochia species",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "23/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risks-associated-use-herbal-products-containing-aristolochia-species"
        },
        {
            "title": "Use of herbal medicinal products containing asarone",
            "category": "Human;Herbal",
            "first_published_date": "23/11/2005",
            "last_updated_date": "23/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-herbal-medicinal-products-containing-asarone"
        },
        {
            "title": "Approaches on how to consider excipients in the context of Regulation 2377/90",
            "category": "Veterinary",
            "first_published_date": "22/11/2005",
            "last_updated_date": "22/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/approaches-how-consider-excipients-context-regulation-2377-90"
        },
        {
            "title": "Impact of lung and heart immaturity when investigating medicinal products intended for neonatal use",
            "category": "Human",
            "first_published_date": "18/11/2005",
            "last_updated_date": "18/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/impact-lung-heart-immaturity-when-investigating-medicinal-products-intended-neonatal-use"
        },
        {
            "title": "Non-clinical testing for inadvertent germline transmission of gene transfer vectors",
            "category": "Human",
            "first_published_date": "17/11/2005",
            "last_updated_date": "17/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-testing-inadvertent-germline-transmission-gene-transfer-vectors"
        },
        {
            "title": "Core summary of product characteristics for human plasma derived von Willebrand factor",
            "category": "Human",
            "first_published_date": "17/11/2005",
            "last_updated_date": "17/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-von-willebrand-factor"
        },
        {
            "title": "Clinical investigation of human plasma-derived von Willebrand factor products",
            "category": "Human",
            "first_published_date": "16/11/2005",
            "last_updated_date": "16/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-human-plasma-derived-von-willebrand-factor-products"
        },
        {
            "title": "VICH GL39 Test procedures and acceptance criteria for new veterinary drug substances and new medicinal products: chemical substances",
            "category": "Veterinary",
            "first_published_date": "15/11/2005",
            "last_updated_date": "15/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl39-test-procedures-acceptance-criteria-new-veterinary-drug-substances-new-medicinal-products-chemical-substances"
        },
        {
            "title": "VICH GL40 Test procedures and acceptance criteria for new biotechnological/biological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "15/11/2005",
            "last_updated_date": "15/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl40-test-procedures-acceptance-criteria-new-biotechnological-biological-veterinary-medicinal-products"
        },
        {
            "title": "Requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "09/11/2005",
            "last_updated_date": "09/11/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-controls-applied-bovine-serum-used-production-immunological-veterinary-medicinal-products"
        },
        {
            "title": "ICH S8 Immunotoxicity studies for human pharmaceuticals",
            "category": "Human",
            "first_published_date": "31/10/2005",
            "last_updated_date": "31/10/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s8-immunotoxicity-studies-human-pharmaceuticals"
        },
        {
            "title": "Similar biological medicinal products",
            "category": "Human",
            "first_published_date": "30/10/2005",
            "last_updated_date": "30/10/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/similar-biological-medicinal-products"
        },
        {
            "title": "Clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women",
            "category": "Human",
            "first_published_date": "13/10/2005",
            "last_updated_date": "13/10/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-hormone-replacement-therapy-oestrogen-deficiency-symptoms-postmenopausal-women"
        },
        {
            "title": "Non-clinical documentation for mixed marketing authorisation applications",
            "category": "Human",
            "first_published_date": "13/10/2005",
            "last_updated_date": "13/10/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-documentation-mixed-marketing-authorisation-applications"
        },
        {
            "title": "Core summary of product characteristics for human tetanus immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-tetanus-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Clinical investigation of steroid contraceptives in women",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-steroid-contraceptives-women"
        },
        {
            "title": "Core summary for product characteristics for human rabies immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-rabies-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Data monitoring committees",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/data-monitoring-committees"
        },
        {
            "title": "Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products"
        },
        {
            "title": "Core summary of product characteristics for human varicella immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-varicella-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Core summary of product characteristics for human tick-borne encephalitis immunoglobulin for intramuscular use",
            "category": "Human",
            "first_published_date": "27/07/2005",
            "last_updated_date": "27/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-tick-borne-encephalitis-immunoglobulin-intramuscular-use"
        },
        {
            "title": "Impact of liver immaturity when investigating medicinal products intended for neonatal use",
            "category": "Human",
            "first_published_date": "20/07/2005",
            "last_updated_date": "20/07/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/impact-liver-immaturity-when-investigating-medicinal-products-intended-neonatal-use"
        },
        {
            "title": "ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products",
            "category": "Human",
            "first_published_date": "01/06/2005",
            "last_updated_date": "01/06/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q5e-biotechnological-biological-products-subject-changes-their-manufacturing-process-comparability-biotechnological-biological-products"
        },
        {
            "title": "Development and manufacture of lentiviral vectors",
            "category": "Human",
            "first_published_date": "26/05/2005",
            "last_updated_date": "26/05/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-manufacture-lentiviral-vectors"
        },
        {
            "title": "Plastic primary packaging materials",
            "category": "Human;Veterinary",
            "first_published_date": "19/05/2005",
            "last_updated_date": "19/05/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/plastic-primary-packaging-materials"
        },
        {
            "title": "VICH GL28 Studies to evaluate the safety of veterinary drugs in human: carcinogenicity testing",
            "category": "Veterinary",
            "first_published_date": "18/05/2005",
            "last_updated_date": "18/05/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl28-studies-evaluate-safety-veterinary-drugs-human-carcinogenicity-testing"
        },
        {
            "title": "ICH M5 EWG Routes of administration controlled vocabulary",
            "category": "Human",
            "first_published_date": "01/05/2005",
            "last_updated_date": "01/05/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m5-ewg-routes-administration-controlled-vocabulary"
        },
        {
            "title": "ICH M5 EWG Units and measurements controlled vocabulary",
            "category": "Human",
            "first_published_date": "01/05/2005",
            "last_updated_date": "01/05/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m5-ewg-units-measurements-controlled-vocabulary"
        },
        {
            "title": "Requirements for vaccine antigen master file certification",
            "category": "Human",
            "first_published_date": "17/03/2005",
            "last_updated_date": "17/03/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-vaccine-antigen-master-file-certification"
        },
        {
            "title": "Evaluation of control samples for non-clinical safety studies: checking for contamination with the test substance",
            "category": "Human",
            "first_published_date": "17/03/2005",
            "last_updated_date": "17/03/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-control-samples-non-clinical-safety-studies-checking-contamination-test-substance"
        },
        {
            "title": "Further guidance on interpretation of the data from VICH GL27",
            "category": "Veterinary",
            "first_published_date": "09/03/2005",
            "last_updated_date": "09/03/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/further-guidance-interpretation-data-vich-gl27"
        },
        {
            "title": "Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function",
            "category": "Human",
            "first_published_date": "17/02/2005",
            "last_updated_date": "17/02/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function"
        },
        {
            "title": "Suitability of the graduation of delivery devices for liquid dosage forms",
            "category": "Human",
            "first_published_date": "01/02/2005",
            "last_updated_date": "01/02/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/suitability-graduation-delivery-devices-liquid-dosage-forms"
        },
        {
            "title": "Assessment of the genotoxic potential of antisense oligodeoxynucleotides",
            "category": "Human",
            "first_published_date": "20/01/2005",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/assessment-genotoxic-potential-antisense-oligodeoxynucleotides"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of obsessive compulsive disorder",
            "category": "Human",
            "first_published_date": "20/01/2005",
            "last_updated_date": "20/01/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-obsessive-compulsive-disorder"
        },
        {
            "title": "Clinical investigation of medicinal products indicated for generalised anxiety disorder",
            "category": "Human",
            "first_published_date": "20/01/2005",
            "last_updated_date": "20/01/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-indicated-generalised-anxiety-disorder"
        },
        {
            "title": "Clinical investigation of medicinal products indicated for panic disorder",
            "category": "Human",
            "first_published_date": "20/01/2005",
            "last_updated_date": "20/01/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-indicated-panic-disorder"
        },
        {
            "title": "VICH GL38 Environmental impact assessments for veterinary medicinal products - Phase II",
            "category": "Veterinary",
            "first_published_date": "01/01/2005",
            "last_updated_date": "01/01/2005",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl38-environmental-impact-assessments-veterinary-medicinal-products-phase-ii"
        },
        {
            "title": "ICH E2E Pharmacovigilance planning (Pvp)",
            "category": "Human",
            "first_published_date": "31/12/2004",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2e-pharmacovigilance-planning-pvp"
        },
        {
            "title": "Impact of renal immaturity when investigating medicinal products intended for paediatric use",
            "category": "Human",
            "first_published_date": "16/12/2004",
            "last_updated_date": "16/12/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/impact-renal-immaturity-when-investigating-medicinal-products-intended-paediatric-use"
        },
        {
            "title": "Requirements for vaccines against foot-and-mouth disease",
            "category": "Veterinary",
            "first_published_date": "01/12/2004",
            "last_updated_date": "01/12/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-vaccines-against-foot-mouth-disease"
        },
        {
            "title": "Core summary of product characteristics for human prothrombin complex products",
            "category": "Human",
            "first_published_date": "21/11/2004",
            "last_updated_date": "21/11/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-prothrombin-complex-products"
        },
        {
            "title": "Clinical investigation of medicinal products indicated for the treatment of psoriasis",
            "category": "Human",
            "first_published_date": "18/11/2004",
            "last_updated_date": "18/11/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-indicated-treatment-psoriasis"
        },
        {
            "title": "Investigation of manufacturing processes for plasma-derived medicinal products with regard to variant Creutzfeldt-Jakob disease risk",
            "category": "Human",
            "first_published_date": "21/10/2004",
            "last_updated_date": "21/10/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-manufacturing-processes-plasma-derived-medicinal-products-regard-variant-creutzfeldt-jakob-disease-risk"
        },
        {
            "title": "Clinical development of medicinal products for the treatment of allergic rhino-conjunctivitis",
            "category": "Human",
            "first_published_date": "21/10/2004",
            "last_updated_date": "21/10/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-medicinal-products-treatment-allergic-rhino-conjunctivitis"
        },
        {
            "title": "Clinical investigation of plasma-derived fibrin sealant/haemostatic products",
            "category": "Human",
            "first_published_date": "29/07/2004",
            "last_updated_date": "29/07/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-plasma-derived-fibrin-sealant-haemostatic-products"
        },
        {
            "title": "Core summary of product characteristics for human plasma coagulation factor VII products",
            "category": "Human",
            "first_published_date": "29/07/2004",
            "last_updated_date": "29/07/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-coagulation-factor-vii-products"
        },
        {
            "title": "First cases of BSE in USA and Canada: risk assessment of ruminant materials originating from USA and Canada",
            "category": "Human",
            "first_published_date": "21/07/2004",
            "last_updated_date": "21/07/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/first-cases-bse-usa-canada-risk-assessment-ruminant-materials-originating-usa-canada"
        },
        {
            "title": "Definition of substances capable of pharmacological action in the context of Council Directive 2001/82/EC as amended, with particular reference to excipients and manufacturing materials",
            "category": "Veterinary",
            "first_published_date": "01/07/2004",
            "last_updated_date": "01/07/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/definition-substances-capable-pharmacological-action-context-council-directive-2001-82-ec-amended-particular-reference-excipients-manufacturing-materials"
        },
        {
            "title": "Inclusion of appendices to clinical study reports in marketing authorisation applications",
            "category": "Human",
            "first_published_date": "23/06/2004",
            "last_updated_date": "23/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/inclusion-appendices-clinical-study-reports-marketing-authorisation-applications"
        },
        {
            "title": "CHMP SWP conclusions and recommendations on the use of genetically modified animal models for carcinogenicity assessment",
            "category": "Human",
            "first_published_date": "23/06/2004",
            "last_updated_date": "23/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/chmp-swp-conclusions-recommendations-use-genetically-modified-animal-models-carcinogenicity-assessment"
        },
        {
            "title": "VICH GL31 Safety studies for veterinary drug residues in human food: repeat-dose (90) toxicity testing",
            "category": "Veterinary",
            "first_published_date": "16/06/2004",
            "last_updated_date": "16/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl31-safety-studies-veterinary-drug-residues-human-food-repeat-dose-90-toxicity-testing"
        },
        {
            "title": "VICH GL32 Studies to evaluate the safety of residues of veterinary drugs in human food: developmental toxicity testing",
            "category": "Veterinary",
            "first_published_date": "16/06/2004",
            "last_updated_date": "16/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl32-studies-evaluate-safety-residues-veterinary-drugs-human-food-developmental-toxicity-testing"
        },
        {
            "title": "VICH GL37 Safety of veterinary drugs in human food repeat-dose (chronic) toxicity testing",
            "category": "Veterinary",
            "first_published_date": "16/06/2004",
            "last_updated_date": "16/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl37-safety-veterinary-drugs-human-food-repeat-dose-chronic-toxicity-testing"
        },
        {
            "title": "Development of CHMP guideline on dosing delivery of injectable liquids",
            "category": "Human",
            "first_published_date": "02/06/2004",
            "last_updated_date": "02/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-chmp-guideline-dosing-delivery-injectable-liquids"
        },
        {
            "title": "ICH M4E Common technical document for the registration of pharmaceuticals for human use - efficacy: questions and answers",
            "category": "Human",
            "first_published_date": "01/06/2004",
            "last_updated_date": "01/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4e-common-technical-document-registration-pharmaceuticals-human-use-efficacy-questions-answers"
        },
        {
            "title": "ICH M4 Common technical document for the registration of pharmaceuticals for human use: questions and answers",
            "category": "Human",
            "first_published_date": "01/06/2004",
            "last_updated_date": "01/06/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4-common-technical-document-registration-pharmaceuticals-human-use-questions-answers"
        },
        {
            "title": "Control of impurities of pharmacopoeial substances",
            "category": "Human",
            "first_published_date": "22/04/2004",
            "last_updated_date": "22/04/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/control-impurities-pharmacopoeial-substances"
        },
        {
            "title": "Thiomersal in vaccines for human use - recent evidence supports safety of thiomersal-containing vaccines",
            "category": "Human",
            "first_published_date": "24/03/2004",
            "last_updated_date": "24/03/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/thiomersal-vaccines-human-use-recent-evidence-supports-safety-thiomersal-containing-vaccines"
        },
        {
            "title": "Requirements for plasma master file certification",
            "category": "Human",
            "first_published_date": "26/02/2004",
            "last_updated_date": "26/02/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/requirements-plasma-master-file-certification"
        },
        {
            "title": "Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products",
            "category": "Human;Veterinary",
            "first_published_date": "28/01/2004",
            "last_updated_date": "28/01/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-veterinary-medicinal-products"
        },
        {
            "title": "VICH GL27 Guidance on the pre-approval information for registration of new veterinary medicinal products for food-producing animals with respect to antimicrobial resistance",
            "category": "Veterinary",
            "first_published_date": "14/01/2004",
            "last_updated_date": "14/01/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl27-guidance-pre-approval-information-registration-new-veterinary-medicinal-products-food-producing-animals-respect-antimicrobial-resistance"
        },
        {
            "title": "Summary of requirements for active substances in the quality part of the dossier",
            "category": "Human;Veterinary",
            "first_published_date": "01/01/2004",
            "last_updated_date": "01/01/2004",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/summary-requirements-active-substances-quality-part-dossier"
        },
        {
            "title": "Stability testing of existing active ingredients and related finished products",
            "category": "Human",
            "first_published_date": "17/12/2003",
            "last_updated_date": "17/12/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-testing-existing-active-ingredients-related-finished-products"
        },
        {
            "title": "Clinical investigation of medicinal products for treatment of rheumatoid arthritis",
            "category": "Human",
            "first_published_date": "17/12/2003",
            "last_updated_date": "17/12/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis"
        },
        {
            "title": "Scientific data requirements for a vaccine antigen master file",
            "category": "Human",
            "first_published_date": "15/12/2003",
            "last_updated_date": "15/12/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/scientific-data-requirements-vaccine-antigen-master-file"
        },
        {
            "title": "Warning on transmissible agents in summary of product characteristics and package leaflets for plasma-derived medicinal products",
            "category": "Human",
            "first_published_date": "26/11/2003",
            "last_updated_date": "26/11/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/warning-transmissible-agents-summary-product-characteristics-package-leaflets-plasma-derived-medicinal-products-0"
        },
        {
            "title": "ICH M4S Common technical document for the registration of pharmaceuticals for human use - safety: questions and answers",
            "category": "Human",
            "first_published_date": "01/11/2003",
            "last_updated_date": "01/11/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4s-common-technical-document-registration-pharmaceuticals-human-use-safety-questions-answers"
        },
        {
            "title": "Quality of water used in the production of vaccines for parenteral use",
            "category": "Human",
            "first_published_date": "20/10/2003",
            "last_updated_date": "20/10/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/quality-water-used-production-vaccines-parenteral-use"
        },
        {
            "title": "West Nile virus and plasma-derived medicinal products",
            "category": "Human",
            "first_published_date": "25/07/2003",
            "last_updated_date": "25/07/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/west-nile-virus-plasma-derived-medicinal-products"
        },
        {
            "title": "Evaluation of anticancer medicinal products - addendum on paediatric oncology",
            "category": "Human",
            "first_published_date": "24/07/2003",
            "last_updated_date": "24/07/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-anticancer-medicinal-products-addendum-paediatric-oncology"
        },
        {
            "title": "ICH M4E Common technical document for the registration of pharmaceuticals for human use - efficacy",
            "category": "Human",
            "first_published_date": "01/07/2003",
            "last_updated_date": "01/07/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4e-common-technical-document-registration-pharmaceuticals-human-use-efficacy"
        },
        {
            "title": "ICH M4S Common technical document for the registration of pharmaceuticals for human use - safety",
            "category": "Human",
            "first_published_date": "01/07/2003",
            "last_updated_date": "01/07/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-m4s-common-technical-document-registration-pharmaceuticals-human-use-safety"
        },
        {
            "title": "Clinical development of fibrinolytic medicinal products in the treatment of patients with ST -segment elevation acute myocardial infarction (STEMI)",
            "category": "Human",
            "first_published_date": "26/06/2003",
            "last_updated_date": "26/06/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-development-fibrinolytic-medicinal-products-treatment-patients-st-segment-elevation-acute-myocardial-infarction-stemi"
        },
        {
            "title": "Description of composition of pegylated (conjugated) proteins in the summary of product characteristics",
            "category": "Human",
            "first_published_date": "14/05/2003",
            "last_updated_date": "14/05/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/description-composition-pegylated-conjugated-proteins-summary-product-characteristics"
        },
        {
            "title": "Development of vaccinia virus-based vaccines against smallpox",
            "category": "Human",
            "first_published_date": "20/02/2003",
            "last_updated_date": "20/02/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-vaccinia-virus-based-vaccines-against-smallpox"
        },
        {
            "title": "ICH Q1A (R2) Stability testing of new drug substances and drug products",
            "category": "Human",
            "first_published_date": "01/02/2003",
            "last_updated_date": "01/02/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1a-r2-stability-testing-new-drug-substances-drug-products"
        },
        {
            "title": "ICH Q1E Evaluation of stability data",
            "category": "Human",
            "first_published_date": "01/02/2003",
            "last_updated_date": "01/02/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1e-evaluation-stability-data"
        },
        {
            "title": "CVMP advisory notice to veterinary surgeons regarding the development of fibrosarcomas at sites of injection of veterinary medicinal products in cats",
            "category": "Veterinary",
            "first_published_date": "01/01/2003",
            "last_updated_date": "01/01/2003",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/cvmp-advisory-notice-veterinary-surgeons-regarding-development-fibrosarcomas-sites-injection-veterinary-medicinal-products-cats"
        },
        {
            "title": "Maximum in-use shelf-life for medicated drinking water",
            "category": "Veterinary",
            "first_published_date": "01/12/2002",
            "last_updated_date": "01/12/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/maximum-use-shelf-life-medicated-drinking-water"
        },
        {
            "title": "Terminology in pharmacogenetics",
            "category": "Human",
            "first_published_date": "21/11/2002",
            "last_updated_date": "21/11/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/terminology-pharmacogenetics"
        },
        {
            "title": "Establishment of maximum residue limits for milk considering the daily intake by children",
            "category": "Veterinary",
            "first_published_date": "01/11/2002",
            "last_updated_date": "01/11/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/establishment-maximum-residue-limits-milk-considering-daily-intake-children"
        },
        {
            "title": "Re-establishment of working seeds and working cell banks using TSE compliant materials",
            "category": "Human",
            "first_published_date": "10/09/2002",
            "last_updated_date": "10/09/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/re-establishment-working-seeds-working-cell-banks-using-tse-compliant-materials"
        },
        {
            "title": "Re-establishment of working seeds and working cell banks using TSE compliant materials",
            "category": "Veterinary",
            "first_published_date": "10/09/2002",
            "last_updated_date": "10/09/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/re-establishment-working-seeds-working-cell-banks-using-tse-compliant-materials-0"
        },
        {
            "title": "Regulatory requirements for the authorisation of low-dose modified-release acetyl-salicylic-acid formulations in the secondary prevention of cardiovascular events",
            "category": "Human",
            "first_published_date": "25/07/2002",
            "last_updated_date": "25/07/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/regulatory-requirements-authorisation-low-dose-modified-release-acetyl-salicylic-acid-formulations-secondary-prevention-cardiovascular-events"
        },
        {
            "title": "Carcinogenic potential",
            "category": "Human",
            "first_published_date": "25/07/2002",
            "last_updated_date": "25/07/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/carcinogenic-potential"
        },
        {
            "title": "EU requirements for batches with maximum and minimum titre or batch potency for developmental safety and efficacy studies",
            "category": "Veterinary",
            "first_published_date": "17/06/2002",
            "last_updated_date": "17/06/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/eu-requirements-batches-maximum-minimum-titre-or-batch-potency-developmental-safety-efficacy-studies"
        },
        {
            "title": "Non-remunerated and remunerated donors: safety and supply of plasma-derived medicinal products",
            "category": "Human",
            "first_published_date": "30/05/2002",
            "last_updated_date": "30/05/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-remunerated-remunerated-donors-safety-supply-plasma-derived-medicinal-products"
        },
        {
            "title": "Risk and regulatory assessment of lactose and other products prepared using calf rennet",
            "category": "Human",
            "first_published_date": "22/05/2002",
            "last_updated_date": "22/05/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-regulatory-assessment-lactose-other-products-prepared-using-calf-rennet"
        },
        {
            "title": "VICH GL25 Biologicals: testing of residual formaldehyde",
            "category": "Veterinary",
            "first_published_date": "30/04/2002",
            "last_updated_date": "30/04/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl25-biologicals-testing-residual-formaldehyde"
        },
        {
            "title": "VICH GL26 Biologicals: testing of residual moisture",
            "category": "Veterinary",
            "first_published_date": "30/04/2002",
            "last_updated_date": "30/04/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl26-biologicals-testing-residual-moisture"
        },
        {
            "title": "Testing for simian virus 40 (SV40) in polio virus vaccines",
            "category": "Human",
            "first_published_date": "25/04/2002",
            "last_updated_date": "25/04/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/testing-simian-virus-40-sv40-polio-virus-vaccines"
        },
        {
            "title": "Need for assessment of reproduction toxicity of human insulin analogues",
            "category": "Human",
            "first_published_date": "01/03/2002",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/need-assessment-reproduction-toxicity-human-insulin-analogues"
        },
        {
            "title": "ICH Q1D Bracketing and matrixing designs for stability testing of drug substances and drug products",
            "category": "Human",
            "first_published_date": "01/02/2002",
            "last_updated_date": "01/02/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products"
        },
        {
            "title": "Core summary of product characteristics for human plasma derived antithrombin",
            "category": "Human",
            "first_published_date": "17/01/2002",
            "last_updated_date": "17/01/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/core-summary-product-characteristics-human-plasma-derived-antithrombin"
        },
        {
            "title": "Clinical investigation of plasma-derived antithrombin products",
            "category": "Human",
            "first_published_date": "17/01/2002",
            "last_updated_date": "17/01/2002",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-plasma-derived-antithrombin-products"
        },
        {
            "title": "Non-clinical assessment of the carcinogenic potential of human insulin analogues",
            "category": "Human",
            "first_published_date": "15/11/2001",
            "last_updated_date": "15/11/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/non-clinical-assessment-carcinogenic-potential-human-insulin-analogues"
        },
        {
            "title": "Coordinating investigator signature of clinical study reports",
            "category": "Human",
            "first_published_date": "18/10/2001",
            "last_updated_date": "18/10/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/coordinating-investigator-signature-clinical-study-reports"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of acute stroke",
            "category": "Human",
            "first_published_date": "20/09/2001",
            "last_updated_date": "20/09/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-acute-stroke"
        },
        {
            "title": "ICH S7A Safety pharmacology studies for human pharmaceuticals",
            "category": "Human",
            "first_published_date": "30/11/2000",
            "last_updated_date": "01/06/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s7a-safety-pharmacology-studies-human-pharmaceuticals"
        },
        {
            "title": "Start of shelf-life of the finished dosage form (Annex to the note for guidance on the manufacture of the finished dosage form)",
            "category": "Human;Veterinary",
            "first_published_date": "31/05/2001",
            "last_updated_date": "31/05/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/start-shelf-life-finished-dosage-form-annex-note-guidance-manufacture-finished-dosage-form"
        },
        {
            "title": "Application with 1. Meta-analyses; 2. One pivotal study",
            "category": "Human",
            "first_published_date": "31/05/2001",
            "last_updated_date": "31/05/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/application-1-meta-analyses-2-one-pivotal-study"
        },
        {
            "title": "Reduction, elimination or substitution of thiomersal in vaccines",
            "category": "Human",
            "first_published_date": "26/04/2001",
            "last_updated_date": "26/04/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/reduction-elimination-or-substitution-thiomersal-vaccines"
        },
        {
            "title": "Use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products",
            "category": "Human",
            "first_published_date": "01/03/2001",
            "last_updated_date": "01/03/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-tumorigenic-cells-human-origin-production-biological-biotechnological-medicinal-products"
        },
        {
            "title": "In-use stability testing of human medicinal products",
            "category": "Human",
            "first_published_date": "01/03/2001",
            "last_updated_date": "01/03/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-stability-testing-human-medicinal-products"
        },
        {
            "title": "Evaluation of bovine spongiform encephalopathy risk via the use of materials of bovine origin in or during the manufacture of vaccines",
            "category": "Human",
            "first_published_date": "28/02/2001",
            "last_updated_date": "28/02/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-bovine-spongiform-encephalopathy-risk-use-materials-bovine-origin-or-during-manufacture-vaccines"
        },
        {
            "title": "Evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines",
            "category": "Human",
            "first_published_date": "28/02/2001",
            "last_updated_date": "28/02/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/evaluation-bovine-spongiform-encephalopathies-bse-risk-use-materials-bovine-origin-or-during-manufacture-vaccines-0"
        },
        {
            "title": "Stability and traceability requirements for vaccine intermediates",
            "category": "Human",
            "first_published_date": "25/01/2001",
            "last_updated_date": "25/01/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/stability-traceability-requirements-vaccine-intermediates"
        },
        {
            "title": "Risk-analysis approach for residues of VMPs in food of animal origin",
            "category": "Veterinary",
            "first_published_date": "01/01/2001",
            "last_updated_date": "01/01/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/risk-analysis-approach-residues-vmps-food-animal-origin"
        },
        {
            "title": "ICH E10 Choice of control group in clinical trials",
            "category": "Human",
            "first_published_date": "01/01/2001",
            "last_updated_date": "01/01/2001",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e10-choice-control-group-clinical-trials"
        },
        {
            "title": "Background to the CPMP Position Paper on possible pre-clinical studies to investigate addiction and dependence/withdrawal related to the use of selective serotonin uptake inhibitors (SSRIs)",
            "category": "Human",
            "first_published_date": "14/12/2000",
            "last_updated_date": "14/12/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/background-cpmp-position-paper-possible-pre-clinical-studies-investigate-addiction-dependence-withdrawal-related-use-selective-serotonin-uptake-inhibitors-ssris"
        },
        {
            "title": "ICH Q7 Good manufacturing practice for active pharmaceutical ingredients",
            "category": "Human",
            "first_published_date": "01/11/2000",
            "last_updated_date": "01/11/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q7-good-manufacturing-practice-active-pharmaceutical-ingredients"
        },
        {
            "title": "Pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products",
            "category": "Human",
            "first_published_date": "27/07/2000",
            "last_updated_date": "27/07/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/pharmacokinetics-pharmacodynamics-development-antibacterial-medicinal-products"
        },
        {
            "title": "VICH GL6 Environmental impact assessment (EIAS) for veterinary medicinal products - Phase I",
            "category": "Veterinary",
            "first_published_date": "30/06/2000",
            "last_updated_date": "20/07/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl6-environmental-impact-assessment-eias-veterinary-medicinal-products-phase-i"
        },
        {
            "title": "VICH GL9 Good clinical practices",
            "category": "Veterinary",
            "first_published_date": "04/07/2000",
            "last_updated_date": "04/07/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl9-good-clinical-practices"
        },
        {
            "title": "Maximum shelf-life for sterile medicinal products after first opening or following reconstitution",
            "category": "Veterinary",
            "first_published_date": "01/07/2000",
            "last_updated_date": "01/07/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/maximum-shelf-life-sterile-medicinal-products-after-first-opening-or-following-reconstitution"
        },
        {
            "title": "ICH E12 Principles for clinical evaluation of new antihypertensive drugs",
            "category": "Human",
            "first_published_date": "01/06/2000",
            "last_updated_date": "01/06/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e12-principles-clinical-evaluation-new-antihypertensive-drugs"
        },
        {
            "title": "VICH GL17 Stability testing of biotechnological/biological veterinary medicinal products",
            "category": "Veterinary",
            "first_published_date": "01/06/2000",
            "last_updated_date": "01/06/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl17-stability-testing-biotechnological-biological-veterinary-medicinal-products"
        },
        {
            "title": "VICH GL4 Stability testing for new veterinary dosage forms",
            "category": "Veterinary",
            "first_published_date": "25/05/2000",
            "last_updated_date": "25/05/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl4-stability-testing-new-veterinary-dosage-forms"
        },
        {
            "title": "VICH GL5 Stability testing: photostability testing of new veterinary drug substances and medicinal products",
            "category": "Veterinary",
            "first_published_date": "25/05/2000",
            "last_updated_date": "25/05/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl5-stability-testing-photostability-testing-new-veterinary-drug-substances-medicinal-products"
        },
        {
            "title": "Background to the CPMP Position Paper on selective serotonin uptake inhibitors (SSRIs) and dependency/withdrawal reactions",
            "category": "Human",
            "first_published_date": "12/04/2000",
            "last_updated_date": "12/04/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/background-cpmp-position-paper-selective-serotonin-uptake-inhibitors-ssris-dependency-withdrawal-reactions"
        },
        {
            "title": "Endpoints in clinical studies with haematopoietic growth factors for mobilisation of autologous stem cells",
            "category": "Human",
            "first_published_date": "01/02/2000",
            "last_updated_date": "01/02/2000",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/endpoints-clinical-studies-haematopoietic-growth-factors-mobilisation-autologous-stem-cells"
        },
        {
            "title": "Clinical investigation of medicinal products for the treatment of venous thromboembolic disease",
            "category": "Human",
            "first_published_date": "16/12/1999",
            "last_updated_date": "16/12/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease"
        },
        {
            "title": "ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances",
            "category": "Human",
            "first_published_date": "01/11/1999",
            "last_updated_date": "01/11/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q6a-specifications-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical-substances"
        },
        {
            "title": "Polysorbate 80",
            "category": "Human",
            "first_published_date": "22/10/1999",
            "last_updated_date": "22/10/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/polysorbate-80"
        },
        {
            "title": "Development pharmaceutics for biotechnological and biological products (Annex to note for guidance on development pharmaceutics)",
            "category": "Human",
            "first_published_date": "21/10/1999",
            "last_updated_date": "21/10/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-pharmaceutics-biotechnological-biological-products-annex-note-guidance-development-pharmaceutics"
        },
        {
            "title": "Wording of Helicobacter pylori eradication therapy in selected summary-of-product-characteristics sections",
            "category": "Human",
            "first_published_date": "23/09/1999",
            "last_updated_date": "23/09/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/wording-helicobacter-pylori-eradication-therapy-selected-summary-product-characteristics-sections"
        },
        {
            "title": "ICH Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological products",
            "category": "Human",
            "first_published_date": "01/09/1999",
            "last_updated_date": "01/09/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products"
        },
        {
            "title": "Plasma-derived medicinal products: ALT testing",
            "category": "Human",
            "first_published_date": "29/07/1999",
            "last_updated_date": "29/07/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/plasma-derived-medicinal-products-alt-testing"
        },
        {
            "title": "Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza vaccines",
            "category": "Human",
            "first_published_date": "29/07/1999",
            "last_updated_date": "29/07/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines"
        },
        {
            "title": "Compliance of veterinary vaccines under the centralised procedure with veterinary vaccine monographs of the European Pharmacopoeia",
            "category": "Veterinary",
            "first_published_date": "01/06/1999",
            "last_updated_date": "01/06/1999",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/compliance-veterinary-vaccines-under-centralised-procedure-veterinary-vaccine-monographs-european-pharmacopoeia"
        },
        {
            "title": "VICH GL1 Validation of analytical procedures: definition and terminology",
            "category": "Veterinary",
            "first_published_date": "10/12/1998",
            "last_updated_date": "10/12/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl1-validation-analytical-procedures-definition-terminology"
        },
        {
            "title": "VICH GL2 Validation of analytical procedures: methodology",
            "category": "Veterinary",
            "first_published_date": "10/12/1998",
            "last_updated_date": "10/12/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/vich-gl2-validation-analytical-procedures-methodology"
        },
        {
            "title": "ICH S4 Duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing)",
            "category": "Human",
            "first_published_date": "30/11/1998",
            "last_updated_date": "30/11/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s4-duration-chronic-toxicity-testing-animals-rodent-non-rodent-toxicity-testing"
        },
        {
            "title": "ICH E5 (R1) Ethnic factors in the acceptability of foreign clinical data",
            "category": "Human",
            "first_published_date": "01/09/1998",
            "last_updated_date": "01/09/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e5-r1-ethnic-factors-acceptability-foreign-clinical-data"
        },
        {
            "title": "Batch potency testing of immunological veterinary medicinal product",
            "category": "Veterinary",
            "first_published_date": "01/09/1998",
            "last_updated_date": "01/09/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/batch-potency-testing-immunological-veterinary-medicinal-product"
        },
        {
            "title": "Premixes for medicated feeding stuffs for veterinary use versus powders/granules for oral use or use in drinking water",
            "category": "Veterinary",
            "first_published_date": "01/08/1998",
            "last_updated_date": "01/08/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/premixes-medicated-feeding-stuffs-veterinary-use-versus-powders-granules-oral-use-or-use-drinking-water"
        },
        {
            "title": "Development pharmaceutics",
            "category": "Human",
            "first_published_date": "28/07/1998",
            "last_updated_date": "",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/development-pharmaceutics"
        },
        {
            "title": "Clinical investigation of medicinal products used in the treatment of osteoarthritis",
            "category": "Human",
            "first_published_date": "23/07/1998",
            "last_updated_date": "23/07/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/clinical-investigation-medicinal-products-used-treatment-osteoarthritis"
        },
        {
            "title": "Viral safety of oral poliovirus vaccine (OPV)",
            "category": "Human",
            "first_published_date": "28/05/1998",
            "last_updated_date": "28/05/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/viral-safety-oral-poliovirus-vaccine-opv"
        },
        {
            "title": "ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products",
            "category": "Human",
            "first_published_date": "31/03/1998",
            "last_updated_date": "31/03/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q5d-derivation-characterisation-cell-substrates-used-production-biotechnological-biological-products"
        },
        {
            "title": "Definition of a new biological active substance in terms of active, passive immunity and immunomodulators which then constitute a new active ingredient in the context of part B of the Annex to Council Regulation (EEC) No 2309/93",
            "category": "Veterinary",
            "first_published_date": "01/02/1998",
            "last_updated_date": "01/02/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/definition-new-biological-active-substance-terms-active-passive-immunity-immunomodulators-which-then-constitute-new-active-ingredient-context-part-b-annex-council-regulation-eec-no-2309-93"
        },
        {
            "title": "Maximum shelf-life for sterile products for human use after first opening or following reconstitution",
            "category": "Human",
            "first_published_date": "28/01/1998",
            "last_updated_date": "28/01/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/maximum-shelf-life-sterile-products-human-use-after-first-opening-or-following-reconstitution"
        },
        {
            "title": "Establishment of maximum residue limits for Salmonidae and other fin fish",
            "category": "Veterinary",
            "first_published_date": "01/01/1998",
            "last_updated_date": "01/01/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/establishment-maximum-residue-limits-salmonidae-other-fin-fish"
        },
        {
            "title": "ICH Q1C Stability testing: requirements for new dosage forms",
            "category": "Human",
            "first_published_date": "01/01/1998",
            "last_updated_date": "01/01/1998",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1c-stability-testing-requirements-new-dosage-forms"
        },
        {
            "title": "Genotoxic and carcinogenic potential of phenolphthalein",
            "category": "Human",
            "first_published_date": "17/12/1997",
            "last_updated_date": "17/12/1997",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/genotoxic-carcinogenic-potential-phenolphthalein"
        },
        {
            "title": "Production of tallow derivatives for use in pharmaceuticals",
            "category": "Human",
            "first_published_date": "17/12/1997",
            "last_updated_date": "17/12/1997",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/production-tallow-derivatives-use-pharmaceuticals"
        },
        {
            "title": "ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals",
            "category": "Human",
            "first_published_date": "30/09/1997",
            "last_updated_date": "30/09/1997",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s6-r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals"
        },
        {
            "title": "Inclusion of antioxidants and antimicrobial preservatives in medicinal products",
            "category": "Veterinary",
            "first_published_date": "07/07/1997",
            "last_updated_date": "07/07/1997",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/inclusion-antioxidants-antimicrobial-preservatives-medicinal-products"
        },
        {
            "title": "ICH Q1B Photostability testing of new active substances and medicinal products",
            "category": "Human",
            "first_published_date": "01/12/1996",
            "last_updated_date": "01/12/1996",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q1b-photostability-testing-new-active-substances-medicinal-products"
        },
        {
            "title": "ICH E3 Structure and content of clinical study reports",
            "category": "Human",
            "first_published_date": "01/07/1996",
            "last_updated_date": "01/07/1996",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e3-structure-content-clinical-study-reports"
        },
        {
            "title": "ICH Q5C Stability testing of biotechnological/biological products",
            "category": "Human",
            "first_published_date": "01/07/1996",
            "last_updated_date": "01/07/1996",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q5c-stability-testing-biotechnological-biological-products"
        },
        {
            "title": "ICH Q5B Analysis of the expression construct in cell lines used for production of rDNA-derived protein products",
            "category": "Human",
            "first_published_date": "01/07/1996",
            "last_updated_date": "01/07/1996",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q5b-analysis-expression-construct-cell-lines-used-production-rdna-derived-protein-products"
        },
        {
            "title": "Virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses",
            "category": "Human",
            "first_published_date": "14/02/1996",
            "last_updated_date": "14/02/1996",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/virus-validation-studies-design-contribution-interpretation-studies-validating-inactivation-removal-viruses"
        },
        {
            "title": "Post-marketing surveillance studies for metered dose inhalers with new propellant",
            "category": "Human",
            "first_published_date": "30/12/1995",
            "last_updated_date": "30/12/1995",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/post-marketing-surveillance-studies-metered-dose-inhalers-new-propellant"
        },
        {
            "title": "ICH S1A Need for carcinogenicity studies of pharmaceuticals",
            "category": "Human",
            "first_published_date": "01/12/1995",
            "last_updated_date": "01/12/1995",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s1a-need-carcinogenicity-studies-pharmaceuticals"
        },
        {
            "title": "Antiarrhythmics",
            "category": "Human",
            "first_published_date": "01/11/1995",
            "last_updated_date": "01/11/1995",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/antiarrhythmics"
        },
        {
            "title": "ICH E1 Population exposure: the extent of population exposure to assess clinical safety",
            "category": "Human",
            "first_published_date": "01/06/1995",
            "last_updated_date": "01/06/1995",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e1-population-exposure-extent-population-exposure-assess-clinical-safety"
        },
        {
            "title": "ICH E2A Clinical safety data management: definitions and standards for expedited reporting",
            "category": "Human",
            "first_published_date": "01/06/1995",
            "last_updated_date": "01/06/1995",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting"
        },
        {
            "title": "Production and quality control of medicinal products derived by recombinant DNA technology",
            "category": "Human",
            "first_published_date": "31/12/1994",
            "last_updated_date": "31/12/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/production-quality-control-medicinal-products-derived-recombinant-dna-technology"
        },
        {
            "title": "Gene therapy product quality aspects in the production of vectors and genetically modified somatic cells",
            "category": "Human",
            "first_published_date": "31/12/1994",
            "last_updated_date": "31/12/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/gene-therapy-product-quality-aspects-production-vectors-genetically-modified-somatic-cells"
        },
        {
            "title": "ICH S3B Pharmacokinetics: repeated dose tissue distribution studies",
            "category": "Human",
            "first_published_date": "30/11/1994",
            "last_updated_date": "30/11/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s3b-pharmacokinetics-repeated-dose-tissue-distribution-studies"
        },
        {
            "title": "ICH S3A Toxicokinetics: the assessment of systemic exposure in toxicity studies",
            "category": "Human",
            "first_published_date": "30/11/1994",
            "last_updated_date": "30/11/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-s3a-toxicokinetics-assessment-systemic-exposure-toxicity-studies"
        },
        {
            "title": "ICH E4 Dose response information to support drug registration",
            "category": "Human",
            "first_published_date": "01/11/1994",
            "last_updated_date": "01/11/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e4-dose-response-information-support-drug-registration"
        },
        {
            "title": "ICH E7 Studies in support of special populations: geriatrics",
            "category": "Human",
            "first_published_date": "01/03/1994",
            "last_updated_date": "01/03/1994",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-e7-studies-support-special-populations-geriatrics"
        },
        {
            "title": "Replacement of chlorofluorocarbons (CFC) in metered dose inhalation products",
            "category": "Human",
            "first_published_date": "01/12/1993",
            "last_updated_date": "01/12/1993",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/replacement-chlorofluorocarbons-cfc-metered-dose-inhalation-products"
        },
        {
            "title": "Investigation of chiral active substances (human)",
            "category": "Human",
            "first_published_date": "01/10/1993",
            "last_updated_date": "01/10/1993",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-chiral-active-substances-human"
        },
        {
            "title": "Investigation of chiral active substances (veterinary)",
            "category": "Veterinary",
            "first_published_date": "01/10/1993",
            "last_updated_date": "01/10/1993",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/investigation-chiral-active-substances-veterinary"
        },
        {
            "title": "Local tolerance of intramammary preparations in cows",
            "category": "Veterinary",
            "first_published_date": "01/11/1992",
            "last_updated_date": "01/11/1992",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/local-tolerance-intramammary-preparations-cows"
        },
        {
            "title": "Use of ionizing radiation in the manufacture of medicinal products",
            "category": "Human;Veterinary",
            "first_published_date": "01/12/1991",
            "last_updated_date": "01/12/1991",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/use-ionizing-radiation-manufacture-medicinal-products"
        },
        {
            "title": "Specifications and control tests on the finished product",
            "category": "Human;Veterinary",
            "first_published_date": "01/12/1991",
            "last_updated_date": "01/12/1991",
            "url": "https://www.ema.europa.eu/en/scientific-guidelines/specifications-control-tests-finished-product"
        }
    ]
}